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1. Vascular development 
The circulatory system is the first functional organ system to appear during embryonal 
development in vertebrates, which is clearly depicting its importance. Developing blood 
vessels bring nutrients and oxygen to fast growing cells of the embryo, overcoming the limits 
of simple diffusion of the oxygen to the cells (1). In 1628, William Harvey discovered that the 
heart pumps blood through arteries which is then returned back to the heart by veins. Later, in 
1661, Marcello Malpighi identified capillaries as the smallest blood vessels connecting arteries 
and veins in developing chick embryo (2).    
There are three main processes of vascular formation; i) vasculogenesis, ii) 
angiogenesis and iii) arteriogenesis. Vasculogenesis is de novo formation of new blood vessels 
from the progenitor cells. Angiogenesis is a process of a growth of vessels from pre-existing 
ones, while arteriogenesis is a process of arterial vessel diameter expansion upon increase in 
blood flow or shear stress (Figure 1). Through coordination of all three processes, a complete 
circulatory system, responsible for tissue oxygenation, nutrient delivery, waste removal, 
immune response, thermoregulation and maintenance of blood pressure, is built (1). 
 
 
Figure 1. Vascular development. Vasculogenesis is a process that implies formation of blood vessels from 
progenitors, while angiogenesis and arteriogenesis are processes of blood vessel growth from pre-existing vessels 
and require recruitment of pericytes (P) and smooth muscle cells (SMC). Lymphatic vessels originate from veins 
[Reprinted from Carmeliet P. et al, 2005 (2)]. 
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1.1. Vasculogenesis 
Vasculogenesis is the process of de novo formation of new blood vessels from 
endothelial progenitor cells, and it occurs both intra- and extra-embryonically (1). Embryonic 
mesoderm, extra-embryonic yolk sac, allantois and placenta are the sources of vascular 
endothelial and hematopoietic progenitor cells (1, 3). The first step in the process is the 
appearance of the hemangioblast, a common progenitor of endothelial and hematopoietic cell 
lineages. In the murine yolk sac, hemangioblasts will form clusters, so called blood islands, at 
embryonic day (E) 6.5-7 and further differentiate into two cell types - angioblasts and 
hematopoietic progenitors. Angioblasts are endothelial progenitors, which will be located at 
the periphery of the blood island while hematopoietic progenitors will be located centrally. 
Angioblasts proliferate, migrate and differentiate into endothelial cells at E8.5 and ultimately 
form a lumenized primitive vascular plexus and deposit basal lamina (1). This process of 
coordination of angioblast assembly with concomitant communication with the cells of other 
embryonic lineages is called vascular patterning and needs to be reproducible both in time and 
space (4). By the 2-somite stage, intra- and extra-embryonic vasculatures have anastomosed, 
but the embryo can still retrieve oxygen by diffusion. The vascular plexus then fuses with the 
developing heart, before the first heartbeat. Blood vessels of some endodermal organs like 
liver, spleen, lung, stomach/intestine and pancreas are also formed by vasculogenesis (5). It 
was demonstrated that vasculogenesis also occurs in adults, as a mechanism of capillary 
formation after ischemic injury (6). The molecular mechanisms of vasculogenesis are not 
completely clear, but signaling pathways like VEGF (7-9), FGF (10), Hedgehog (11), 
Neuropilin (12) and TGF-β (13, 14), are implicated in this complex process. 
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1.2. Angiogenesis 
Angiogenesis, in contrast to vasculogenesis, is the process of formation of blood vessels 
from pre-existing ones. During embryonic development, angiogenesis starts around E9.5 and 
most of the embryonic vessels are formed by this mechanism (1). In the adult organism, most 
of the vessels are quiescent and angiogenesis occurs only during cyclic changes of the female 
ovary and uterus, as well as in placenta during pregnancy, or during healing. Endothelial cells 
retain their ability to be activated and rapidly divide upon a physiological stimulus like hypoxia 
in case of blood vessels and inflammation in case of lymphatic vessel. Angiogenesis and 
lymphangiogenesis are therefore especially important during wound healing and injury. Extent 
of blood vessel growth needs to be tightly controlled since excessive or insufficient 
angiogenesis is leading to different pathologies. Overgrowth of blood vessel is associated with 
malignant, ocular and inflammatory disorders, as well as conditions like diabetes, 
endometriosis, AIDS, bacterial infections, asthma and multiple sclerosis. On the other side, 
ischemic diseases and preeclampsia are characterized with insufficient angiogenesis causing 
endothelial cell dysfunction, vessel malformation and lack of tissue vascularization and 
regeneration (2) . In 1971, Judah Folkman presented a theory that targeting angiogenesis is a 
strategy for anti-tumor treatment (15). Most of the research about angiogenesis has primarily 
been driven with the aim to develop anti-angiogenic drugs to fight cancer. The details about 
angiogenic process will be described in the following chapters.  
1.3. Arteriogenesis 
Arteriogenesis is the process of arterial enlargement under the conditions of increased 
blood flow and shear stress (16-18). The growth of pre-existing collateral arteries by 
arteriogenesis is a powerful mechanism by which a blood supply can be delivered to distal 
ischemic tissues in a situation of chronic occlusion of main feeding artery. During the process, 
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arteries enlarge in diameter (up to five-fold) and length as they become more tortuous (18). In 
some cases, patients with a chronic coronary artery occlusion can be asymptomatic due to the 
collateral artery growth which compensate the lack of blood flow. Collateral artery growth 
seems not to be regulated by hypoxia, nor by increase in VEGF expression (19). Main driver 
of arteriogenesis are biomechanical forces and there are evidences that change in fluid shear 
stress is the main stimulus for arterial enlargement (20). Fluid shear stress acts tangential to the 
vascular wall and in the arteries ranges between 10-70 dyn cm-2 (17). Endothelial cells are the 
one directly sensing the change in fluid shear stress induced by an increase of blood flow 
velocity which is the consequence of pressure difference created by the occlusion in the artery 
(18). Smooth muscle cells in tunica media are not in direct physical contact with endothelial 
cells since they are separated by internal elastic lamina and basement membranes, so their 
communication is mediated by secreted factors. The mediation of molecular signal probably 
goes through expression of nitric oxide (NO) by endothelial nitric oxide synthase (e-NOS) 
through stress-activated Ca2+ channel TRPV4. In turn, NO can activate smooth muscle cells to 
initiate vasodilatation (18). Monocytes have a central role in arteriogenic process and they are 
recruited by monocyte chemoattractant protein-1 (MCP-1, or CCL2) expressed by activated 
endothelial cells. Mice lacking CCR2, receptor for MCP-1 chemokine, have impaired 
arteriogenesis (21).  Expression of intercellular adhesion molecule-1 (ICAM-1) and vascular 
adhesion molecule-1 (VCAM-1) facilitates monocyte recruitment. Subsequently, monocytes 
become macrophages and start to secret several factors like tumor necrosis factor-α (TNF-α) 
(22), granulocyte-monocyte colony stimulating factor (GM-CSF) (23), matrix metalloprotease-
2, -9 (MMP-2, MMP-9) (24) that synergistically induce cell proliferation and matrix 
degradation, ultimately leading to enlarged arteries. Given that arteriogenesis has a clear 
beneficial therapeutic effect, other stimuli that induce collateral growth have been investigated. 
One of the simplest way is physical exercise, as it is the most natural way to stimulate 
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collateralization (25, 26). Other therapeutic avenue could be treatment with statins (3-Hydroxy-
3-methylglutaryl-coenzyme A reductase inhibitors) in patients with hypercholesterolemia (27), 
due to negative effect of hypercholesteremia on monocyte function and arteriogenesis (28). 
1.4. Vascular heterogeneity  
The circulatory system is made of two types of vessel networks; the blood and the 
lymphatic vasculatures. The blood vascular system is a closed circulatory complex consisting 
of arteries and veins which are connected by the capillaries. The lymphatic system is blind-
ended and unidirectional, and it is comprised of lymphatic vessels (lymphatic capillaries, pre-
collecting and collecting lymphatic vessels), lymph nodes and associated lymphoid organs. 
Main function of lymphatic system is recycling of extravasated fluid and macromolecules 
through collecting lymphatic vessel and thoracic and right lymphatic ducts, back to the venous 
blood circulation. Lymphatic vessels also participate in fat absorption, tissue cholesterol 
clearance and immune cell trafficking. Morphologically, in blood vasculature, larger arteries 
and veins contain three distinct layers; tunica intima which is composed of endothelial cells, 
tunica media which contains smooth muscle cells (SMCs) and elastic fibers (thicker in arteries), 
and tunica adventitia which is made of connective tissue. Smallest blood capillaries can be 
continuous, fenestrated or discontinuous, depending on the extent of basement membrane 
(BM) and pericyte coverage, which is determining capillary permeability. Both collecting 
lymphatic vessels and veins have valves which prevent backflow of blood/lymph. Mural cells 
(pericytes, SMCs and hepatic stellate cells) coverage also differs among different vessel types. 
The walls of larger caliber blood vessels contain SMCs, which are essential for vascular 
stability and tone, and blood pressure regulation. Small vessel like blood capillaries and 
venules are covered by pericytes. Pericytes make contacts with the endothelium to regulate 
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vessel stability, transendothelial transport and blood–brain barrier (BBB) formation (29) 
(Figure 2). 
 
Figure 2. Vascular organization. The circulatory system is divided into blood and lymphatic vascular networks. 
Blood vascular system is hierarchically divided into larger arteries and veins, smaller arterioles and venules and 
blood capillaries. Arteries and veins are made out of three functional layers; tunica intima (endothelium), tunica 
media (smooth muscle cells; SMCs) and tunica adventitia (connective tissue). Blood capillaries can be continuous, 
fenestrated or discontinuous, depending on the extent of basement membrane (BM) and pericyte coverage. 
Collecting lymphatic vessel contain sparse SMC coverage and luminal valves that help with pumping and prevent 
backflow of the lymph. Lymphatic capillaries have discontinuous BM and are made out of oak-leaf-shaped ECs 
with specialized button-like junctions and anchoring filaments that pull the ECs apart and allow the entry of fluid 
under conditions of high interstitial pressure [Reprinted from Potente, M. et al. 2017 (29)] 
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1.4.1. Tissue-specific vasculature 
Different organs have different functions and therefore vasculature of individual tissues 
and organs needs to adapt according to the specific environment. Endothelial cells in the brain 
establish the highly selective blood-brain barrier (BBB), which protects neurons from toxic 
molecules, immune cells and pathogens. Capillaries in the brain have continuous endothelium 
that is linked by specialized tight junctions and adherens junctions, a low rate of transcytosis, 
and the suppression of leukocyte adhesion. Since neurons rely on glucose as the major source 
of energy, ECs in the BBB preferentially express the glucose transporter GLUT1, which 
facilitates the transfer of glucose from the blood to the brain (29, 30). Organs that are involved 
in secretion, absorption and filtering, like kidney, small intestine, exocrine and endocrine 
glands, contain permeable ECs, enabling rapid exchange, uptake and secretion of fluids, solutes 
and molecules (31). Liver sinusoidal endothelial cells have even higher permeability. These 
ECs are discontinuous, lack an organized BM and have large non-diaphragmed fenestrae that 
are organized in sieve plates, allowing the passage of small particles from the blood to 
hepatocytes (31). Lung ECs are specialized for efficient gas exchange at the extremely thin 
blood–air barrier. Pulmonary capillaries make dense network through which blood flows as a 
sheet (32). ECs in bone tissue are divided in two types; type H and type L. Type H ECs have 
higher expression of CD31 (PECAM1) as compared to type L cells. Type H ECs are located at 
metaphysis and endosteum of long bones and are responsible for bone angiogenesis, giving 
rise to type L ECs, found in diaphysis of long bones (33). Contrary to most blood vessels, 
lymphatic capillaries are highly permeable given that their main function is fluid uptake. 
Lymphatic capillaries have button-like junctions and anchoring filaments, which together 
facilitate fluid uptake when interstitial pressure is high (34). 
Endothelial specialization can be instructed either by cell-intrinsic mechanisms or by 
external tissue-derived signals given by the local tissue microenvironment. Some of these 
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mechanisms involve biochemical signals, transcriptional regulation, biomechanical forces 
(flow-driven shear stress, luminal pressure, cyclic circumferential stretch, and cellular 
transmigration) and metabolic environment (29). 
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2. Cellular and molecular mechanisms of angiogenesis 
Angiogenesis is a process of formation of new blood vessels from pre-existing ones, 
and as such is the predominant way of growth of new blood vessels in adult organism. There 
are two main cellular mechanisms or types of angiogenesis; sprouting and intussusceptive 
(splitting) angiogenesis (Figure 3).  
 
 
 
 
Figure 3. Types of angiogenesis. There are two main modes of 
vessel growth by mechanism of angiogenesis; sprouting and 
intussusceptive (splitting) angiogenesis. Sprouting angiogenesis 
implies formation of a vessel sprout that will extend and form a 
lumen, while intussusception is a process of longitudinal splitting 
of the mother vessel into two new daughter vessels [Reprinted from 
Prior, B.M. et al. 2004 (35)]  
 
 
 
 
2.1. Sprouting angiogenesis 
Sprouting angiogenesis is predominant cellular mechanism of adult angiogenesis and 
it is most studied and best described (36). The process has several phases. First, endothelial 
cells are activated by angiogenic stimulus like vascular endothelial growth factor (VEGF). 
Since ECs and pericytes are joined together with a basement membrane, ECs need to be 
liberated in order to grow. Pericytes will detach from the vessel and basement membrane will 
be degraded by matrix metalloproteases. Next, one endothelial cell will be selected to become 
a tip cell, a migratory and invasive cell that is extending its filopodia, following gradient of 
VEGF in the surrounding extracellular matrix, and guiding the sprout. The neighboring ECs, 
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called stalk cells, are proliferating, creating new cells necessary to build growing vessel. Two 
tip cells will eventually come in contact, bridge the gap and fuse together. Ultimately, lumen 
of the new vessel will be formed. Process will restart with new tip cell appearing (Figure 4).  
 
Figure 4. Sprouting angiogenesis. The process of sprouting angiogenesis initiates with appearance of a tip cell, 
a specialized ECs that can sense the gradient of VEGF and guide the sprout by extending its filopodial protrusions. 
Adjacent ECs, called stalk cells, proliferate and build up a new vessel. When two tip cells meet they fuse together 
and lumen of new vessel is formed [Reprinted from Adams, R.H. et al. 2010 (37)] 
 
ECs express guidance molecules including ROBO4 (Roundabout 4), UNC5B, Plexin-
D1, Neuropilins, and Eph family members, that help guide the nascent sprout (36). ROBO4 
maintains vessel integrity and its deﬁciency induces leakages and hyper-vascularization (38). 
Molecularly, it decreases the permeability by impeding VEGF-R2-mediated activation of the 
SRC kinase. ROBO4 does not contain domains for binding of SLITs (ROBO-ligands), but it 
was shown that ROBO4 can bind UNC5B, another guidance receptor, which suggests that 
ROBO4/UNC5B complex preserves vessel integrity by UNC5B activation (36, 39). 
Expression of UNC5B, which is also a Netrin receptor, is enriched in tip cells. Both UNCB5 
and Netrin1 are associated with suppression of vessel growth, since inactivation of UNC5B 
results in enhanced sprouting while Netrin1 is causing ﬁlopodia retraction in ECs. Since this 
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function of Netrin1 has not been described by others, there is a possibility that Netrin1 might 
have other unidentiﬁed receptors (37). It was also shown that UNC5B can induce apoptosis of 
ECs, even without the ligand (40). Other class of guidance molecules involved in tip cell 
guidance are semaphorins. They are secreted or membrane-bound proteins that interact with 
receptor complexes, made solely by Neuropilins (NRPs) or by NRPs and Plexin family proteins 
(41). Semaphorin 3E (Sema3E) induces vessel repulsion through interaction with Plexin-D1, 
which is expressed by EC. This interaction fine-tunes balance between tip and stalk cells, 
especially important for control of even-growing vascular beds (42). Eph receptors and their 
ephrin ligands are another class of cell guidance molecules involved in angiogenesis. They are 
regulators of cell-contact-dependent signaling and mostly generate repulsive signals (43). It 
was demonstrated that disrupted ephrinB2 signaling impairs sprouting because ECs cannot 
internalize VEGF-R2 and VEGF-R3 and properly transmit VEGF signals (44, 45). 
Stalk cells have also very important role in angiogenic process. Compared to tip cells, 
stalk cells produce fewer ﬁlopodia, proliferate more, and form a vascular lumen. They produce 
components of basement membrane in order to insure integrity of the sprout. Stalk cells 
establish junctions with neighboring cells and make tubes and branches of nascent vessel (46). 
Both tip and stalk cells are transient ECs phenotypes and not stable cell fates. In order to expand 
vascular network, ECs undergo iterative cycles of sprouting, branching, and tubulogenesis, and 
dynamic transitions between tip and stalk cell phenotypes, are part of this process (46, 47). 
In the last phase of sprouting angiogenesis, nascent sprouts need to form a lumen. This 
happens by different mechanisms, including vacuolar fusion, cord hollowing and inverse 
membrane blebbing (29). Vacuolar fusion is the process observed in intersomitic vessels and 
includes lumen formation by coalescence of intracellular (pinocytic) vacuoles, which 
interconnect with vacuoles from neighboring ECs (36). Cord hollowing is alternative 
mechanism described in large axial vessels. It suggests that ECs adjust their shape and 
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rearrange their junctions to open up a lumen (cord hollowing). In this model, apical-basal 
polarity of endothelial cell is established. Then, apical (luminal) membrane becomes covered 
by negatively charged glycoproteins that confer a repulsive signal, opening up the lumen. 
Subsequent changes in endothelial cell shape, driven by VEGF and RHO-associated protein 
kinase (ROCK), expand the lumen (36, 48, 49). Inverse membrane blebbing is the third 
described mechanism which involves spherical deformations of the apical membrane of 
endothelial cells induced by blood flow. Endothelial cells react to these membrane intrusions 
by local and transient recruitment and contraction of actomyosin. This mechanism is required 
for single, unidirectional lumen expansion in angiogenic sprouts. This process does not require 
specific EC polarity (50). Finally, neighboring luminized sprouts anastomose (fuse together), 
either through sprout hollowing (generating a multicellular tube) or through membrane 
invagination (resulting in a unicellular tube) (51). After that, newly established blood flow 
stabilizes the vessel and non-perfused segments regress in the process of vascular pruning (52). 
2.2. Intussusceptive angiogenesis  
Intussusceptive (“growth within itself”) or splitting angiogenesis is first described in 
developing lungs of rabbits (53) and rats (54), but best studied in chicken chorioallantoic 
membrane (CAM) (55). It is an alternative mechanism of blood vessel growth that does not 
include specification of tip and stalk cells. The process of intussusceptive angiogenesis (IA) or 
intussusception is divided in four phases:  
I) In the first phase, contact between endothelial cells located directly opposite to each 
other in capillary wall, is established. This happens by intraluminal endothelial cell protrusion 
until the contact is made. The contact zone marks the area of interendothelial transluminal pillar 
bridge which is approximately 1 µm in diameter. This is the initiation step that sets the stage 
for pillar formation. 
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II) In the second phase, endothelial bilayer is perforated. Under electron microscope, 
this can be seen as appearance of tiny holes in the enlarged capillaries. 
III) After perforation, a cylindrical tissue bridge is formed and extends across the 
lumen. Pericytes and fibroblasts insert their cytoplasmic processes inside the newly formed 
pillar and extend it. At this stage, pillar size is <2.5 µm in diameter.  
IV) In the last phase, the pillars increase in girth and can potentially reshape and fuse 
with the neighboring pillars which results in splitting of the primary vessel into two new 
daughter vessels. In this phase, morphological structure of the pillar is not changing  (56, 57) 
(Figure 5). 
 
Figure 5. Intussusceptive or splitting angiogenesis. The process of intussusception is depicted by three-
dimensional scheme of morphological changes (A-D), and two-dimensional representation of cellular events (A’-
D’). The process starts when endothelial cells (EC), covered by pericytes (Pr) and basement membrane (BM) start 
protruding in the capillary lumen (A-B, A’-B’). ECs from opposite capillary walls come into contact (C, C’; 
arrows pointing to the place of contact). Endothelial bilayer is centrally perforated and the transluminal pillar is 
formed (D). The pericytes and fibroblasts (Fb) invade the pillar, deposit collagen fibrils (Co) and expand the pillar 
in girth. ECs retract, creating two daughter vessels (D’) [Adapted from Makanya, A.N. et al. 2009 (58)] 
 
Based on the final outcome, the process of intussusceptive angiogenesis can be divided 
into three major phases. All three phases are characterized by tissue pillar formation, but the 
difference is inherent in direction and arrangement of the pillars. The three phases include 
intussusceptive microvascular growth (IMG), intussusceptive arborization (IAR), and 
intussusceptive branching remodeling (IBR) (58, 59). Intussusceptive microvascular growth 
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encompasses the process of pillars formation, their growth and subsequent vessel splitting. The 
process of IMG leads to the amplification of the vascular exchange surface and vascular 
volume and formation of organ-specific angioarchitecture (59). This process was observed in 
many animal models (55, 60-63), different organs (64-66) and even in tumors (67). 
Intussusceptive arborization is the process that results in formation of a supplying vascular tree. 
The original pattern of blood vessels formed either through vasculogenesis or through 
sprouting angiogenesis has disorganized structure and does not resemble the tree-like 
arrangement of the mature vasculature. The fine adaptation of the organ vascular tree is 
achieved through IAR (58). The process of IAR was observed in two developing vascular 
systems: in the chorioallantoic membrane of the chicken and the choroid vasculature of the eye 
(62, 68). The process of intussusceptive branching remodeling results in adaptation of the 
architecture and number of vascular branches according to local tissue demands and it is 
influenced by flow properties. The IBR occurs via transluminal pillars that are formed close to 
arterial or venous bifurcation sites (58). By the means of IBR, hemodynamic conditions can be 
optimized, leading to optimal branching pattern that resembles the one predicted by Murray’s 
Law of minimal power consumption and constant shear stress (59, 62, 69). Additionally, during 
the remodeling of mature vessels by IBR, a process known as intussusceptive vascular pruning 
(IPR) also takes place. The IPR is achieved through eccentric repetitive pillar formation at 
bifurcation sites. Pillars are oriented in rows across the breadth of the target vessel. Expansion 
and subsequent fusion of pillars results in reduced blood ﬂow, consequently leading to 
regression, retraction, and atrophy of the affected vessel (58).  
Blood flow and shear stress are important factors in angiogenic process.  Blood ﬂow 
within vessels results in stress, referred to as shear stress. Shear stress can be laminar (acting 
tangentially or parallelly to the endothelial surface), or oscillatory (turbulent) (58). The role of 
hemodynamics in the control of IA was demonstrated in developing CAM microvasculature. 
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One of the dichotomous branches of an artery upstream of the investigated area was clamped 
and increase in blood ﬂow and pressure resulted in almost immediate effect on branching 
morphology. Transluminal pillars, as a hallmark of IA, began to appear 15–30 min after start 
of the clamping (62). This indicates that alterations in hemodynamics result in an immediate 
vascular adaptation without changes in gene expression. Based on the hemodynamic 
parameters obtained from in vivo experiments, computational models calculated that 
transluminal pillars are appearing in regions of low shear stress (<1 dyn/cm2). Flow simulations 
indicated that the pillars were spatially constrained by neighboring regions of higher shear 
stress (70). Generally, pillar development is caused by increased flow and it occurs in areas 
characterized by low shear and turbulent flow conditions (57, 62, 70).  
It was reported that capillary growth in muscles with increased blood ﬂow occurs 
through intraluminal splitting, without sprouting. It was demonstrated that this happens without 
endothelial cell proliferation or breakdown of the basement membrane (71). Additionally, 
VEGF signaling is necessary for shear stress-dependent splitting of capillaries in skeletal 
muscle (72). Furthermore, we found that overexpression of different VEGF doses in skeletal 
muscle induces new vascular networks by process of intussusceptive remodeling through 
endothelial cell proliferation. In skeletal muscle, this process starts with initial vascular 
enlargements, followed by longitudinal vessel splitting (73). It was also demonstrated that in 
chicken CAM model, VEGF induces growth of new blood vessel by intussusception (74, 75). 
In conclusion, both sprouting angiogenesis and intussusception are processes that are 
crucial for development of functional organ-specific vasculature, both during development and 
in adult period. They can complement each other, as it was shown that blood vessels in chick 
CAM grow initially by sprouting and then mainly by intussusception (76). Intussusception is 
much faster process in comparison to sprouting. It appears to be more economical from 
energetic and metabolic point of view, as extensive cell proliferation, basal membrane 
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degradation and invasion of the surrounding tissue are not required to that extent as for the 
sprouting angiogenesis. Also, during the IA, blood flow is continuous, in contrast to capillary 
sprouting (59). 
2.3. VEGF signaling 
Vascular endothelial growth factor (VEGF) is the master regulator of angiogenesis and 
it starts complex signaling cascade, leading to different morphological and biochemical 
changes that happen during angiogenesis. In the following text, VEGF receptors and ligands 
along with downstream signaling, will be described, as well as the role of VEGF in 
angiogenesis, especially focusing on crosstalk between VEGF and Notch signaling.  
2.3.1. VEGF ligands and receptors 
VEGF was first isolated from a conditioned medium from guinea pig tumor cell line 
and it was named “vascular permeability factor” (VPF) as it was able to induce vascular leakage 
in the skin (77). The VEGF family members are secreted, dimeric glycoproteins of molecular 
weight of around 40 kDa. The family consists of vertebrate VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, placenta growth factor (PlGF), parapoxvirus VEGF-E and snake venom VEGF-F. 
Vertebrate VEGFs are structurally similar molecules and have a crucial role in regulation of 
vascular development and function. VEGF molecules can bind three distinct receptors in 
mammals; VEGF-R1 (Fms-like tyrosine kinase 1 or Flt-1 in mouse), VEGF-R2 (kinase insert 
domain receptor or KDR in human; fetal liver kinase-1 or Flk-1 in mouse) and VEGF-R3 (Flt-
4 in mouse) (Figure 6). In zebrafish, there are four distinct genes coding for the VEGF 
receptors. Based on the chromosomal location of ﬂt-1, kdrb, and ﬂt-4 genes, which correspond 
to homologous genes in mammals, we can conclude that they are indeed the zebraﬁsh 
orthologues of human VEGF-R1, -R2, and -R3. Fourth gene, flk-1, is partially similar to both 
VEGF-R1 and -R2 and its homologue was found in chicken and opossum. It was apparently 
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eliminated during, or after the divergence of marsupial and placental mammals. Additionally, 
there are two coreceptors, Neuropilin-1 and -2 (NRP1, NRP2) (78-80). 
 
 
 
Figure 6. VEGF receptors and ligands. In vertebrates, there are five VEGF (vascular endothelial growth factor) 
ligands (VEGF-A, -B, -C, -D and Placental Growth Factor-PlGF) that bind receptors as homodimers. 
Transmembrane VEGF receptors contain seven IgG-like domains in extracellular portion, transmembrane domain 
(TMD), juxtamembrane domain (JMD), two tyrosine kinase domains (TKD), kinase insert domain (KID) and a 
C-terminal domain. There are three VEGF receptors (VEGF-R1, -R2, and -R3) which assemble as homodimers, 
but also VEGF-R1/VEGF-R2 and VEGF-R2/VEGF-R3 heterodimers are possible. There are also truncated, 
soluble forms of VEGF-R1 (sVEGF-R1) and VEGF-R2 (sVEGF-R2) [Adapted from Koch, S. et al. 2011 (81)]  
 
VEGFs have a prominent role in central nervous system (CNS) (82), as well as in 
kidney, lung and liver (78). VEGF-A is the most important family member controlling blood 
vessels angiogenesis, while VEGF-C and -D are regulating lymphangiogenesis. Genetic 
experiments demonstrated crucial role of VEGF-A (referred to as VEGF), as deletion of only 
one allele of Vegfa gene in mice leads to death in utero by E11-12 due to lack of functional 
vasculature and the absence of blood islands (8). The human Vegfa gene contains 8 exons and 
7 introns. Alternative exon splicing leads to generations of several protein isoforms, some of 
them being pro-angiogenic and some anti-angiogenic (80, 83) (Figure 7).  Generally, VEGF-
A isoforms have different heparin-binding affinity, depending on how many heparin-binding 
domains (HPD) they contain. One very important feature of VEGF is that it can form gradient 
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of concentration in extracellular matrix, as it diffuses from the source of its production, 
providing guideline for migration and invasion of tip cells during sprouting angiogenesis. 
Ability to form gradient is directly correlated with ability of the protein to bind heparin. For 
example, VEGF-A121 does not bind neither extracellular matrix (ECM), nor NRP1, whereas 
VEGF-A165 contains basic amino acid motifs in exon 8 and therefore binds to the ECM and 
forms gradients. Affinity for heparin is even stronger in VEGF-A189 and VEGF-A205, as they 
contain additional HPDs. Importance of VEGF gradient in vivo was demonstrated in mouse 
retina model, where mice expressing only VEGF-A120 (corresponds to human VEGF-A121, 
note: mouse isoforms have one amino acid less then human counterparts) had fewer branches, 
while mice expressing only VEGF-A188 had more branches (41, 84).  
 
Figure 7. VEGF-A splice isoforms. Vegfa mRNA and it exons (A). By the process of alternative splicing, 
different pro-angiogenic (B) and anti-angiogenic (C) VEGF-A isoforms can be produced [Adapted from Fearnley, 
G.W. et al 2013 (83)] 
 
VEGFRs contain extracellular domain with seven IgG-like subdomains, 
juxtamembrane domain (JMD), transmembrane domain (TMD), two tyrosine kinase domains 
(TKD), kinase insert domain (KID) and a C-terminal domain (Figure 6). VEGF binds to 
VEGFR and induces receptor homodimerization or heterodimerization, leading to 
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autophosphorylation of tyrosine residues in the receptor intracellular domains, receptor 
internalization and signaling activation, similarly to activation of other tyrosine kinase 
receptors (78). 
VEGF-R1 is widely expressed, but it seems not to be critical in endothelial cell 
physiology. It is expressed by monocytes and it is involved in the processes of immune cell 
recruitment and fatty acid uptake. It binds VEGF-A, PlGF and VEGF-B (85). Mice lacking 
VEGF-R1 do not have impairment of endothelial cell differentiation, but nevertheless have a 
disorganized vasculature and die at E8.5-9 (86-88). On the other side, deletion of the VEGF-
R1 tyrosine kinase domain is compatible with vascular development (89). Even though there 
is a tenfold excess of VEGF-R2 molecules on the surface of cultured endothelial cells, in 
comparison to VEGF-R1 (90), VEGF-R1 has higher affinity for VEGF-A (10 pM) as compared 
to VEGF-R2 (100 pM) (78, 91). Nevertheless, VEGF-R1 poorly transduces downstream VEGF 
signaling, and it is generally considered as a negative regulator of VEGF signaling in vascular 
physiology (78). VEGF-R1 exists as a full-length protein and alternatively spliced soluble 
form, sVEGF-R1 (sFlt-1) (92). Soluble Flt1 is expressed in a controlled manner during 
gestation, but its excessive expression was associated with development of preeclampsia (93). 
Other pathological conditions related with inflammation and recruitment of bone marrow-
derived myeloid cells, as well as tumor and metastasis progression, were associated with 
VEGF-R1 (85).  
VEGF-R2 is the main receptor on endothelial cells and it has a key role in angiogenesis. 
In mice, deletion of flk-1 leads to death in utero between E8.5-9.5 (7, 94). VEGF-R2 binds 
VEGF-A and processed VEGF-C and -D. VEGF-R2 can also be alternatively spliced to soluble 
VEGF-R2 (sVEGF-R2), found in different tissues such as ovary, spleen, skin, kidney, heart, 
and in plasma (85). Soluble VEGF-R2 can bind VEGF-C and prevent it from binding to VEGF-
R3, consequently inhibiting lymphatic endothelial cell proliferation (95). VEGF-R2 has also 
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been associated with pathological conditions, especially with tumor angiogenesis, and several 
small molecular weight VEGF-R2 inhibitors are being used in clinics in order to block 
pathological angiogenesis in cancer (85). 
VEGF-R3 can bind VEGF-C and -D and it is crucial for lymphangiogenesis. Generally, 
it mainly functions in lymphatic vessels, but its expression was also confirmed in capillaries 
and venous endothelium, as well as in neuronal progenitors, macrophages and osteoblasts (78). 
It was shown that its expression is re-introduced during angiogenic sprouting in retina (96). It 
was demonstrated that VEGF-C-mediated activation of AKT pathway is required for both 
embryonic and adult lymphangiogenesis (97). During embryogenesis, activation of VEGF-R3 
by VEGF-C induces migration of Prospero homeobox protein 1 (PROX1)-positive lymphatic 
progenitors from the cardinal vein, giving rise to lymphatic vessels (98). In zebrafish, SoxF 
transcription factors and transcriptional modulator MafBa, had been identified as downstream 
effectors regulating lymphatic endothelial cell migration (99).  
2.3.2. VEGF-R2 signaling complexes 
VEGF-R2 can be activated by canonical ligands (VEGFs) and non-canonical mediators 
(non-VEGF ligands and other stimuli). It is the main transducer of VEGF-A effects and it 
regulates vascular permeability, endothelial cell differentiation, proliferation, migration, and 
formation of the vascular tube (78, 85). VEGF-R2 signaling can involve multiprotein 
complexes composed of ligands, receptors, co-receptors and several other non-VEGF binding 
auxiliary proteins (78) (Figure 8).  
 Binding of VEGF dimer to receptor induces its dimerization and stabilization. It was 
shown that IgG-like subdomain 7 is involved in homotypic receptor interactions (79, 100). 
Besides VEGF-R2 homodimers, dimerization can also occur through VEGF-R2/VEGF-R3 
(101) and VEGF-R1/VEGF-R2 heterodimers. Ligand binding induces change of configuration 
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of the transmembrane domains, which is accompanied by rotation of the dimers. This rotation 
is critical for full activation of kinase activity (78). 
VEGF co-receptors, Neuropilin-1, Neuropilin-2 (NRP-1 and -2) and heparan sulfate 
proteoglycans (HSPGs), have important role in modulation of VEGF-R2 signaling. They act 
as stabilizers of ligand-receptor interactions and in that way, make signaling stronger (78), 
especially in case of HSPGs (102). NRP-1 and NRP-2 are transmembrane glycoproteins that 
bind both to VEGFs as well as to class 3 semaphorins, which are axonal guidance molecules 
that can bind Plexin receptors (103, 104). We recently demonstrated that Sema3A, a member 
of class 3 semaphorin family, is a mediator of vessel stabilization modulated by VEGF dose 
(105). VEGF-A binds NRP-1 and NRP-2 through specific motifs in exon 7 and 8, and it has 
50-fold higher affinity for NRP-1 as compared to NRP-2  (106). Mice lacking NRP-1 die in 
utero due to severe cardiovascular and CNS defects (107, 108). Interestingly, when Nrp1 has 
a mutation in VEGF-A-binding site (Tyr297 or Ser320), vascular development is not affected, 
suggesting it functions independently of VEGF binding (109, 110). Even though it was 
demonstrated that VEGF binds to NRPs and VEGFRs and induces formation of NRP-VEGFR 
complexes (110, 111), configuration of such NRP-1-VEGF-A-VEGF-R2 complex is not 
known. Potentially, this interaction can be directly or indirectly mediated by HSPGs like 
syndecan and glypican. NRP-1 can also bind PDZ-domain-containing protein synectin (also 
known as GIPC1) with its C-terminal PDZ-binding domain, and regulate VEGF-R2 
intracellular trafficking by a VEGF-R2-NRP-1-synectin-myoVI complex (78) (Figure 8).  
Besides in cis binding, NRP-1 can also bind in trans, between adjacent cells. In that case, NRP-
1-VEGF-A–VEGF-R2 complex keeps the receptor on the cell surface and inhibits 
angiogenesis (112) (Figure 8). 
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Figure 8. VEGF-R2 signaling complexes. Upon VEGF binding, VEGF-R2 dimerizes, either as a homodimer or 
a heterodimer with VEGF-R1 or VEGF-R3. VEGF-R2 can bind ephrinB2 in cis, enhancing the receptor 
internalization. Complex of VEGF-R2 with integrins (integrin-β1 and integrin-αVβ3) can also enhance 
downstream signaling. In arterial endothelium, VEGF-R2 can make a complex with Neuropilin (NRP) co-
receptors and heparan sulfate (HS) proteoglycans like syndecan and glypican. This complex involves synectin 
and myosin VI (myoVI). In tumors, VEGF-R2 can bind Neuropilins in trans. In endothelial junctions, VEGF-R2 
can make a complex with vascular endothelial cadherin (VE-cadherin) and phosphatases DEP1 (density-enhanced 
phosphatase 1) and VEPTP (vascular endothelial protein tyrosine phosphatase) [Adapted from Simons, M. et al. 
2016 (78)] 
 
Other important partners in VEGF-R2 signaling complexes are integrins, particularly 
integrin-β1 and integrin-β3. The sequence motif involved in this interaction still needs to be 
clarified. VEGF-A induces VEGF-R2–integrin-β3 association, resulting in integrin-β3 tyrosine 
phosphorylation (113). This interaction is required for complete VEGF-R2 activation (114), 
and can involve other partners such as syndecan 1 and SRC. ECM-binding VEGF-A isoforms 
promote VEGF-R2–integrin-β1 complex formation. This directs VEGF-R2 localization to 
focal adhesions, which is accompanied by prolonged receptor activation (115) (Figure 8). 
Tetraspanin CD63 is another member of the VEGF-R2–integrin-β1 complex, and loss of CD63 
expression impairs VEGF-R2 signaling (116). 
EphrinB2, a member of a family of axon guidance molecules, is involved in VEGFR 
trafficking. Deletion of ephrinB2, which interacts with both VEGF-R2 and VEGF-R3, leads to 
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a complete lack of VEGF-R2 endocytosis in blood vascular endothelial cells after stimulation 
with VEGF-A (44). Same effect is observed for VEGF-R3 uptake after stimulation with VEGF-
C in lymphatic endothelial cells (45).  EphrinB2 deletion is consequently leading to disruption 
of both postnatal angiogenesis and lymphangiogenesis. Molecularly, ephrinB2 regulates 
VEGF-R2 endocytosis through interaction with disabled homologue 2 (DAB2) and the cell 
polarity regulator partitioning defective 3 homologue (PAR3) (117). This complex favors 
internalization of the VEGF-R2 in RAB5+EEA1+ endosomes, enhancing VEGF signaling 
(Figure 9). The details about ephrin/Eph signaling will be discussed in next chapters. 
 
Figure 9. VEGF-R2 receptor endocytosis. VEGF-R2 internalization is modulating downstream signaling 
activation. When VEGF-R2 is associated with VE-cadherin-VEPTP (vascular endothelial protein tyrosine 
phosphatase) -DEP1 (density-enhanced phosphatase 1) complex at endothelial cell junctions, the receptor is 
dephosphorylated and inactive. Neuropilin-1 (NRP-1) can bind VEGF-R2 in trans and prevent its internalization, 
favoring activation of ERK2 and PLCγ over other signaling molecules. When NRP-1 binds VEGF-R2 in cis, 
receptor is internalized and trafficked to RAB5+ EEA1+ (early endosome antigen 1) endosomes by a NRP-1–
synectin–myoVI complex. VEGF-R2 may also be constitutively recycled via RAB4 endosomes independently of 
ligand binding. EphrinB2 can form a complex with VEGF-R2 together with DAB2 (disabled homologue 2) and 
PAR3 (partitioning defective 3 homologue), which enhance receptor internalization and downstream signaling. 
Signaling continues within endosomes until p-Tyr1173 (pY1173) in VEGF-R2 is dephosphorylated by PTP1B 
(protein tyrosine phosphatase 1B). After that, VEGF-R2 can be degraded by shuttling to RAB7 endosome or it 
can be recycled to the cell surface by RAB11 endosomes [Adapted from Simons, M. et al. 2016 (78)]  
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VE-cadherin is another VEGF-R2-interacting protein that controls its endocytosis. 
Interactions between these two molecules occur at cell-cell junctions (118). VE-cadherin keeps 
VEGF-R2 inactive by recruitment of VEPTP and DEP1 phosphatases (Figure 8, Figure 9). 
Deletion of Cdh5 gene, coding for VE-cadherin, leads to enhanced VEGF-R2 endocytosis and 
activation of ERK signaling (78, 119). 
Epsins, membrane proteins involved in regulation of membrane curvature, have also 
been reported to affect VEGF-R2 and VEGF-R3 endocytosis. Specific deletion of both epsins 
in endothelium, leads to enhanced VEGF-R2 signaling and excessive non-productive 
angiogenesis (78, 120). 
Besides VEGFs, non-canonical ligands and stimuli can also activate VEGF-R2. Some 
non-VEGF ligands include β-galactoside-binding proteins, called galectins (121), lactate, low-
density lipoproteins (122-124), bone morphogenetic protein (BMP) antagonist gremlin 
(GREM1) (125) and mechanical forces, such as shear stress (126, 127). Fluid shear stress can 
induce phosphorylation of VEGF-R2 through formation of mechanosensory complex that 
includes, in addition to VEGF-R2, platelet endothelial cell adhesion molecule 1 (PECAM1, 
also called CD31) and VE‑cadherin (81, 127). Alternatively, purinergic receptor P2Y2 and G 
proteins Gq and G11 (Gq/G11) have also been implicated in fluid shear stress-induced 
endothelial responses by activation of SRC, AKT, endothelial nitric oxide synthase (eNOS) 
and phosphorylation of PECAM1 and VEGF-R2 (128). 
2.3.3. Downstream VEGF-R2 signaling 
After stimulation of VEGF-R2 either by canonical or non-canonical activators, VEGF-
R2 is auto-phosphorylated, internalized and further downstream signaling leads to expression 
of specific genes which regulate angiogenesis (Figure 10). There are three main intracellular 
signaling pathways downstream of VEGF-R2. First one involves phospholipase Cγ (PLCγ)–
ERK1/2 pathway. This signaling branch controls cell proliferation and has a central role during 
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vascular development and in adult arteriogenesis. Second one is the PI3K–AKT–mTOR 
pathway, controlling cell survival, vasomotion and barrier function. The third pathway involves 
SRC and small GTPases and it regulates cell migration, polarization, cell shape, endothelial 
junctions and barrier function. Other pathways involving stress kinases like p38 MAPK, 
STATs and G protein-coupled receptor (GPCR)-dependent signaling, are poorly understood 
(78). 
 
Figure 10. VEGF-R2 downstream signaling. Binding of VEGF to VEGF-R2 induces phosphorylation of several 
tyrosines (marked with numbers) in the receptor. Phosphorylated Y1175 (Y1173 in mouse) is a docking site for 
PLCγ and adapter proteins SHB (SH2-domain-containing adaptor protein B), SCK [SHC (SRC homology and 
collagen homology)-transforming protein] and GRB2 (Growth factor receptor-bound protein 2) which then 
recruits nucleotide-exchange factor SOS (Son of sevenless). MAPK pathway (RAF-MEK-ERK), regulating 
proliferation, is activated through Ca2+-dependent protein kinase C (PKC), protein kinase D (PKD) and 
sphingosine kinase (SPK). PKD activation promotes nuclear translocation of HDAC (histone deacetylase) 
followed by phosphorylation of CREB (cAMP-response-element-binding protein) as well as HSP27 (heat-shock 
protein 27). VEGF-induced RAS activation leads to production of prostaglandins like PGI2 (prostaglandin I2) via 
cPLA2 (cytoplasmic phospholipase A2). Phosphorylated Y951 is a binding site for SH2-domain-containing TSAd 
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(T-cell-speciﬁc adapter molecule) which forms a complex with SRC and regulates cell permeability together with 
VE-cadherin. Phosphorylated Y1214 is a docking site for NCK–FYN complex which mediates phosphorylation 
of PAK2 (p21-activated protein kinase 2) and activation of CDC42 (cell division cycle 42) and p38MAPK, 
ultimately regulating cell migration. The docking protein GAB1 (GRB2-binding protein 1) contains a binding site 
for the p85 subunit of PI3K which activates AKT, also known as PKB (protein kinase B) through PDK1 
(phosphoinositide-dependent kinase 1) and PDK2. AKT phosphorylates BAD [Bcl (B-cell lymphoma)-2-
associated death promoter] and caspase 9 and inhibits apoptosis together with anti-apoptotic proteins Bcl-2, A1 
and IAP (inhibitor of apoptosis) [Adapted from Koch, S. et al. 2011 (81)] 
PLCγ–ERK1/2 pathway 
ERK1/2 signaling induced by VEGF is crucial in endothelial cell biology since it 
controls endothelial cell proliferation, migration, arterial fate specification and homeostasis. 
The pathway activation cascade initiates by phosphorylation of Y1173 in VEGF-R2 in mice 
(Y1175 in the human protein). Phosphorylated Y1173 is the docking site for PLCγ. Mutation 
of tyrosine 1173 to phenylalanine is lethal and phenocopies Vegfr2 gene inactivation (129, 
130). Upon binding, PLCγ is activated and through its enzymatic activity generates inositol 
1,4,5- trisphosphate (IP3) and diacylglycerol (DAG). IP3 induces release of Ca2+ from the 
endoplasmic reticulum, which together with DAG activates Ca2+-dependent protein kinase Cβ2 
(PKCβ2), which then regulates the RAF1–MEK–ERK1/2 cascade. Phosphorylation of the 
activating Ser338 and de-phosphorylation of the inhibitory Ser259 site are required for RAF1 
activation. Many kinases are controlling this process so this is the point of interaction with 
other signaling like PI3K–AKT and LATS–Hippo (78). VEGF-R2 signaling bypasses the more 
common RTK-induced RAS activation of the RAF1–MEK–ERK1/2 cascade (78, 131). Still, 
it was reported that VEGF can induce activation of RAS in cultured cells (132). Knockdown 
of PLCγ in zebrafish leads to a complete loss of VEGF-induced ERK1/2 activation (133), but 
deletion of Prkcb in mice, encoding both PKCβ1 and PKCβ2 isoforms, did not induce any 
vascular malformations (134). This suggests that PKCβ-RAF1–MEK–ERK1/2 pathway can be 
either compensated by other PKCs or there is alternative non-PKCβ- dependent pathways for 
activation of VEGF-induced ERK1/2 activation (78). The pY1173 is also a docking site for 
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adapters SH2 domain-containing adapter protein B (SHB) and SHC-transforming protein 2 
(SHC2; also known as SCK). The PLCγ–PKC pathway activates E26 transformation-specific 
(ETS) family of transcription factors (135) and mediates phosphorylation of histone 
deacetylase 7 (HDAC7) (136), both of which are regulating many genes involved in endothelial 
cell physiology. Fibroblast growth factor (FGF) and VEGF signaling are probably connected 
through ERK1/2 pathway. FGF can upregulate Vegfr2 expression through ERK1/2 dependent 
pathway. Additionally, VEGF inhibition is blocking FGF-driven angiogenesis, suggesting that 
FGF controls angiogenesis upstream of VEGF (78).  
PI3K-AKT-mTOR pathway 
Phosphoinositide 3 kinase (PI3K) is not activated directly by VEGF-R2 since VEGF-
R2 does not contain a binding site for the SH2-domain-containing p85 subunit of PI3K, but 
indirectly, either by SRC, VE-cadherin (137) or by AXL (138). Activated PI3K phosphorylates 
phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3), a second messenger that binds to plextrin homology (PH) domain of AKT family of 
serine/threonine kinases. AKT kinases are regulating cell survival, proliferation and apoptosis 
(139). The AKT family consists of three members (AKT1-3), with AKT1 being the 
predominant isoform which regulates both pathological and adult angiogenesis, as well as 
vascular maturation and metabolism, through activation of the mTOR complex 2 (140). It was 
demonstrated that p110α catalytic subunit of PI3K is necessary for normal vascular 
development as embryos with kinase dead p110α subunit develop vascular defects that are 
caused by the reduction in small GTPases activation and suppression of endothelial migration 
(141). In endothelial cells, small GTPases RHO, CDC42 and RAC1 are responsible for 
regulation of cell morphology, adhesion, migration, junctional integrity and cytoskeletal 
organization (78). 
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SRC pathway  
The SRC proteins are a family of cytoplasmic tyrosine kinases and the members found 
in endothelium are SRC, YES and FYN. Activation of the SRC pathway is controlled by 
phosphorylation of Y949 (in the mouse protein; Y951 in the human protein) in the receptor 
kinase insert of VEGF-R2, which is a docking site for SH2 domain of T cell- specific adapter 
(TSAd), which in turn binds to the SH3 domain of SRC. SRC pathway is controlling 
cytoskeleton remodeling, such as actin and cell–cell adhesion components, vascular 
permeability and leakage, as well as the cell-matrix adhesion process (78). SRC signaling can 
be activated by shear stress (142). SRC can phosphorylate focal adhesion kinase (FAK) and in 
that way, regulate cell shape and adhesion (143). Furthermore, SRC regulates endothelial 
adherens junctions by phosphorylating VE-cadherin in response to VEGF, leading to increased 
vascular permeability (78). 
2.4. Notch signaling 
Besides VEGF, Notch signaling also has a critical role in vascular system. Notch 
pathway is evolutionary highly conserved and it is controlling many different biological 
processes. Mutation in genes involved in Notch pathway have been associated with several 
disorders like T-cell acute lymhoblastic leukemia, Alagille syndrome (developmental 
abnormalities affecting many tissues), spondylocostal dysostosis (vertebral development 
disorder), CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) syndrome and some congenital heart defects like tetralogy of Fallot and 
aortic valve disease (144). All disorders are characterized by dysregulation of cell proliferation 
and differentiation, but it is important to note that the outcome of Notch signaling is context 
dependent so it can promote tissue growth and cancer progression in some cases, while in the 
other situations it can induce cell death and tumor suppression (145). 
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2.4.1. Notch receptors and ligands 
 In mammals, Notch receptor family consist of four type I transmembrane receptors 
(Notch1-4) that regulate cell fate through cell-cell interactions. There are five Notch ligands: 
Jagged1 (Serrate1), Jagged2 (Serrate2), Delta-like1 (Dll1), Delta-like3 (Dll3), and Delta-like4 
(Dll4), collectively referred to as the DSL (Delta/Serrate/Lag-2) family (Figure 11). 
Notch receptors are translated as large precursor proteins (~300 kDa) which are cleaved 
in trans-Golgi network by furin at S1 cleavage site producing extracellular fragment (NotchEC) 
and an extracellular-transmembrane-intracellular fragment (NotchTM) that is expressed on the 
cell surface as a noncovalently linked heterodimer stabilized by a Ca2+ ions (Figure 13). 
Extracellular domain (ECD) of mature Notch receptors contains 29–36 multiple epidermal 
growth factor (EGF)-like repeats and 3 lin-12/Notch (LNR) motifs. EGF-like repeats are 
involved in ligand binding, while LNR motifs are preventing activation of receptor in the 
absence of a ligand (146) (Figure 11). 
Figure 11. Notch ligands and 
receptors. In mammals, there are 
four Notch receptors (Notch1-4) and 
five ligands (Jagged1, Jagged2, Dll1, 
Dll3 and Dll4). Notch receptors are 
expressed on the cell surface as 
heterodimers stabilized by calcium 
ions. Extracellular domain of human 
Notch receptors contains 29–36 
epidermal growth factor (EGF)-like 
repeats, 3 Lin- 12/Notch (LNR) 
repeats, and a heterodimerization domain. The intracellular domain contains an RBP-Jκ-associated molecule 
(RAM) domain, 7 ankyrin (ANK) repeats, 2 nuclear localization signals (NLS), a transactivation (TAD) domain, 
and a PEST domain. The extracellular domain of Notch ligands contains unique a Delta/Serrate/Lag2 (DSL) 
domain and 7-16 EGF repeats. Jagged1 and Jagged2 also contain a cysteine-rich domain and a von Willebrand 
factor type C domain. PDZ (PSD-95/Dlg/ZO-1) domain is found in Jagged1 and Dll1, and it plays a role in 
downstream signaling [Reprinted from Niessen, K. et al. 2007 (146)]  
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Glycosylation in EGF repeats in ECD domain is profoundly affecting receptor 
activation by the ligands. Modifications include O-fucosylation, O-glucosylation, and O-
GlcNAcylation. This process is controlled by several glycosyltransferases like POFUT1 
(Protein O-fucosyltransferase 1), POGLUT1 (Protein O-glucosyltransferase 1), and EOGT1 
[(Epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (GlcNAc) 
transferase 1)]. Xylosyltransferases GXYLT1/2 (Glucoside xylosyltransferase 1) and 
XXYLT1 (Xyloside Xylosyltransferase 1) can further modify O-glucose, while Fringe family 
of GlcNAc-transferases modifies O-Fucose. Interestingly, modiﬁcations at EGF6 and 36 in 
Notch1 ECD (added by Manic and Lunatic, but not Radical Fringe) speciﬁcally inhibited 
Notch1 activation by Jagged1, clearly depicting importance of glycosylation in modulation of 
Notch signaling (147). 
The intracellular domain (ICD) of Notch receptors contains a RAM [recombination 
signal binding protein-1 for Jκ (RBP-Jκ)-associated molecule] domain, 7 cdc10/ankyrin repeats 
(only six C-terminal repeats assume proper ankyrin fold), and a transactivation domain (TAD), 
which is not present in Notch4 receptor. Additionally, there are two nuclear localization 
signals, glutamine-rich stretch and a PEST [rich in proline (P), glutamic acid (E), serine (S) 
and threonine (T) residues] domain (146). The RAM domain and ankyrin repeats are 
interacting with the transcription factor CSL, also known as RBP-Jκ in mouse or CBF1 in 
human [CSL: C promoter binding factor-1 (CBF1), suppressor of hairless, Lag-1; RBP-Jκ: 
Recombination Binding Protein for immunoglobulin kappa J region; CBF-1: C-repeat/DRE 
Binding Factor 1]. Additionally, the seventh ankyrin repeat together with TAD domain recruit 
transcriptional activators such as mastermind-like (MAML) and the histone acetyltransferase 
(HAT) complex. The PEST domain regulates protein half-life of the Notch receptors (146) 
(Figure 11).  
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Notch ligands are also type I transmembrane proteins, with an extracellular domain 
comprised of 7–16 EGF-like repeats and a DSL domain, which is unique to Notch ligands. 
Jagged1 and Jagged2 have additional cysteine-rich domain and a von Willebrand factor type C 
domain in the extracellular region. The EGF-like repeats probably stabilize receptor-ligand 
complex while the DSL domain interacts with EGF-like repeats 11 and 12 of the Notch 
receptors and is responsible for Notch receptor activation. The cysteine-rich domains of Jagged 
ligands are thought to control Notch receptor binding speciﬁcity, while the von Willebrand 
factor type C domain regulates ligand dimerization. DSL ligands have short intracellular 
regions that contain PDZ domain (absent in Dll3), which is believed to activate downstream 
signaling (146) (Figure 11). Notch receptors and ligands can interact in cis (in the same cell) 
and in trans (different cells). In trans ligand-receptor binding will activate receptor, while in 
cis interaction will lead to inhibition of signaling (148). Dll3 does not bind Notch receptor in 
trans, and does not activate Notch signaling (149), so the role of Dll3 in Notch signaling still 
needs to be clarified (148). 
Besides canonical ligands, Notch signaling can also be regulated by non-canonical 
ligands, which can have both inhibitory or activating role. So far, several non-canonical Notch 
ligands have been identified and the members found in vertebrates will be shortly described. 
They can be divided into three groups: transmembrane, glycosylphosphatidylinositol (GPI)-
linked and secreted (Figure 12). Transmembrane ligands include Dlk-1 (Delta-like 1), Dlk-2 
(Delta-like 2)/EGFL9 (Epidermal growth factor-like protein 9), DNER (Delta/Notch-like EGF-
related receptor) and Jedi (Jagged and Delta protein). Dlk-1 and Dlk-2 can antagonize Jagged-
1-induced Notch activation (150, 151). DNER can bind Notch receptor in trans and activate 
CSL reporter (152). Jedi has very weak inhibitory effect on Notch signaling and its role as a 
non-canonical Notch ligand has been poorly investigated (148). Other two members are 
F3/contactin1 and NB3/contactin6, GPI-linked neural cell adhesion molecules that can induce 
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oligodendrocyte differentiation by activation of Notch signaling (153, 154). However, it has 
not been demonstrated that they can induce CSL-dependent activation of Notch downstream 
target genes (148). Secreted non-canonical Notch ligands are CCN3 (connective tissue growth 
factor/ cysteine-rich 61/nephroblastoma overexpressed gene), MAGP-1 (microfibril-
associated glycoprotein-1), MAGP-2, thrombospondin 2 (TSP2), YB1 (Y-box protein-1) and 
EGFL7 (EGF-like domain-containing protein 7). CCN3, MAGP-1, MAGP-2, TSP-2 and YB1 
were described as activators of Notch signaling (148, 155-157), while EGFL7 inhibits Notch 
signaling and reduces neural stem cell renewal and proliferation (158). EGFL7 is expressed by 
endothelial cells during active angiogenesis (159). 
 
Figure 12. Non-canonical Notch ligands. 
Non-canonical Notch ligands in vertebrates 
are structurally diverse and lack a DSL 
(Delta/Serrate/LAG-2) domain. They can be 
divided into three groups: integral-membrane 
bound, GPI (glycosylphosphatidylinositol)-
linked and secreted. Integral members (Dlk-
1, -2, DNER, Jedi) contain EGF-like 
domains, either the one with 6 cysteines (6-
cysteine epidermal growth factor-like 
repeat), found in canonical ligands or the one 
with 8 cysteines (EGF-like motif with 8 
cysteines that is not laminin-like), 
transmembrane domain (TM) and emilin-like 
domain (EMI). GPI -linked members (F3, 
NB3) contain immunoglobulin-containing 
cell adhesion molecule domain (IgCAM) and 
fibronectin type III domain (FNIII). Secreted 
members are structurally very diverse. CCN3/NOV contains insulin-like growth factor-binding protein-like 
domain (IGFBP), von Willebrand factor type C-like domain (VWF-C), thrombospondin type 1-like domain (TSP-
1) and Notch receptor binding C-terminal cysteine knot domain (CTCK). MAGP-1 and MAGP-2 contain matrix 
binding domain (MBD) which binds Notch receptor, and either glutamine-rich region (Q) or integrin- binding 
motif (RGD). TSP-2 additionally contains N-terminal domain (NT), calcium-binding wire and lectin-like domain. 
YB-1 has specific cold shock domain (CSD), while EGFL7 contains EGF-like repeats and EMI domain, which 
are both Notch receptor binding regions [Adapted from D’Souza, B. et al. 2010 (148)].  
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2.4.2. Downstream Notch signaling  
After binding of the ligand, Notch receptor is enzymatically cleaved at three sites. First, 
extracellular domain is cleaved by ADAM10 (A disintegrin and metalloprotease 10) or 
ADAM17/TACE (tumor necrosis factor-α converting enzyme) at the S2 cleavage site. Next 
two intramembranous cleavage steps, at S4 (between Ala1731-Ala1732 in mouse Notch1) and 
S3 site (Val1744 in mouse Notch1), are processed by γ-secretase which is a 170 kDa integral 
membrane protein complex composed of four proteins. Presenilin (Presenilin1 or Presenilin2) 
provides catalytic domain to the complex, Pen-2 is required for the maturation of the Presenilin, 
Aph-1 (Aph-1a or Aph-1b) helps in γ-secretase complex assembly, while Nicastrin stabilizes 
the complex, and is potentially involved in substrate recognition. After two cleavage steps, 
Notch intracellular domain (NICD) is released, and subsequently translocates in the nucleus 
mediating gene expression (Figure 13). Endocytosis of ligand-receptor complex into ligand-
bearing cell via clathrin-dependent vesicles, seems to play a crucial role in activation of the 
Notch cleavage, as it generates mechanical forces that trigger enzymatic cleavage (147, 160). 
It was demonstrated that ubiquitinoylation by E3 ubiquitin ligases Mindbomb and Neuralized, 
and subsequent endocytosis of the ligand is a prerequisite to render the ligand active (144, 148, 
161). 
CSL transcription factor is the main effector of Notch signaling pathway. In non-
activated state, it binds to one of two repressor complexes; SMRT/NcoR/HDAC-1 (SMRT: 
silencing mediator of retinoid and thyroid hormone receptors, NcoR: nuclear receptor 
corepressor, HDAC-1: histone deacetylase-1) or CIR/HDAC2/SAP30 (CIR: CBF1 interacting 
corepressor, HDAC-2: histone deacetylase-2, SAP30: Sin3A-associated protein, 30 kDa). 
When NICD translocates to the nucleus it binds to CSL. The mechanism of activation is not 
completely elucidated, but it was shown that NICD complex includes Ski interacting protein 
(SKIP), a protein that can interact with CSL, Notch, or SMRT, but promotes NICD-CSL 
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interactions over CSL-SMRT interaction. Additionally, the coactivator MAML can bind to 
transcription machinery, help in displacement of co-repressor complex and enhance gene 
expression. MAML binds only NICD-CSL complex but does not bind either NICD or CSL 
independently. Hairy and enhancer of split-related (HESR) genes, which encode basic helix-
loop-helix (bHLH) transcriptional repressors, are key genes activated by Notch signaling. Two 
most important families in this group of genes are Hes (hairy enhancer of split) and Hey 
(hairy/enhancer of split-related with YRPW motif), also called CHF or Hrt. Other activated 
gens are cyclinD1, p21, glial ﬁbrillary acidic protein (GFAP), Nodal, Myc, PTEN, ephrinB2, 
and smooth muscle α-actin (SMA) (146, 162).   
Figure 13. Notch processing and 
downstream signaling. Full length Notch 
receptor protein is glycosylated and 
subsequently cleaved in Golgi at S1 site by 
PC5/furin, further glycosylated by 
glycosyltransferase Fringe and then 
translocated to the cell surface as a functional 
heterodimer receptor stabilized by 
noncovalent interactions. Upon ligand 
binding, receptor is cleaved at S2 site by 
ADAM metalloproteases generating the 
membrane-anchored Notch extracellular 
truncation (NEXT) fragment, a substrate for 
the γ-secretase complex which further cleaves 
at S4 and S3 sites. This generates Notch 
intracellular domain (NICD) and Nβ peptide. 
γ-Secretase cleavage can occur both at the cell 
surface and in endosomal compartments, but 
cleavage in the endosome results in a less 
stable form of NICD (NICD*). NICD then 
enters the nucleus where it associates with the DNA-binding protein CSL (CBF1/Su(H)/Lag-1). In the absence of 
NICD, CSL can associate with ubiquitous corepressor (Co-R) proteins and histone deacetylases (HDACs) and 
repress gene transcription. Upon NICD binding, allosteric changes may occur in CSL facilitating displacement of 
transcriptional repressors. Subsequently, transcriptional coactivator Mastermind (MAM) binds NICD/CSL 
complex, further association of coactivators (Co-A) proceeds and transcription is activated [Reprinted from 
Kopan, R. et al. 2009. (163)] 
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The NICD is phosphorylated in the PEST domain by the cyclin C/cyclin-dependent 
kinase-8 (Cyc:CDK8) complex and glycogen synthase kinase 3β (GSK-3β). NICD 
phosphorylation is followed by ubiquitylation by E3 ubiquitin ligase Fbxw7 (F-box and WD-
40 domain protein 7) also known as CDC4 and SEL10, leading to the its rapid proteasomal 
degradation and termination of downstream signaling (162, 164). 
2.4.3. Notch signaling in the vascular system 
Notch signaling is regulating vasculogenesis, angiogenesis and arterio-venous 
specification. At embryonic day 9.5 (E9.5) Notch1, Notch4 and Dll4 are expressed in primitive 
vascular plexus. At E13.5 Notch1, Notch2, Notch4, Dll4, Jagged1 and Jagged2 are mainly 
expressed by the arteries, while Notch1 and Dll4 can also be found in capillaries (146). 
Notch signaling is regulating arterio-venous specification by promoting arterial, while 
suppressing venous phenotype. The arterio-venous specification begins even before the start 
of the circulation and differential gens expression is crucial for this process. Both VEGF and 
Notch signaling were shown to positively regulate expression of arterial marker ephrinB2 (165-
169). VEGF initially upregulates Dll4, one of the main arterial markers (170), but later, Notch 
activity is maintaining Dll4 expression through RBPJ and SoxF transcription factors (171). In 
venous endothelium, COUP-TFII (chicken ovalbumin upstream promoter transcription factor 
II), a nuclear orphan receptor transcription factor, suppresses arterial phenotype by suppressing 
Notch activity, NRP-1 expression and MAPK signaling. Downregulation of Notch signaling 
leads to reduced expression of ephrinB2 and upregulation of EphB4 (168, 172).  
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Table 1. Mutants of Notch pathway components and their phenotype 
Mouse model Survival Vascular defects 
Notch1-null Embryonic lethal before E10.5 
- Defective remodeling of vascular plexus 
- Highly disorganized intersomitic vessels 
- Dorsal aorta and cardinal vein reduced in 
size (173)  
Notch2-null Embryonic lethal at E11.5 
- Several cardiovascular and renal defects 
(174, 175) 
Notch3-null Mice are viable 
- Some arteries are covered with thinner 
smooth muscle cell coating (176, 177)  
Notch4-null Mice are viable 
- No vascular defects 
- Slightly elevated systolic blood pressure 
after induction of ischemia (178, 179) 
Jagged1-null Embryonic lethal at E11.5 
- Defective remodeling of vascular plexus 
- Hemorrhage early during embryogenesis 
(180) 
Jagged2-null Mice die perinatally 
- No vascular defects 
- Defects in craniofacial morphogenesis 
- Syndactyly (181)  
Dll1-null Embryonic lethal at E12 - Severe hemorrhages (182) 
Dll3-null Mice are viable 
- No vascular defects 
- Severe vertebral and rib deformities (183) 
Dll4-
haploinsufficiency 
Embryonic lethal 
- Defective remodeling of vascular plexus 
- Severe defects of arterial vasculature (184) 
 
Some disorders in human, which affect vascular system, are associated with mutations 
in some of the components of Notch pathway. CADASIL (Cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy) is a disorder characterized by 
the defect in arterial vascular homeostasis, migraine headaches and mood disturbances (185). 
Missense point mutations in Notch3 gene, expressed mostly in smooth muscle cells, that result 
in an odd number of cysteine residues in the EGF repeat regions, are found in 95% of 
CADASIL cases. This disorder is characterized by loss of arterial vascular smooth muscle cells 
and increased vascular ﬁbrosis, leading to narrowing of the lumen of small and medium 
arteries. Mutations in the Notch1 locus have been associated with different heart defects like 
bicuspid aortic valve disease and calciﬁcation of the aortic valve (186). Mutations in the 
Jagged1 locus are found in 94% of patients with Alagille syndrome (AGS), a disorder 
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associated with abnormalities of the intrahepatic bile ducts, kidney, heart, eyes and the 
skeleton.  Most common cardiovascular defect in patients with AGS is peripheral pulmonic 
stenosis. Furthermore, 13% of AGS patients have Tetralogy of Fallot (187, 188). Jagged1-
independent AGS can also be caused by mutation in Notch2 locus (146, 189). 
Notch4 or int-3 was first identified for its oncogenic effects in MMTV (mouse 
mammary tumor virus)-induced mammary gland tumors, as int-3 locus is a frequent target for 
insertional activation by MMTV proviral DNA (190). It is interesting that Notch1/Notch4 
double deficient mice have more severe vascular phenotype, as compared to Notch1-deficient 
mice. This suggests that loss of Notch4 can somehow worsen the phenotype of Notch-1 null 
mice (178), even though Notch4-deficient mice show no apparent vascular phenotype and are 
viable (178). Notch4 is mostly produced by endothelial cells, but its role in the vasculature is 
still not completely clear (190). Polymorphisms in Notch4 gene are associated with 
development of brain arterio-venous malformations and hemorrhagic presentations (191). 
Constitutively active Notch4 signaling induces arterio-venous malformations (AVM) (192-
196) accompanied with lack of small branched vessels and vessel integrity (197). During the 
process of AVM development, expression of EphB4 is markedly reduced, but restored during 
the AVM normalization, as the process of normalization is accompanied by venous phenotype 
restoration (195). Some groups demonstrated that Notch4 can be activated by canonical Notch 
ligands (198, 199), but others reported that Notch4, unlike Notch1, cannot be activated by the 
ligands (200, 201).  Additionally, it was shown that Notch4 can even dose-dependently inhibit 
ligand-induced Notch1 signal activation in cultured cells (201). The role of Notch4 in the 
angiogenic process remains to be elucidated.  
2.4.4. Notch signaling in sprouting angiogenesis 
VEGF is activating endothelial cell and starting the complex signaling cascade. In 
sprouting angiogenesis, specification of tip and stalk cell, as an initial step in this process, is 
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regulated by Notch signaling (36, 46, 47). Notch ligand Dll4 is expressed at high levels in tip 
cells. VEGF activates VEGF-R2 and upregulates expression of Dll4 in all cells, but some of 
them will express it faster or at higher levels and get an advantage to become tip cell. Repressor 
complex TEL/CtBP at the Dll4 promoter can be transiently disassembled upon VEGF 
stimulation, allowing fast pulse of Dll4 expression, allowing fast specification into tip cell 
(202). Dll4 will activate Notch1 in neighboring endothelial cells, which then become stalk 
cells, by downregulating VEGF-R2, VEGF-R3 and NRP-1, while upregulating VEGF-R1 (46, 
203). VEGF-R1 is helping in the guidance of the sprout and inhibits tip cell formation (203). 
Inhibition of Dll4 or Notch signaling in tumor or during development leads to hypersprouting 
due to increase in tip cell number (204). Jagged1, in contrast to Dll4, is expressed in stalk cells. 
Jagged1 is a poor Notch1 activator, as modiﬁcation of Notch by Fringe glycosyltransferases 
favors activation by Dll4 (47, 205). Some Dll4 can still be detected in the stalk cells, but 
Jagged1 antagonizes Dll4 signaling back to the tip cells, and in that way maintains differential 
Notch activity (36) (Figure 14).  
 
 
Figure 14. Notch signaling in tip-stalk specification. 
During sprouting angiogenesis, VEGF upregulates Dll4 
expression in tip cell, which in turn activates Notch1 on 
stalk cells, downregulating VEGF-R2 and -R3, and 
upregulating Jagged1 in stalk cells. Jagged1 antagonizes 
Notch1-Dll4 signaling back to the tip cell, maintaining tip-
stalk phenotype. Differential regulation of Notch1 activity 
by Dll4 and Jagged1 is controlled by glycosylation of the 
receptor by Fringe [Reprinted from Kume, T. 2009 (206)] 
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3. Vessel maturation 
After vessel network had expanded through either process of sprouting or splitting 
angiogenesis, it needs to mature. Vessel maturation is the process that involves vessel network 
remodeling according to the local tissue needs. This process involves recruitment of mural 
cells; pericytes and vascular smooth muscle cells (vSMCs) and deposition of extracellular 
matrix (36). Pericytes were first described by Rouget in 1873, and Zimmerman later coined a 
term ‘pericytes’ to describe their close proximity to endothelial cells (207). Definition of a 
pericyte is still not completely clear, but it is generally considered that a pericyte is the cell that 
is imbedded within the vascular basement membrane (207). Vascular smooth muscle cells on 
the other side are separated from endothelial cells by matrix (208). Pericytes are defined by 
their location and morphology, but recent studies tried to understand their unique gene 
expression profile as well (209). Pericytes are embedded in vascular basement membrane, and 
over 1000 direct contacts between two cells occur in a peg-socket interface, where pericyte 
cytoplasmic ﬁngers (pegs) are inserted into endothelial invaginations (pockets). Other contact 
morphologies include close/occluding contacts, when membrane of a pericyte and endothelial 
cell come very close together. These types of connections possible play a role in anchoring 
since they are found at the edge of the pericyte processes. Third type of contacts, referred to as 
adhesion plaques, resemble adherence junctions, but are not completely investigated. Under 
electron microscope, adhesion plaques are seen as microfilament bundles at pericyte membrane 
and electron-dense material in the endothelial cytoplasm (207) (Figure 15).  
Pericytes can be defined by different makers, like PDGF-Rβ (platelet-derived growth 
factor receptor-beta), αSMA (α-smooth muscle actin), NG2 (chondroitin sulfate proteoglycan 
4), CD13 and desmin, but none of which is entirely unique pericyte marker (207). 
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Figure 15. Vessel mural cell coverage. (A) Arterioles are wrapped by circular layer of smooth muscle cells 
(SMC) which are flattened, spindle-shaped cells with few cytoplasmic processes. Precapillary arterioles are 
associated with SMC that extend their processes around the endothelium. Capillaries, on the other hand, are 
covered by pericytes, which have round cell body, from which primary and then perpendicular, secondary 
processes extend. Postcapillary venules are associated with flattened mural cells with many slender, branching 
processes. Venules have big, stellate-shape SMCs that, unlike arteriolar SMCs, do not wrap circularly around 
endothelium. (B) Pericytes (P) and endothelial cells (E) share basement membrane, but they come into direct 
contact only through adhesion plaques and peg-socket contacts. Many actin filaments stretch in primary and 
secondary cytoplasmic processes of pericytes and numerous caveolae are found in abluminal pericyte surface 
[Reprinted from Armulik, A. et al. 2011 (207)] 
 
Pericyte abundance also greatly varies between different tissue and organs. Vasculature 
in central nervous system has the highest pericyte coverage, with EC: pericyte ratio of 1:1-3:1 
(210). In some studies, it was reported that EC: pericyte ratio in human skeletal muscle 
vasculature is 100:1 (211, 212), while others reported it to be higher (213). The pericyte 
coverage is correlating with the permeability of endothelial-blood barrier (very low in CNS), 
endothelial proliferation (higher EC turnover correlates with less coverage) and orthostatic 
blood pressure (207). Pericyte origin is not completely clarified. Generally, it is believed that 
pericyte are mesenchymal cells. Probably, all the SMCs and pericytes in CNS (214-217) and 
thymus (218, 219) are coming from ectoderm-derived neural crest. Pericytes of coelomic 
organs like gut (220), lung (221), and liver (222) have been mapped to the mesothelium, the 
single-layer squamous epithelium that lines the coelomic cavities and its organs. Interestingly, 
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SMCs of the aorta and its proximal branches are derived from at least four different sources, 
i.e. secondary heart ﬁeld, neural crest, somites, and splanchnic mesoderm (207).  
Vessel maturation is connected with vessel quiescence. Quiescence is a reversible state 
in which ECs are not dividing or migrating. It is common for both blood and lymphatic vessel, 
but its regulation is not completely elucidated. Different signaling molecules like RAS, PTEN 
phosphatase, FOXO1, Alk-1, endoglin, BMP-9, -10 and others have been implicated in vessel 
quiescence. Understanding of endothelial quiescence is especially important in order to 
understand different vascular pathologies where this process is dysregulated (29). Endothelial 
cell-pericyte crosstalk is regulated by different signaling pathways (Figure 16). PDGF/PDGF-
Rβ, Ang/Tie-2, TGFβ/TGF-Rβ, ephrinB2/EphB4 are one of the most important so they will be 
briefly described.  
 
Figure 16. Pericyte-endothelial crosstalk. 
Recruitment of pericytes to the endothelium is 
controlled by many ligand/receptor 
complexes (the ligand and receptor are 
indicated with the same color): PDGF-B 
/PDGFRβ, SDF-1α (stromal-derived factor 1-
alpha)/CXC4R, heparin- binding epidermal 
growth factor (HB-EGF)/ErbB, sonic 
hedgehog (Shh)/Patched (Ptc), Ang1/Tie-2 
and sphingosine-1 phosphate (S1P)/S1P1. 
Ang-2 induces vessel destabilization and 
pericyte loss. TGFβ signaling regulates 
proliferation and differentiation of both 
pericytes and endothelial cells. Notch, 
ephrinB2 and N-cadherin signaling require 
direct contact between pericyte and 
endothelial cell [Reprinted from Armulik, A. 
et al. 2011 (207)]  
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3.1. PDGF signaling in pericyte recruitment  
Platelet derived growth factor (PDGF) signaling plays a central role in pericyte 
recruitment. Two tyrosine kinase receptors, PDGF-Rα and PDGF-Rβ, are evolutionarily and 
structurally related to VEGF receptors. There are four PDGF isoforms (PDGF-A, -B, -C, -D) 
that make homo- or heterodimers, giving rise to five different ligands, namely PDGF-AA, -
BB, -AB, -CC, and -DD. Endothelial cells, especially tip cells, express PDGF, while mural 
cells express PDGF receptors (168). Mice that have null-mutation of either Pdgfb or Pdgfrb, 
die in utero due to capillary dilatations and microaneurism ruptures leading to severe 
hemorrhaging together with renal, cardiac and placental defects. Mutant mice displayed 
pericyte/SMC detachment and overall reduction of mural cell coverage (223-225). VEGF can 
have a negative effect on pericyte recruitment by formation of receptor complex between 
VEGF-R2 and PDGF-Rβ (226). We have demonstrated that PDGF-BB can normalize aberrant 
angiogenesis induced by high VEGF doses, demonstrating the importance of pericytes in 
prevention of pathological angiogenesis (227, 228).  
3.2. Angiopoietin/Tie2 signaling 
Angiopoietins are other signaling molecules important for EC-pericyte crosstalk. There 
are four ligands- Angiopoietin-1 (Ang-1), Ang-2, Ang-3 and Ang-4 that bind to two Tie 
(tyrosine kinase with immunoglobulin and EGF homology domains) receptors- Tie-1 (Tie in 
mouse) and Tie-2 (Tek in mouse) (229) (Figure 17). Ang-1 and Ang-2 are best studied and it 
was demonstrated that even though both of them bind Tie-2 with similar affinities, they have 
different effects on angiogenic process (168, 230). Ang-1 has positive effect since it can 
promote vascular growth, endothelial cell survival and maturation process by preventing 
apoptosis and inflammation. Ang-2, on the other side, acts like Ang-1 antagonist and enhances 
vascular regression, pericyte detachment, vessel destabilization and endothelial cell death (231, 
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232). It also increases vascular permeability, facilitating infiltration of immune cells and 
cytokine and growth factor secretion (229). Ang-1 is expressed by perivascular mesenchymal 
cells like pericytes, vascular smooth muscle cells, fibroblast and tumor cells (207, 229), while 
Ang-2 is mostly produced by endothelial cells and upon stimulation released from vesicles 
called Weibel–Palade bodies. Tie-2 is predominantly produced by endothelial cells (207). Ang-
2 promotes dissociation of pericytes and mice with inactivated Tek (Tie-2) die in midgestation 
due to the abnormalities in capillary plexus remodeling and maturation, hematopoiesis and 
heart development. Inactivation of Tie (Tie-1) is also lethal, causing impairment of vascular 
integrity, but with normal hematopoiesis (231). Mice with null mutation for Ang-1 die in utero 
having similar phenotype of Tek-deficient mice, while Ang-2-null mice are born normally, but 
die postnatally due to defects in lymphatic system (233, 234).  
 
Figure 17. Angiopoietin/Tie-2 
signaling. (A) Extracellular domain of 
Tie receptors contains 3 IgG-like 
domains, 3 EGF-like repeats and 3 
fibronectin type II domains. Tyrosine 
kinase domain is located 
intracellularly. Angiopoietins are 
soluble proteins that contain 
superclustering domain (SCD) that 
allows homodimers to multimerize, 
coiled-coil domain (CCD) and Tie-
receptor-binding fibrinogen-like 
domain (FReD). (B) Upon ligand-
receptor binding, the complexes multimerize, bringing receptor tyrosine kinase domains in close proximity, 
leading to phosphorylation and signal initiation [Reprinted from Fagiani, E. et al. 2013 (229)] 
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3.3. TGF-β signaling 
Transforming growth factor β (TGFβ) signaling is important in physiology of both 
endothelial cells as well as pericytes. It can induce mural cell proliferation and their 
differentiation from undifferentiated mesenchyme. TGFβ signaling regulates proliferation and 
differentiation of endothelial cells as well. There are three major types of TGFβ receptors: 
TGF-β receptor type I (TβRI), type II (TβRII) and type III (TβRIII). Ligand binding assembles 
a hetero-tetrameric receptor complex consisting of two type I (signal propagating) receptor 
components and two type II (activator) components (235, 236). Type II receptor components 
phosphorylate type I components, which in turn propagate the signal through activation of 
SMAD [Caenorhabditis elegans SMA protein; mothers against decapentaplegic (MAD)] 
proteins. SMAD2 and SMAD3 are inducing cell cycle arrest while SMAD1/5/8 are activating 
cell proliferation (235) (Figure 18). The TGF-β superfamily is composed of more than 30 
chemokines that can be ligands for TGFβ receptors. The superfamily includes TGF-β1-3, 
activins, anti-Müllerian hormone (AMH), bone morphogenetic proteins (BMPs), growth and 
differentiation factors (GDFs) and NODAL (235). TGF-β1 is translated as a large precursor 
pre-proprotein, which undergoes two proteolytic cleavage events. First, signal peptide is 
cleaved in rough endoplasmic reticulum, Then, furin convertase cleaves the protein in two 
fragments-mature TGF-β1 and latency-associated protein (LAP). LAP remains in the complex 
and it serves as a functional inhibitor, and it needs to be displaced from the complex to release 
mature TGF-β1, and allow signaling (235).  
In humans, there are seven TβRIs, also known as activin receptor-like kinases (Alk), 
and five TβRIIs. Alk-1 and Alk-5, expressed in both endothelial and mural cells, are the most 
investigated, in the context of angiogenesis. It is interesting that Alk-1 and Alk-5 trigger 
different and opposing cellular effects, where Alk-5, through SMAD2/3, promotes 
proliferation arrest and differentiation of mesenchymal cells into smooth muscle cells, while 
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Alk-1, through SMAD1/5 promotes cell proliferation and migration, inhibiting SMC 
differentiation (207). TGF-β accessory receptor, endoglin, enhances Alk-1 signaling and 
inhibits Alk-5 cytostatic action (235).  
Knockout of different TGF-β signaling pathway genes in mice like tgfb1 (237), alk1 
(238), alk5 (239), tgfbr2 (14), smad4 (240), smad5 (241, 242) and endoglin (243), is 
embryonically lethal due to severe vascular abnormalities like defects in yolk sac vasculature 
remodeling, arterio-venous anastomoses, defective mural cells differentiation and in some 
mutants, defective hematopoiesis (207). TGF-β in endothelial cells cooperates with other 
signaling pathways like Notch by cooperatively regulating expression of N-cadherin (244), a 
molecule important in pericyte-endothelial crosstalk (207). TGF-β also upregulates the 
expression of other molecules involved in angiogenic process such as VEGF, PDGF-A, PDGF-
B and nitric oxide synthase 3 (NOS3) (235). 
Figure 18. TGFβ signaling. TGFβ 
signaling can have opposing effects on cell 
proliferation. (A) It can induce cell cycle 
arrest by downstream activation of 
SMAD2/3 effector proteins, that associate 
to SMAD4 and FOXO1 (foxhead box O-1) 
protein, and act as transcription factors. 
They can upregulate expression of p21Cip1 
(CDKN1A) and p15Inkab (CDKN2B), 
which in turn inhibit cyclin-dependent 
kinase 1 (CDK1) and CDK4, resulting in 
cell cycle arrest. FOXG1 (Foxhead box 
G1), AKT and SMAD7 are antagonizing 
this pathway. Blue dots represent protein 
phosphorylation. (B) TGFβ can also induce 
cell proliferation and angiogenesis thorough activation of SMAD1/5/8 effector proteins and subsequent 
expression of transcription factors ID1 (inhibitor of DNA-binding protein 1) and ID3, which are involved in cell 
cycle progression [Reprinted from Guerrero, P.A. et al. 2017 (235)]  
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3.4. Ephrin/Eph signaling 
Eph (erythropoietin-producing human hepatocellular) receptors are the largest family 
of tyrosine kinase receptors in human (245-249). They were first identified in human 
carcinomas, were they were found overexpressed. The Eph receptors with their ligands, called 
ephrins (Eph receptor-interacting proteins) transmit the signal upon cell-cell contact and 
regulate cell shape, movement, survival, and proliferation. In human, there are nine type A 
(EphA1-9) and five type B (EphB1-5) receptors, as well as five glycosylphosphatidylinositol 
(GPI)-linked type A (ephrinA1-5) and 3 transmembrane type B (ephrinB1-3) ligands  (245) 
(Figure 19A). B-class receptors promiscuously bind B-class ligands while A-class receptors 
bind A-class ligands, with some exceptions. When interacting in trans, ephrin/Eph downstream 
signaling can be bidirectional, which means it can proceed both in receptor-bearing cell 
(forward signaling), as well as in ligand-bearing cell (reverse signaling) (Figure 19B). When 
expressed in the same cell, ephrins and Eph receptors can inhibit the signaling induced by in 
trans interactions (248, 250, 251).  
 
Figure 19. Ephrin/Eph and signaling possibilities. Both Eph receptors and ephrin ligands are membrane bound 
proteins that signal upon cell-cell contact. (A) Eph receptors are divided into two classes-class A and class B. 
Both EphA and EphB receptors are transmembrane tyrosine kinase receptors composed of ligand binding domain 
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(LBD), Cys-rich domain made of Sushi domain and epidermal growth factor (EGF)-like domain. There are two 
fibronectin (FN) domains, transmembrane (TM) region, as well as tyrosine kinase (TK) domain, the sterile alpha 
motif (SAM) and PDZ domain, located intracellularly. Ephrin ligands exist as ephrinA and ephrinB class and both 
classes contain receptor-binding domain (RBD). EphrinA ligands are linked to the membrane via a 
glycosylphosphatidylinositol (GPI) anchoring, whereas the ephrinB class has a transmembrane domain and an 
intracellular PDZ domain. (B) Ephrin/Eph signaling can proceed both in receptor-bearing cell (forward signaling) 
and in ligand-bearing cell (reverse signaling), or in both cells (bidirectional). Parallel signaling is occurring when 
both ephrins and Ephs are expressed on the same cell, and they signal in response to Ephs and ephrins, 
respectively, present on a neighboring cell. Anti-parallel signaling is, on the other side, a simultaneously occurring 
forward signaling. Unlike parallel signaling, in anti-parallel signaling, ephrin–Eph signals are propagated in both 
cells [Adapted from Kania, A. et al. 2016  (247)] 
 
In developing nervous system, ephrin/Eph signaling controls tissue patterning and 
serves as axonal guidance cue, inducing collapse or immobilization of axonal growth cones. 
Besides nervous system, ephrin/Eph signaling controls bone homeostasis, insulin secretion, 
stem cell renewal, but it also plays an important role in vascular system, as ephrinB2/EphB4 
interaction is regulating arterio-venous specification (245, 247, 248). Ephrin/Eph signaling is 
also implicated in many pathologies like neurodegeneration, neuropathic pain, cancer and 
androgen-induced alopecia. EphrinB2 and ephrinB3 can even serve as entry molecules for 
henipaviruses (245). Generally, tyrosine kinase receptor (RTK) signaling induces cell 
migration, proliferation and survival, while Eph signaling can also mediate inhibition of cell 
growth and induce cell repulsion. 
Ephrin/Eph downstream signaling is complex and involves many interactions. After 
ephrin/Eph interaction, many such ligand-receptor complexes oligomerize, forming a cluster, 
which is critical for activation of the downstream signaling (252, 253). Close proximity of the 
receptors will lead to trans-phosphorylation of two conserved tyrosines in the juxtamembrane 
domain (248). It seems that phosphorylation of Eph receptors is less critical for receptor 
activation, as compared to other RTKs, but might be important for its maximal activity (254, 
255). Phosphorylation of the receptor will lead to recruitment of SH2-domain containing 
proteins like members of non- receptor tyrosine kinases SRC and ABL families and adaptors 
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NCK and CRK, which are crucial for signal transduction. RTKs are usually internalized 
through endocytosis and can continue to signal intracellularly until they are dephosphorylated 
and degraded. Eph receptors and ligands are both membrane bound so endocytosis is carried 
out in a different way (43, 256, 257). Ligand-receptor complex can be internalized in both cells, 
where endocytic vesicles contain plasma membrane of both cells. This process is called trans-
endocytosis, and it can be “forward”-when the complex is internalized in receptor-expressing 
cell or, “reverse”-when the complex is internalized in ligand-expressing cell (Figure 20). Trans-
endocytosis is regulated by RAC1 and ubiquitin ligase Cbl which can ubiquitinylate several 
Eph receptors and induce their internalization and degradation (258, 259). 
 
 
 
Figure 20. Trans-endocytosis. Upon EphrinB/EphB 
interaction, the trans-endocytosis of the ligand-
receptor complex can proceed in the receptor-bearing 
cell (forward endocytosis) (A) or in the ligand-bearing 
cell (reverse endocytosis) (B). Both processes lead to 
internalization of full-length ligand and receptor 
[Reprinted from Salvucci, O. et al 2012 (249)]  
 
 
 
Eph receptor-ephrin complex can induce cell repulsion by activating metalloproteases, 
such as ADAM family members (248). Transmembrane ADAM10 protease can bind to 
ephrinA2 in cis and cleave it following EphA receptor binding in trans to enable repulsive 
axon guidance (260) (Figure 21).  
PDZ domain-containing proteins are also binding to the carboxy-terminal tails of Eph 
receptors and they also contribute to forward signaling. RHO and RAS family GTPases as well 
I. Introduction  
51 
 
as AKT/mTORC1 are particularly important. RHO GTPase family members RHOA, RAC1 
and CDC42, which are involved in reorganization of actin cytoskeleton, are activated by Eph 
forward signaling (261, 262). RHOA is mostly involved in the formation of stress fibers and 
focal adhesions and contraction of the actomyosin cytoskeleton, whereas RAC1 and CDC42 
regulate the formation of protrusive structures such as lamellipodia and filopodia, respectively 
(248, 263). Most of RTKs phosphorylate ERK1 and ERK2 through activation of H-RAS 
GTPase, but it was shown that Eph signaling can inhibit ERK activation induced by FGF 
receptor (264, 265). Common mechanism of Eph-inhibition of ERK is through activation of 
p120RASGAP, which inactivates H-RAS (266, 267) (Figure 21). Still, it was demonstrated 
that ephrinB1/EphB signaling can also activate ERK to promote proliferation and regulate 
immediate early gene transcription (268), suggesting that Eph signaling is far more complex 
and needs further investigation. Similarly, Eph signaling can inhibit and activate PI3K-AKT 
pathway, common downstream effector of many RTKs (248).  
Reverse signaling, i.e. signaling in ligand-bearing cell is mediated by ephrins, which 
lack an enzymatic domain, but upon receptor-ligand interaction, are phosphorylated by SRC 
kinases like FYN, creating binding sites for the SH2 domains of signaling proteins such as the 
adaptor Grb4 (248). Termination of forward signaling can be mediated by phosphatases like 
protein tyrosine phosphatase 1B (PTP1B) which dephosphorylate Eph receptor (269).  
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Figure 21. Ephrin/Eph downstream signaling. (A) Ephrin/Eph complex structure. (B) Upon ephrin/Eph 
interaction, the ligand-receptor complexes multimerize and the clusters comprising four Ephs and four ephrins 
are a functional signaling unit. Eph receptor activation involves the release of the Eph juxtamembrane domain 
leading to extension of the cytoplasmic domain allowing Eph kinase domain to be activated. Activated Ephs 
recruit the metalloprotease ADAM10 (a disintegrin and metalloprotease domain-containing protein 10), which 
cleaves ephrins from the interacting cell surface to allow endocytosis to proceed, probably via a clathrin-mediated 
mechanism. Protein tyrosine phosphatases (PTPs), including PTP-RO and PTP1B are controlling Eph 
phosphorylation. Clustering of ephrinA ligands causes recruitment and activation of SRC kinases as well as RAC, 
RHOA, ROCK (RHO-associated protein kinase) and paxillin, which all together promote cytoskeletal changes. 
Additionally, ephrin reverse signaling might be implicated in cell survival regulation through p75 neurotrophin 
receptor (p75NTR) and inhibition of epidermal growth factor receptor (EGFR) degradation. Mediators of forward 
signaling are tyrosine kinases (red), serine/threonine kinases (pink), SH2 adaptors (light green), RHO GTPases 
(green) and their GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs) (orange). 
Regulation of cell cytoskeleton is mediated by RHOA, RAC, and repressor/activator protein 1 (RAP1; also known 
as TERF2IP), resulting in cell contraction or spreading and adhesion. This process is regulated by a range of 
kinases and signaling mediators such as SRC kinases and focal adhesion kinases (FAKs). Activation of the Eph 
downstream signaling leads to recruitment of SH2 adaptors such as p130CAS, CT10 regulator of kinase (CRK), 
CRK2, non-catalytic region of tyrosine kinase adaptor protein 1 (Nck1) and GAPs and GEFs (including ephexin, 
α-chimerin and C3G), as well as activation of Vav and Tiam1 (T lymphoma invasion and metastasis-inducing 
protein 1). Inhibition of cell migration, adhesion and proliferation is achieved through phosphorylation of CRK 
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by ABL kinase, disrupting CRK–p130CAS and CRK– DOCK1 (dedicator of cytokinesis protein 1) complexes. 
FAK kinases are positively regulating these processes through phosphorylation of p130CAS that promotes its 
binding to CRK33. Eph downstream signaling can inhibit cell proliferation via activation of p120RASGAP which 
inhibits RAS–MAPK/ERK kinase (MEK)–mitogen-activated protein kinase (MAPK) signaling [Reprinted from 
Boyd, A.W. et al. 2014 (246)]  
 
3.4.1. EphrinB2/EphB4 signaling in angiogenesis 
EphrinB2/EphB4 signaling has a very important role in vascular system, specifically 
during arterio-venous specification in embryonal development. While there is promiscuity in 
binding of different Eph receptor and ephrin ligands members, ephrinB2/EphB4 interaction is 
specific (270). EphrinB2 is an arterial while EphB4 is a venous marker (249, 271, 272). These 
two molecules regulate first arterial-venous differentiation event in development i.e. formation 
of dorsal aorta and cardinal vein. It was demonstrated, both in zebrafish and mouse models, 
that dorsal aorta assembles first and it contains a mixed of ephrinB2+ and EphB4+ precursor 
cells. EphrinB2:EphB4 repulsive signaling repels arterial (ephrinB2+) from venous (EphB4+) 
endothelial cells. EphB4+ endothelial cells then assemble the cardinal vein (247, 273, 274). 
 
Figure 22. EphrinB2/EphB4 signaling. 
EphrinB2/EphB4 is regulating arterio-venous 
differentiation in primary vascular plexus, where 
ephrinB2 is marking arterial and EphB4 venous 
territory, later leading to formation of ephrinB2+ 
arteries and EphB4+ veins [Reprinted from 
Salvucci, O. et al. 2012 (249)] 
 
Mice with deletion of either ephrinB2 or EphB4 die in utero due to defects in 
remodeling of primary vascular plexus (271). Since knockout of both proteins has similar 
phenotype, it is clear that early vascular remodeling requires both forward and reverse 
ephrinB2/EphB4 signaling. EphrinB2 is expressed in the endothelium and mural cells of adult 
arteries, arterioles, and capillaries in many tissues, and its expression increases during 
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angiogenic process (275-277). EphrinB is broadly phosphorylated in angiogenic vessels, but 
not in the resting endothelium (278). Since EphB4 is expressed mostly in venous endothelial 
cells, first it was thought that ephrinB2/EphB4 signaling can occur only on arterial/vein 
boundaries. Later, it was shown that expression of ephrinB2 and EphB4 partially overlaps in 
retinal vessels, as well as in endothelial cells of umbilical vein, human aorta, and dermal 
microvasculature, suggesting that ephrinB2/EphB4 interactions can occur in many locations 
(249). 
In development, ephrinB2 is phosphorylated in retinal vessels, and after they have been 
fully developed, it subsequently dephosphorylates (249, 278). During sprouting, ephrinB2 is 
specifically expressed by tip cells and their filopodia (44, 45). It was demonstrated that mice 
carrying an allele of ephrinb2 with the mutation in PDZ domain, had impaired retinal vascular 
development, as tip cells displayed signiﬁcantly reduced ability to form ﬁlopodia (44). Cultured 
endothelial cells with silenced ephrinB2 fail to assemble in networks. The same outcome has 
been observed if ephrinB2 is overexpressed in endothelial cells, suggesting that expression of 
ephrinB2 needs to be tightly controlled (44, 45, 278). EphrinB2 reverse signaling can directly 
regulate VEGF signaling by controlling the internalization of both VEGF-R2 and VEGF-R3 
upon ligand binding. EphrinB2 promotes clathrin-dependent VEGF receptor internalization, 
and consequently downstream signaling and sprouting through interaction with the clathrin-
associated protein disabled 2 (DAB2) and the cell polarity regulator PAR3 (44, 45, 117, 247) 
(Figure 9). It is interesting that phosphorylation of ephrinB2 is not necessary for modulation 
of VEGF receptor internalization, but this process depends on its PDZ-binding site, possibly 
through activation of SRC kinases (44, 45, 247). With that in line, experiments showed that 
inactivation of ephrinB2 leads to defective VEGF-R2 and VEGF-R3 signaling, i.e. VEGFR 
phosphorylation is decreased and activation of downstream signaling effectors RAC1, 
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ERK1/2, and AKT is reduced (44, 45). Furthermore, ephrinB2 can, to a certain extent, 
modulate VEGF-R2 internalization even in the absence of VEGF (44). 
Regulation of VEGF signaling by EphB4 forward signaling is still not clear. Some 
experiments demonstrate that activation of EphB4 has opposite outcome as compared to 
ephrinB2 reverse signaling, as EphB4 decreased endothelial cell proliferation, migration and 
adhesion (279, 280). Other instead showed that EphB4 activation stimulates cell proliferation 
(281). EphB4 forward signaling seems to play an important role in lymphatic valve 
development (282).  
EphrinB2 signaling plays an important role in pericyte-endothelial crosstalk. 
Inactivation of ephrinB2 specifically in mural cells by using Pdgfrb-cre mice, led to perinatal 
death due to edema and extensive hemorrhaging in a variety of tissues. Interestingly, even 
though the ephrinB2-null pericytes were morphologically normal, they associated poorly with 
the vessels (283). When these pericytes/smooth muscle cells were cultured, they were 
elongated, did not properly spread, and cell-cell contact was impaired. Even though the cells 
were migrating more, migration was random, due to defective focal adhesion formation. This 
phenotype could be reversed by re-expression of ephrinB2 or RHO-like GTPases (283). 
EphB4, which is expressed by endothelial cells, can activate ephrinB2 on mural cell and 
enhance association of these two cell types within tumor blood vessels (284). 
Mechanistically, ephrinB2 in mural cells interacts with PDGFRβ. Specifically, 
ephrinB2 controls membrane distribution, endocytosis and signaling output of PDGFRβ and 
in that way, promotes proliferation of vascular smooth muscle cells and prevents their 
differentiation (247, 285). In vitro experiments with vascular smooth muscle cells suggested 
that ephrinB2 is required for the balanced activation of multiple signaling cascades in the 
PDGF pathway (247). 
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4. Therapeutic angiogenesis 
Therapeutic angiogenesis is a strategy for induction of growth of new blood vessel for 
therapeutic purposes. It is especially important in field of tissue engineering, as well for 
treatment of ischemic diseases and non-healing wounds. Ischemic diseases are group of 
conditions characterized by low blood tissue perfusion and hypoxia, leading to tissue damage. 
There are three main types of ischemic diseases: peripheral artery disease (PAD), coronary 
artery disease (CAD) and cerebrovascular disease (286, 287). The main pathophysiological 
process causing ischemia is atherosclerosis. Atherosclerosis is a progressive disease that is 
characterized by accumulation of lipids, immune cells and fibrotic material in the inner arterial 
wall. This leads to lumen stenosis and ultimately to the occlusion of the artery. Patients with 
significant stenosis of the arterial lumen will experience pain during exercise, and this 
condition is associated with stable angina pectoris or intermittent claudication. Further 
progression of stenosis leads to serious ischemia and pain at rest. This condition is associated 
with development of unstable angina pectoris or critical chronic limb ischemia (CLI). 
Ultimately, rupture of atherosclerotic lesion can lead to life-threatening events like myocardial 
infarction and stroke, caused by atherothrombotic events (286). 
4.1. Peripheral artery disease 
Peripheral artery disease (PAD) is mostly caused by atherosclerosis, but vasculitis, 
thrombosis and embolic disease can also lead to development of the disease. Major risk factors 
for PAD are smoking, diabetes, dyslipidemia and hypertension (288-290). PAD can affect 
arteries of lower and upper extremities, the carotid and mesenteric vessels. We will concentrate 
on PAD of lower limb extremities, due to its clinical importance (288, 290). PAD was affecting 
202 million of people worldwide in 2010, 69.7% of them in low- or middle-income countries 
(288, 289) with 15% to 20% of patients being over 70 years of age. PAD is slightly more 
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prevalent in men than in women (291). The annual incidence of critical limb ischemia is 500 
to 1000 and of major amputations from 120 to 500 new cases per million population (288). 
Atherosclerosis, as a systemic disease, can also lead to coronary artery and cerebrovascular 
diseases, which are the major causes of death in people with PAD (288, 290). Depending on 
the degree of arterial stenosis and claudication, patients suffering from PAD can be or 
asymptomatic, have leg pain during exercise or walking (intermittent claudication) or at severe 
degree of stenosis (critical limb ischemia) have pain of the affected leg even at rest and 
ulceration and gangrene of the foot. Clinical severity of PAD is classified according to Fontaine 
and Rutherford classiﬁcations (292). PAD is a major cause of decreased mobility, functional 
capacity, quality of life and it increases the risks of amputation and/or death (290, 293, 294). 
4.2. Gene therapy in PAD 
Therapeutic angiogenesis is a strategy to improve blood flow by induction of new 
capillary growth. Increase in blood flow and shear stress created by new vessels can 
subsequently lead to opening of collateral arteries in the process of arteriogenesis, leading to 
functional improvement and tissue regeneration. Proangiogenic molecule like VEGFs, FGFs, 
HIF-1α (hypoxia-induced factor 1α) and HGF (hepatocyte growth factor) were used in almost 
all the clinical trials for PAD and CAD. First-in-human trials using gene transfer of VEGF and 
FGF-2 for treatment of PAD were performed in late 90-s by intramuscular plasmid delivery 
(295, 296). Initial trials with intramuscular adenoviral gene delivery were also performed in 
that period (297). Shortly after that, RAVE trial, first randomized, double-blind, placebo-
controlled study of intramuscular adenoviral gene transfer for the treatment of PAD, was 
performed. The study found no significant differences between groups in the primary or 
secondary efficacy endpoints (298). The appearance of peripheral edema was associated with 
use of short isoform VEGF-A121. Parallelly, in two separate clinical trials, recombinant VEGF 
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and FGF-2 proteins were used as an alternative to gene transfer. Both VIVA (VEGF protein) 
(299) and TRAFFIC (FGF-2 protein) (300) trials failed to show a significant improvement in 
the treated patient group. The reason for poor outcome was fast protein clearance upon 
intramuscular injection (301). Since then, other clinical trials were performed using various 
gene transfer vectors, like plasmids, adenoviruses, adeno-associated viruses, and retroviruses. 
Most recently, 40 different clinical trials using gene delivery of VEGF, FGF and HGF for PAD 
treatment, were systematically reviewed and the conclusions are: i) growth factors may 
improve hemodynamic measures as well as ulceration and rest pain in people with PAD of the 
lower extremities up to one year, but they have little or no effect on walking ability, ii) rate of 
major amputation was similar, while rate of minor limb amputations was decreased in patients 
treated with growth factor. However, effects on major limb amputations and on death are 
uncertain, iii) there was no relevant difference in effects between growth factors (FGF, HGF 
and VEGF) (290).  
4.2.1. Gene therapy limitations 
The reasons for not very successful clinical translation of cardiovascular gene therapy 
can be many, but the main ones are: i) induction of leaky, non-stable vessels insufficient for 
functional improvement, ii) transduction efficacy is too low or duration of gene expression is 
too short, iii) insufficient knowledge about underlying pathophysiological mechanism, iv) 
underpowered clinical trial design and patient selection (302).  
Currently, it is difficult to achieve more than 10% - 20% transduction efficiency in 
human heart or peripheral muscle (302) so selection of vector type, as well as gene transfer 
route are very important in order to achieve sufficient local concentration of growth factor in 
the affected tissue. Intra-muscular gene transfer is more efficient than intra-arterial delivery 
(297) and virus-mediated gene delivery is more efficient then naked plasmid. It is challenging 
to deliver locally enough growth factor using safe vector doses. High amounts of VEGF 
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delivered to the limb skeletal muscle can induce aberrant vessel growth and fibrosis (303). 
Normalization of the aberrant, leaky and non-stable vessels is one important avenue that needs 
to be further explored. Recently, retroviral delivery of both VEGF-A and pro-stabilizing factor 
Angiopietin-1 is going in that direction (287). Usage of modified growth factors, like VEGF-
DdNdC, that can induce both blood and lymphatic vessel growth, can potentially lead to a better 
outcome in comparison to induction of blood vessel growth alone (302). 
The selection of patients is probably responsible for the observed outcome as well, as 
most of them were “no option” cases and were not eligible for any other type of treatment. As 
such, they potentially already have serious impairment of endogenous angiogenesis and are not 
able to respond to angiogenic therapies. This is the reason for recruitment of healthier patients 
in future trials, or by development of novel biomarkers, select responder patients. Ultimately, 
clinical trial endpoints should be revised as well, in order to evaluate improvement in severely 
affected patients more rationally (302). 
4.3. Total vs microenvironmental VEGF dose: myoblast-mediated gene 
delivery 
Previous work from our group has investigated the dose-dependent effects of VEGF 
gene delivery to the clinically relevant target tissue of skeletal muscle. We developed a specific 
cell-based gene delivery system in which primary myoblasts were retrovirally transduced to 
produce VEGF (304). Once these transduced myoblasts were implanted in skeletal muscle, 
they induced aberrant angiogenesis, and ultimately led to hemangioma growth. Dilution of 
cells could not prevent hemangioma growth, even though total dose of produced VEGF was 
decreased from 60 ng/106 cells/day to only 5 ng/106 cells/day (305). Every cell in the 
population produces different levels of VEGF depending on the number of viral vector copies 
integrated and site of integration. That is why we next sorted single cells from the parental 
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polyclonal myoblasts population and expanded them. Now we got a series of monoclonal cell 
populations, where every single cell within a population produced the same amount of VEGF. 
A range of different clones expressing increasing amount of VEGF (5-200 ng/106 cells/day) 
was implanted in murine muscles, and now we could identify a threshold of concentration 
below we could induce only normal, pericyte-covered capillaries (5-70 ng/106 cells/day), and 
above hemangiomas were observed (100 ng/106 cells/day and above) (Figure 23) (305). After 
myoblast transduction, a polyclonal population consists of cells that express heterogenous 
VEGF levels, and high-producing cell will always be “hotspots” for angioma growth due to 
high microenvironmental VEGF concentration caused by limited diffusion of VEGF from a 
producing cell. Dilution of polyclonal cell population, and decrease of total dose of VEGF, still 
leads to appearance of aberrant vessel, since there will always be some high-producing cells 
present in the population (306). By using monoclonal myoblast population, we can achieve that 
all the cells produce VEGF at the concentration below the one at which hemangiomas are 
induced. In that way, angiogenesis can be induced in an efficient and safe way (306). This 
clearly demonstrated that in order to prevent aberrant angiogenesis, the dose of VEGF needs 
to be controlled at the microenvironmental level, rather at the level of total dose. The concept 
of microenvironmental dose can also explain inefficacy of gene delivery in previous clinical 
trials for therapeutic angiogenesis, since only total dose of viral vector or plasmid was 
controlled, but not its microenvironmental distribution in the affected tissue (306).  
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Figure 23. Myoblast based VEGF-delivery. (A) Myoblast are retrovirally transduced to express VEGF. Parental 
polyclonal population of transduced myoblast is composed of cells expressing different levels of VEGF. 
Individual cells can be isolated and expanded in order to produce monoclonal cell populations were every cell 
within a population expresses same amount of VEGF. (B) After intramuscular implantation of different 
monoclonal populations expressing increasing microenvironmental VEGF concentrations, a dose threshold can 
be identified, below which only normal capillaries are induced, and above, hemangiomas are formed. The clone 
expressing low levels of VEGF (V-low) is inducing normal angiogenesis, while V-high clone expresses high 
levels of VEGF and induces aberrant angiogenesis.  
 
Myoblast based delivery of VEGF is a very useful tool in order to study the effect of 
VEGF dose on vessel growth. Here, we used two different VEGF clones, namely V-low, 
producing ~70 ng/106cells/day that induces normal capillaries and V-high, producing ~100 
ng/106cells/day and induces aberrant angiogenesis (Figure 23). Myoblast-based VEGF 
delivery, was also complemented with other systems, like fibrin-based VEGF protein delivery 
system, as well as adenoviral gene transfer. 
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Ischemic diseases are characterized by reduced blood flow leading to poor tissue 
oxygenation and tissue damage (1, 2), Peripheral artery disease (PAD) is a type of ischemic 
condition caused by peripheral artery occlusions. PAD is a major cause of decreased mobility, 
functional capacity and quality of life. It increases the risks of amputation and/or death (3-5). 
Therapeutic angiogenesis is a promising strategy for PAD treatment, as it aims to induce 
growth of new blood vessels, restore blood flow and ultimately improve tissue regeneration. 
Different growth factors, predominantly VEGF, are used for induction of angiogenesis. Gene 
therapy approach was employed in almost all the clinical trials that aimed to deliver growth 
factors to the affected tissue, as direct protein delivery did not give satisfying results due to fast 
protein degradation. Systemic review of results obtained from 40 different clinical trials, that 
used VEGF, FGF or HGF gene delivery, showed no clear therapeutic benefit of the treatment. 
Even though treatment improved hemodynamic measures as well as ulceration and rest pain in 
patients, there was no clear improvement in walking ability and amputation rate (3). A potential 
reason has been identified in low transduction efficiency, leading to low local growth factor 
concentrations, at safe vector doses. Increasing the dose of delivered gene therapy vectors can 
lead to higher VEGF concentrations in the tissue, but it is accompanied by side effects like 
aberrant vessel growth and tissue damage (6). This creates an apparently very narrow 
therapeutic window, as low vector doses are inefficient, while higher doses become rapidly 
toxic. Therefore, there is a need to elucidate the molecular mechanisms of aberrant vessel 
growth in order to develop druggable targets to normalize vessel morphology, and allow the 
safe use of higher vector doses, ultimately leading to more robust induction of physiological 
functional vessels and increased therapeutic efficacy. We have previously demonstrated that 
stimulation of pericytes recruitment by PDGF-BB co-expression can normalize aberrant vessel 
growth induced by high and uncontrolled VEGF levels and ensure the induction of exclusively 
normal and mature microvascular networks (7, 8). Further, our group has also previously found 
II. Aims  
100 
 
that VEGF expression in skeletal muscle, at the doses required for therapeutic benefit, induced 
vascular growth essentially without sprouting and rather by the process of intussusception (9), 
whose molecular regulation is still poorly understood. Therefore, the aim of the Thesis is to 
elucidate molecular signals in the pericyte-endothelial cell crosstalk that regulate 
intussusceptive angiogenesis and are responsible for the switch between normal and aberrant 
angiogenesis in skeletal muscle, in order to identify druggable targets to enable safe and 
effective vascular growth by robust therapeutic delivery of VEGF. 
In Aim 1 (Chapter III), we focused on the three most important pathways regulating 
pericyte-endothelial interaction, namely TGFβ/TGFβR, Ang/Tie-2 and ephrinB2/EphB4. By 
complementary loss- and gain-of-function approaches, we identified a specific role for 
ephrinB2/EphB4 signaling in determining the outcome of VEGF-induced intussusceptive 
angiogenesis. We further showed that pharmacologic stimulation of EphB4 signaling can 
prevent aberrant angiogenesis despite high and uncontrolled VEGF levels, yielding instead 
robust growth of normal and mature microvascular networks, with functional benefit in a 
mouse model of hind-limb ischemia. 
In Aim 2 (Chapter IV), we investigated the crosstalk between EphB4 and Notch4 
signaling, as other findings in our group showed that Notch4 loss-of-function phenocopies 
EphB4 stimulation in switching aberrant angiogenesis by VEGF to normal. 
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Introduction 
Angiogenesis plays a key role in the pathophysiology of a widespread variety of human 
diseases, both degenerative and neoplastic, as well as in physiological tissue regeneration (1). 
Vascular Endothelial Growth Factor-A (VEGF) is the master regulator of vascular growth in 
development and postnatal life, and it is therefore the key molecular target to promote the 
growth of new blood vessels in ischemic diseases, such as myocardial infarction, stroke or 
peripheral vascular disease (2, 3). However, simple VEGF gene delivery for therapeutic 
angiogenesis has failed to prove clinical efficacy to date, despite the clear biological activity 
of the factor (2, 4), highlighting the need to better understand the mechanisms of physiological 
vascular growth by VEGF, especially under therapeutically relevant conditions of factor 
delivery. 
The best understood mode of angiogenesis is sprouting, which is mostly studied during 
development, when specialized endothelial tip cells migrate from pre-existing vessels, 
followed by proliferating stalk cells, to invade surrounding avascular tissue (5). However, 
blood vessels can also grow by the alternative mechanism of intussusception, or splitting 
angiogenesis, whereby rows of intraluminal endothelial pillars split pre-existing vessels 
longitudinally into new ones (6). Intussusception is increasingly recognized as a therapeutically 
important mode of angiogenesis, both in tumor resistance to anti-angiogenic treatments and in 
reparative vascular growth  (7-9), but very little is known about its molecular regulation due to 
a paucity of appropriate models. 
Taking advantage of a cell-based platform that we developed for the controlled 
expression of specific and homogeneous doses of angiogenic factors in vivo, we previously 
found that: 1) VEGF can induce either normal and functional capillary networks or aberrant 
angioma-like vascular structures depending on its concentration in the microenvironment 
around each producing cell in vivo (10); and 2) VEGF doses required for therapeutic efficacy 
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(11), induce robust vascular growth in skeletal muscle essentially through intussusception (9). 
Interestingly, both normal and aberrant vascular structures form through a first stage of 
circumferential enlargement within the first 4 days, followed by intussusceptive remodeling by 
7 days (9), whereas the transition from normal to aberrant angiogenesis is determined by the 
retention or loss of pericytes during the initial stage of vascular enlargement (12). 
Here, we took advantage of this unique and well-characterized model of VEGF dose-
dependent intussusceptive angiogenesis to investigate its molecular regulation. We dissected 
the role of specific pericyte-mediated signaling pathways and we identified a critical function 
for ephrinB2/EphB4 signaling, but not TGF- or angiopoietin signaling. Specifically, we show 
that the endothelial receptor EphB4 controls the outcome of intussusceptive angiogenesis by 
fine-tuning the degree of endothelial proliferation caused by specific VEGF doses and therefore 
the size of initial vascular enlargement, without directly affecting VEGF-R2 activation, but 
rather modulating its downstream signaling through MAPK/ERK. Together, these results 
identify the ephrinB2/EphB4 pathway as a key regulator of intussusceptive angiogenesis and a 
druggable target to modulate the therapeutic outcome of VEGF delivery. 
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Materials and Methods 
Construction of blocker retroviral vectors 
 
Retroviral vectors were constructed encoding the following soluble blockers of TGF-
1, Ang/Tie2 and ephrinB2/EphB4 signaling, respectively: a) the Latency-Associated Peptide 
(LAP), which associates with TGF-1 to form the non-functional latent TGFβ complex, 
thereby inhibiting the biological activity of endogenous TGF-β1 (13); b) a receptor-body 
formed by fusing a truncated version of the receptor Tie2 and the Fc portion of IgG 
immunoglubulin (sTie2Fc), which sequesters angiopoietins and prevents them from signaling 
(14); and c) a monomeric truncated version of the receptor EphB4 (sEphB4), which binds 
membrane-bound ephrinB2 without activating it, as it does not form multimers, but prevents it 
from binding and activating the endogenous endothelial EphB4 receptor (15). The cDNAs of 
human LAP, murine sTie2Fc and human sEphB4 were cloned into the pAMFG retroviral 
vector in a bicistronic cassette (16), linked through an internal ribosomal entry sequence (IRES) 
to a truncated version of rabbit CD4 as a convenient cell surface marker, producing the 
pAMFG.CD4, pAMFG.CD4.LAP, pAMFG.CD4.sTie2Fc and pAMFG.CD4.sEphB4 
retroviral vectors. 
VEGF164 ELISA 
The production of VEGF164 in cell culture supernatants was quantified by a Quantikine 
mouse VEGF Immunoassay ELISA kit (R&D Systems, Abingdon, UK). One ml of fresh 
medium was incubated for 4 hours on myoblasts seeded overnight in a 60 mm dish, filtered 
and analyzed in duplicate. Results were normalized by the number of cells and time of 
incubation. Four dishes of cells were assayed per cell type (n=4). 
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In vivo myoblast implantation 
To avoid an immunological response to transduced myoblasts expressing xenogenic 
proteins (LacZ, rabbit CD4, human LAP and sEphB4), immunodeficient SCID CB.17 mice 
(Charles River Laboratories, Sulzfeld, Germany) were used. Myoblasts were dissociated in 
trypsin, resuspended at a concentration of 108 cells/ml in sterile PBS with 0.5% BSA (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) and 106 cells were injected into the Tibialis 
anterior (TA) and Gastrocnemius (GC) muscles in the lower hindlimb, using a 30-gauge needle 
syringe, as previously described (10). All experiments were performed with similar number of 
samples from both muscle locations and the results were pooled together. Mice of 8-12 weeks 
of age, with equal representation of both genders, were randomly assigned to experimental 
groups, with a minimum of n=4 mice/group. 
Recombinant VEGF delivery by fibrin hydrogels 
The transglutaminase substrate sequence NQEQVSPL (α2-PI1–8) was fused to the N 
terminus of the mouse VEGF-A164 cDNA by PCR. The fusion protein was expressed into 
Escherichia coli strain BL21 (De3) pLys (Novagen, Madison, WI) and isolated as described 
previously (17). Fibrin matrices of optimized composition were prepared as previously 
described (18), incorporating 56 mg/ml of aprotinin-α2-PI1–8, to ensure controlled duration of 
degradation over 4 weeks, and 50 μg/ml of α2-PI1–8-VEGF164. For in vivo delivery, 6- to 8-wk-
old immunodeficient CB.17 SCID mice (Charles River Laboratories) were used to avoid an 
immunological response to human fibrinogen and cross-linking enzymes. A liquid volume of 
50 μl was aspirated rapidly with a 0.3-ml insulin syringe with integrated 30-gauge needle 
(Becton Dickinson, Basel, Switzerland) and injected into the GC muscle of the mice previously 
anesthetized with 3% isofluorane inhalation. After injection, in situ polymerization was 
allowed for 20 s before slowly extracting the needle. 
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
109 
 
Recombinant adenovirus production and in vivo implantation 
Recombinant adenoviruses expressing mouse VEGF164 or human VEGF165, were 
produced using the Adeno-XTM Expression System (Clontech, Saint- Germain-en-Laye, 
France) according to the manufacturer’s recommendations. Adenoviral vectors were diluted in 
physiological solution and injected in TA and GC muscles in the lower hind limb of immune-
deficient CB.17 SCID mice (Charles River Laboratories) at the titer of 1x108 infectious 
units/injection, with a 30-gauge needle syringe, as previously described (19). Information on 
ischemia experiments is provided below. 
EphrinB2-Fc treatment 
To stimulate EphB4 signaling in vivo, mice received 1 mg/kg of mouse ephrinB2-Fc 
(R&D Systems) or control Fc (Abcam, Cambridge, UK) by intraperitoneal injections twice 
weekly, starting 3 days before the myoblast injection, according to published protocols (20). 
RNA extraction and quantitative real-time PCR 
For RNA extraction from total muscles, freshly harvested tissue was frozen in liquid 
nitrogen and disrupted using a Qiagen Tissue Lyser (Qiagen) in 1 ml TRIzol reagent 
(Invitrogen, Basel, Switzerland) for 100 mg of tissue. Total RNA was isolated from lysed 
tissues or in vitro cultured myoblasts, RAW264.7 and human dermal microvascular endothelial 
cells (HDMEC) with an RNeasy Mini Kit (Qiagen, Basel, Switzerland) according to 
manufacturer’s instruction. RNA was reverse transcribed into cDNA using the Omniscript 
Reverse Transcription kit (Qiagen) at 37°C for 60 minutes. Quantitative Real-Time PCR (qRT-
PCR) was performed on an ABI 7300 Real-Time PCR system (Applied Biosystems, Basel, 
Switzerland). Expression of genes of interest was determined using the following TaqMan 
Gene Expression assays (Applied Biosystems) according to manufacturer’s instructions: 
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mouse Tnfa (Mm00443258_m1); mouse Gapdh (Mm03302249_g1); mouse Pdgfb 
(Mm00440678_m1); mouse Pdgfrb (Mm00435545_m1); human Igfbp3 (Hs00365742_g1); 
human Esm1 (Hs00199831_m1) and human Gapdh (Hs02758991_g1). Reactions were 
performed in triplicate for each template, averaged and normalized to expression of the same-
species Gapdh housekeeping gene. 
Immunofluorescence tissue staining 
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and 
sacrificed by intravascular perfusion of 1% paraformaldehyde in PBS pH 7.4. TA and GC 
muscles were harvested, post-fixed in 0.5% paraformaldehyde in PBS for 2 h, cryoprotected in 
30% sucrose in PBS overnight at 4°C, embedded in OCT compound (CellPath, Newtown, 
Powys, UK), frozen in isopentane, and cryosectioned. The areas of engraftment were identified 
by tracking implanted myoblasts by X-gal staining (20-µm sections) or adenoviral infection 
sites by the typical mononuclear infiltrate with H&E (10-µm sections) in adjacent serial 
sections, as described previously (10). For immunofluorescence staining, 10-µm tissue sections 
were stained with the following primary antibodies and dilutions: rat monoclonal anti-mouse 
CD31 (clone MEC 13.3, BD Biosciences, Basel, Switzerland) at 1:100; mouse monoclonal 
anti-mouse α-SMA (clone 1A4, MP Biomedicals, Basel, Switzerland) at 1:400; rabbit 
polyclonal anti-NG2 (Merck Millipore, Darmstadt, Germany) at 1:200; rat monoclonal anti-
VE-Cadherin (clone 11D4.1, BD Biosciences, Basel, Switzerland) at 1:200, rabbit polyclonal 
anti-Ki67 (Abcam, Cambridge, UK) at 1:100; rabbit polyclonal anti-laminin (Abcam) at 1:200, 
rabbit polyclonal anti-pHH3-Ser28 (Cell Signaling Technology, Danvers, USA) at 1:100 and 
goat polyclonal anti-EphB4 at 1:50 (R&D Systems). Fluorescently labeled secondary 
antibodies (Invitrogen) were used at 1:200. 
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For pERK1/2 staining, tissue sections were permeabilized with ice-cold methanol for 
10 min, and blocked with 5% goat serum and 2% BSA in PBS with 0.3% Triton-X for 1 h at 
RT. Rabbit monoclonal anti-phospho-ERK1/2 antibody (Thr202/Tyr204, clone D13.14.4E, 
Cell Signaling Technology) was used at 1:100. 
To study vessel perfusion, 100 μg of FITC-labeled Lycopersicon esculentum lectin in 
50 μl (Vector Laboratories, Burlingame, USA) was injected into the femoral vein and allowed 
to circulate for 4 minutes before intravascular perfusion with 1% paraformaldehyde and muscle 
collection as described above. 
Vascular analyses 
 
Qualitative analysis of vascular morphology in immunofluorescence images was 
performed on all vascular structures visible in at least 3 fields/section with a 40X objective on 
a Carl Zeiss LSM710 3-laser scanning confocal microscope (Carl Zeiss, Feldbach, 
Switzerland) in at least 5 sections/muscle, cut at 100-150 μm of distance from each other (n=4 
muscles/group). 
Vessel diameters were measured in fluorescently immunostained sections as described 
(10). Briefly, 10 to 20 fields/muscle (n=4 muscles/group) were analyzed, measuring a total of 
minimum 300 diameters/group. Captured microscopic images were overlaid with a square grid, 
squares were randomly chosen and the diameter of each vessel (if any) in the center of selected 
squares was measured. To avoid selection bias, the shortest diameter in the selected vascular 
segment was systematically measured. All images were taken with a 20X objective on an 
Olympus BX63 microscope (Olympus, Volketswil, Switzerland) and analyses were performed 
with Cell Sens software (Olympus). 
Ki67+ and pHH3+ endothelial cells were quantified as a percentage of all endothelial 
cells in analyzed vascular structures. 300–3000 endothelial cells were analyzed/group in 3–5 
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fields taken from each area of effect. At least five areas with a clear angiogenic effect were 
analyzed per group (n=4 muscles/group). 
HDMEC in vitro assays 
Human microvascular endothelial cells (HDMEC) were isolated as previously 
described (21) and cultured in Endothelial Cell Basal Medium (EBM, Vitaris, Baar, 
Switzerland) supplemented with 10% FBS, 1% penicillin/streptomycin, 10 µg/ml sodium 
heparin, and 2.5 ng/ml FGF-2. Before each assay, cells were starved in EBM with 1% FBS for 
2 hours. 
Flow Cytometry analysis was performed with the following antibodies and dilutions: 
PE-conjugated mouse anti-VE-Cadherin (clone BV9, Biolegend, San Diego, CA) and PE-Cy7-
conjugated rat anti-CD31 (clone 390, Biolegend) at 1:100; goat anti-EphB4 and goat anti-
ephrinB2 (R&D Systems) at 1:50. 
Cell cycle analysis. 100,000 HDMEC were seeded in p60 dishes overnight and then 
stimulated with different combinations of the following reagents: 50 ng/ml hVEGF165 (R&D 
Systems), 50 ng/ml or 2 μg/ml ephrinB2-Fc (R&D Systems) and 25 ng/ml FGF-2 (BD 
Biosciences). After 24 hours, cells were collected, fixed and permeabilized with the FOXP3 
Fix/Perm kit (Biolegend) according to the manufacturer’s instructions, stained with rabbit 
polyclonal anti-Ki67 (Abcam), detected with an Alexa546-anti-rabbit secondary (Invitrogen), 
and with Alexa647-anti-pHH3 (clone HTA28, Biolegend). Finally, cells were incubated with 
Hoechst 33342 (Life Technologies, Zug, Switzerland) for 2 hours in the dark at 4°C and 
analyzed with a Fortessa FACS analyzer (Becton Dickinson). 
Internalization assay. 50,000 HDMEC were seeded in 6-well plate overnight and then 
stimulated with different combinations of the following reagents: 50 ng/ml hVEGF165, 2 μg/ml 
ephrinB2-Fc, and 30 µM Axitinib (Tocris Bioscience, Bristol, UK)  (22). After 30 minutes of 
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stimulation, cells were collected and stained for surface and total VEGF-R2, as previously 
described (23). Briefly, non-fixed and non-permeabilized HDMEC were first stained with 
Alexa647-anti-VEGF-R2 (clone HKDR-1; Biolegend) to label only the surface receptor. 
Subsequently, cells were fixed and permeabilized with the FOXP3 Fix/Perm buffer 
(Biolegend) and were split into two tubes, where one half was stained again with PE-anti-
VEGF-R2 (clone 7D4-6, Biolegend) in FOXP3 Perm buffer to visualize total cellular VEGF-
R2, while the other half was not stained. Analysis was performed with a Fortessa FACS 
analyzer (Becton Dickinson). 
Phosphorylation assay. 10,000-15,000 HDMEC were cultured in 8-well culture slides 
(Corning) and stimulated with 50 ng/ml hVEGF165 and 2 μg/ml ephrinB2-Fc alone or together 
for 10 min. Cells were immediately washed with PBS, fixed with 4% paraformaldehyde in 
PBS, blocked with 5% goat serum and 2% BSA in PBS with 0.3 % Triton-X for 1h at RT and 
stained with a rabbit monoclonal anti-phosphoTyr1175-VEGF-R2 antibody (clone D5B11, 
Cell Signaling Technology) and a goat anti-VE-Cadherin (C-19, Santa Cruz Biotechnology, 
Santa Cruz, CA), both at 1:200, followed by secondary antibody detection as described above. 
All samples were batch-stained together with same master mix of antibodies. In order to 
quantify the amount of phosphoVEGF-R2, stained cells where analyzed on a LSM710 3-laser 
scanning confocal microscope (Carl Zeiss), acquiring 8-bit images (Z-Stack, 1024x1024) with 
a 40X objective and maintaining the same acquisition settings for all samples. The amount of 
phosphoVEGF-R2 protein was measured by quantifying the staining intensity and normalized 
by the endothelial volume from the VE-Cadherin staining, using the Imaris 7.6.4 software 
(Bitplane, Zürich, Switzerland) to measure total pixel intensity of endothelial-specific 
phosphoVEGF-R2 immunostaining. 
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Hind-limb ischemia, gene transfer and analysis 
Immune-competent genetically hyperlipidemic female LDLR-/-ApoB100/100 mice (age 
of 14-15 months, n=20), which are deficient for the LDL receptor and express only 
apolipoprotein B100 in C57Bl/6J genetic background (24), were fed on a standard chow diet. 
Experimental unilateral hindlimb ischemia was induced by permanent ligation of both common 
femoral artery and vein proximal to the origin of the profound femoral artery branch. Post-
operatively, the posterior calf muscles received intramuscular injections of 2x1010 pfu/ml 
adenoviral vectors expressing either human VEGF-A165 (Ad-hVEGF) or beta-galactosidase 
(Ad-LacZ) as control. Mice were treated with i.p. injections of ephrinB2-Fc (R&D Systems) 
or control Fc (Abcam) as described above 0, 3, 6 and 9 days after the gene transfer. All animals 
were assigned to the different treatment groups by randomization before surgery. 
Contrast enhanced ultrasound imaging of perfusion and data analysis. To follow 
muscle blood flow recovery after ischemia, contrast enhanced ultrasound imaging (CEU) was 
performed pre-operatively and 0, 4, 7 and 11 days post-operation with a Siemens Acuson 
Sequoia 512 system equipped with 15L8 transducer using the Cadence contrast pulse 
sequencing (CPS) imaging mode with the following parameters: frequency 14 MHz, power 8 
dB, mechanical index 0.25, CPS gain 0 and depth 20 mm (25). Transverse plane perfusion 
video clips of both ischemic and intact hind limbs were recorded upon the administration of an 
intravenous bolus injection of 50 μl of Sonovue contrast agent (Bracco, Milano, Italy) via the 
jugular vein. Maximal signal intensity (dB) of the video clips, representing relative perfusion, 
was quantified with Datapro software v2.13 (Noesis, Courtaboeuf, France) and signal intensity-
time curves were created (n=4-6 animals/group). 
Histological analyses. Animals were sacrificed on day 11. Posterior calf muscles were 
collected for histological analysis after perfusion-fixation with 1% paraformaldehyde. Muscle 
samples were further immersed for 4h in 4% paraformaldehyde-sucrose and then in 15% 
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sucrose before paraffin embedding. Four-µm thick transversely cut sections were used to 
analyze muscle tissue damage by H&E staining and vascularity by CD31 
immunohistochemistry. For tissue damage assessment, four different histological muscle areas 
were classified on H&E-stained sections as: 1) normal; 2) necrotic (myofibers with no nuclei); 
3) early regeneration (appearance of basophilic satellite cells), or 4) late regeneration 
(eosinophilic myofibers with angular shape and centrally positioned nuclei). Each 
corresponding muscle area was quantified using analySIS imaging software (Soft Imaging 
System GmbH, Münster, Germany) and expressed as a percentage of the whole cross-sectional 
muscle area (n=4-5 animals/group). 
Vascularity was assessed by immunohistochemical staining with a rat monoclonal anti-
mouse CD31 primary antibody (clone MEC 13.3, BD Biosciences Pharmingen, dilution 1:25, 
overnight at +4°C), with blocking in 10% rabbit serum, 2% mouse serum and 1% BSA 1h at 
RT, followed by a biotinylated rabbit anti-rat secondary antibody (BA-4001, Vector 
laboratories, dilution 1:200, 30min at RT) and detection with the avidin-biotin-horseradish 
peroxidase system (Vector Laboratories) with tyramide signal amplification (TBA, Biotin 
System, PerkinElmer, Shelton, USA) and DAB as a chromogen (Zymed, San Francisco, USA). 
Micrographs of the stained sections were acquired with 200x magnification using an Olympus 
AX-70 light microscope (Olympus Optical, Tokyo, Japan) and analySIS imaging software 
(Soft Imagining System GmbH). Vessel diameters were quantified from 5 fields/sample of 
CD31-stained sections acquired within regenerating muscle tissue (n=4-5 muscles/group), 
using Cell Sens software (Olympus) and the smallest diameter was measured. All 
measurements were performed by a blinded observer. 
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Statistical analysis 
Data are presented as mean±standard error. The significance of differences was 
assessed with the GraphPad Prism 6 software (GraphPad Software). The normal distribution 
of all data sets was tested and, depending on the results, multiple comparisons were performed 
with the parametric 1-way analysis of variance (ANOVA) followed by the Bonferroni test, or 
with the non-parametric Kruskal-Wallis test followed by Dunn’s post-test, while single 
comparisons were analyzed with the non-parametric Mann-Whitney test or the parametric one-
tailed t-test. Gene expression data representing fold-changes versus control, which are 
asymmetrically distributed, were first normalized by logarithmic transformation and then 
analyzed by 1-way ANOVA followed by the Bonferroni test for multiple comparisons, or by 
t-test with Welch’s correction for single comparisons. Vessel diameter values were first 
normalized by log2-transformation and then analyzed by 1-way ANOVA followed by 
Bonferroni test for multiple comparisons or by one-tailed t-test for single comparisons. p<0.05 
was considered statistically significant. 
Study approval 
Animal studies were performed in accordance with the Swiss Federal guidelines for 
animal welfare and were approved by the Veterinary Office of the Canton of Basel-Stadt 
(Basel, Switzerland; Permit 2071). All experimental procedures for ischemia studies in LDLR-
/-ApoB100/100 mice were approved by the National Animal Experiment Board of Finland (license 
number: ESAVI/5343/04.10.07/2014) and carried out in accordance with the guidelines of the 
Finnish Act on Animal Experimentation. 
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Results 
Generation and validation of blockers of pericyte-endothelium paracrine 
signaling 
To determine whether and which pericyte-derived signals may control normal vascular 
morphogenesis induced by moderate VEGF doses, we blocked the three main signaling 
pathways responsible for the crosstalk between pericytes (P) and endothelial cells (EC), i.e. the 
TGF-β1, Angiopoietin (Ang)/Tie2 and ephrinB2/EphB4 axes. A clonal myoblast population 
that homogeneously expresses moderate VEGF levels (V-low=61±2.9 ng/106 cells/day) was 
selected to induce normal angiogenesis (9, 16), or myoblasts that do not express VEGF as 
control (Ctrl). Both populations were transduced with retroviral vectors co-expressing soluble 
blockers of the TGF-1 (Latency-Associated Peptide, LAP), Ang/Tie2 (sTie2Fc) and 
ephrinB2/EphB4 (sEphB4) signaling, together with a truncated version of CD4 (trCD4) in a 
bicistronic cassette (Supplementary Figure 1A) as a FACS-quantifiable surface marker (16) 
(Supplementary Figure 1B). ELISA measurements confirmed that all blocker-expressing V-
low populations maintained a similar VEGF production as the original V-low clone (V-low = 
64±3, V-low LAP = 64±6, V-low sTie2Fc = 79±4, V-low sEphB4 = 62±5 ng/106 cells/day). 
Specific expression of each blocker was confirmed by RT-PCR on the in vitro cultured 
myoblast populations (Supplementary Figure 1C), while the functional activity of the secreted 
proteins was verified by appropriate in vitro assays on myoblast conditioned media 
(Supplementary Figure 1D-F). 
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Blockade of ephrinB2/EphB4 signaling, but not of TGF-β1/TGF-βR or 
Angiopoietin/Tie2, switches VEGF-induced angiogenesis from normal to 
aberrant 
Simultaneous blockade of all three pathways of the P-EC crosstalk was achieved by co-
implanting the individual blocker-expressing populations into hind-limb muscles of adult mice 
(Figure 1). After 2 weeks, myoblasts expressing only the blockers in the absence of VEGF 
(Ctrl 3b) did not perturb the pre-existing vasculature compared to controls (Ctrl CD4). Low 
levels of VEGF induced the growth of normal mature capillaries, tightly associated with 
NG2+/α-SMA- pericytes, but co-expression of the three soluble inhibitors converted these into 
aberrant vascular structures, characterized by enlarged and irregular diameters and covered by 
a patchy layer of SMA+/NG2- smooth muscle cells instead of pericytes (V-low 3b), similar to 
the angioma-like structures induced by another monoclonal myoblast population expressing 
high VEGF levels alone (10) (V-high = 137.7±1.6 ng/106 cells/day). 
 
Figure 1. Triple blockade of TGF-β1, Angiopoietin/Tie2, and ephrinB2/EphB4 paracrine signals causes 
aberrant angiogenesis with low VEGF levels. Immunofluorescence staining of endothelium (CD31, red), 
pericytes (NG2, green), smooth muscle cells (α-SMA, cyan) and nuclei (DAPI, blue) on frozen sections of limb 
muscles injected with myoblast clones expressing different VEGF levels (V-low and V-high, respectively) or co-
expressing low VEGF with blockers of the TGF-β1, Angiopoietin/Tie2 and ephrinB2/EphB4 pathways (V-low 
3b). Cells expressing only CD4 surface marker (Ctrl CD4) or blockers (Ctrl 3b) served as controls. After two 
weeks V-low induced normal pericyte-covered capillary networks compared to controls, but these were switched 
to aberrant, enlarged and smooth muscle-covered vessels in the presence of the three blockers, similar to those 
induced by high VEGF alone (V-high). Scale bar = 25 μm. 
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To determine whether any of the three signaling pathways was individually responsible 
for the switch, each blocker-secreting V-low population was injected separately (Figure 2A). 
By 2 weeks ephrinB2/EphB4 blockade caused the appearance of irregularly enlarged aberrant 
vascular structures, similar to those induced by high VEGF alone, whereas neither TGF-
β1/TGF-βR nor Ang/Tie2 blockade affected the normal angiogenesis induced by V-low. 
Quantification of vessel diameter distributions showed that V-low induced angiogenesis 
characterized by homogeneous capillary-size vessels with a median of 4.0 μm and 90th 
percentile of 6.1 μm. However, inhibition of ephrinB2/EphB4 signaling gave rise to a fraction 
of significantly enlarged structures, with 13% of vessels having diameter >10 μm, compared 
to 2% and 1% that could be observed in muscles implanted with control cells expressing only 
sEphB4 and no VEGF, or with V-low cells alone, respectively (Figure 2B). The nature of mural 
cells associated with vessels induced by V-low alone or with sEphB4 was further investigated 
by co-staining for the vascular basal lamina. As can be seen in Figure 2C, normal capillaries 
induced by low VEGF were associated with NG2+ pericytes that were completely embedded 
in the laminin-positive basal lamina, whereas the mural cells associated with the aberrant 
vascular structures induced in the presence of sEphB4 were both α-SMA+ and positioned 
externally to the basement membrane, and were therefore identified as smooth muscle cells 
rather than pericytes. 
 Intravascular staining by FITC-labeled tomato lectin, which binds to the luminal 
surface of endothelial structures only if they are connected to the systemic circulation, co-
localized with endothelium staining (CD31), indicating that the aberrant structures caused by 
V-low sEphB4 cells were not simply endothelial clusters, but were functionally perfused 
(Supplementary Figure 2). This is in agreement with previous findings for angioma-like 
structures induced by high VEGF alone (11). Lastly, to determine the evolution of the 
morphological changes caused by ephrinB2/EphB4 blockade, tissues were analyzed after 12 
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weeks, showing that the aberrant structures observed by 2 weeks continued growing in size 
(Supplementary Figure 3). 
Altogether, these results suggest that the ephrinB2/EphB4 pathway, but not TGF-
β1/TGF-βR and Ang/Tie2, has a function in the development of normal angiogenesis by low 
VEGF doses and its blockade causes the switch to an aberrant phenotype resembling the 
angioma-like vascular structures induced by high VEGF alone. 
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Figure 2. Blockade of ephrinB2/EphB4 signaling switches VEGF-induced angiogenesis from normal to 
aberrant. (A) Immunofluorescence staining of endothelium (CD31, red), pericytes (NG2, green), smooth muscle 
cells (α-SMA, cyan) and nuclei (DAPI, blue) on frozen sections of limb muscles injected with the V-low myoblast 
clone or control cells (Ctrl) co-expressing either of the 3 soluble blockers (LAP, sTie2Fc or sEphB4) or just the 
CD4 marker. Two weeks later inhibition of ephrinB2/EphB4 signaling, but not of the other two pathways, 
switched the normal angiogenesis induced by low VEGF to aberrant vascular structures. (B) Distribution of vessel 
diameters, showing the induction of a population of aberrantly enlarged vessels >10µm by ephrinB2/EphB4 
blockade. (C) Immunofluorescence staining for mural cell markers (NG2 or α-SMA, both green) and basal lamina 
(laminin, purple) shows that aberrant vessels induced by ephrinB2/EphB4 blockade are associated with smooth 
muscle (α-SMA+ outside the basal lamina) rather than pericytes (NG2+ embedded inside the basal lamina). Scale 
bar = 25 μm. 
 
Activation of EphB4 signaling prevents aberrant angiogenesis induced by 
high VEGF doses 
To complement the ephrinB2/EphB4 inhibition data above, we asked whether the 
pharmacological activation of EphB4 might prevent aberrant angiogenesis by high VEGF 
levels. A recombinant ephrinB2-Fc chimeric protein, whereby fusion with the immunoglobulin 
Fc portion enables the formation of dimers of ephrinB2 extracellular domains, was used to 
activate the EphB4 receptor (26). V-high clonal myoblasts were injected in leg muscles of adult 
mice that were treated systemically with ephrinB2-Fc or Fc control protein by intraperitoneal 
injection (27). Two weeks later, high VEGF induced heterogenous enlarged vascular structures 
associated with smooth muscles cells (Figure 3A). As normal muscle capillaries have 
homogeneous sizes smaller than 10 µm, vessel diameter distribution was quantified and 
showed that 12% of induced structures were larger than 10 µm (Figure 3C). On the other hand, 
treatment with ephrinB2-Fc yielded networks of pericyte-covered normal capillaries (Figure 
3B), similar to those induced by V-low alone (Figure 2A) and with a homogeneous diameter 
distribution (Figure 3C; median = 4.0 μm and 2% of vessels larger than 10 µm). 
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These results were confirmed independently of cell-based VEGF delivery, using an 
optimized fibrin-based platform that we recently developed for controlled release of VEGF 
recombinant protein at specific doses and with duration up to 4 weeks in skeletal muscle (18). 
An engineered version of murine VEGF164 was fused to the transglutaminase substrate 
octapeptide NQEQVSPL (α2-PI1–8-VEGF), to allow its covalent cross-linking into fibrin 
hydrogels by the coagulation factor XIIIa and release only by enzymatic cleavage (28, 29). 
Fibrin hydrogels containing a high dose of α2-PI1–8-VEGF (50 μg/ml), which we previously 
found to induce aberrant angiogenesis (18), were injected in gastrocnemius muscles and the 
animals were treated systemically with ephrinB2-Fc. In agreement with the myoblast-based 
experiments, ephrinB2-Fc treatment prevented the appearance of heterogeneous, enlarged and 
smooth muscle-covered vascular structures induced by the high VEGF dose, yielding instead 
homogeneous networks of pericyte-covered capillaries by 7 days (Figure 3D-F).  
The observed prevention of aberrant vascular structures could be due to either their 
switch to a normal phenotype or to their regression. Since regressing vessels leave behind their 
basal lamina, a staining for laminin was performed to detect so-called “empty sleeves” of 
vascular basement membrane, which provide a sort of historical record of pre-existing vessels 
(30). As shown in Supplementary Figure 4, by 7 days after injection of V-high myoblasts we 
could not identify laminin sleeves in the tissues treated with ephrinB2-Fc compared with the 
controls treated with Fc only. On the other hand, many empty sleeves were clearly visible in 
positive control tissues treated with the potent VEGF blocker Aflibercept, which caused the 
regression of vascular structures induced by high VEGF, suggesting that EphB4 stimulation 
could prevent the formation of aberrant structures by regulating VEGF-induced vascular 
morphogenesis. 
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
123 
 
Altogether, the results of these inhibition and stimulation experiments indicate that the 
ephrinB2/EphB4 signaling pathway determines whether a specific VEGF dose induces normal 
or aberrant angiogenesis. 
 
 
Figure 3. Activation of EphB4 by ephrinB2-Fc prevents aberrant angiogenesis. A high VEGF dose was 
delivered to limb muscles of mice either by genetically modified myoblasts (V-high clone, A-C) or as fibrin-
bound recombinant protein (Fibrin-High V, D-F) and animals were treated intraperitoneally with ephrinB2-Fc or 
control Fc recombinant protein. (A-B and D-E) Immunostaining of frozen sections for endothelium (CD31, red), 
pericytes (NG2, green), smooth muscle cells (α-SMA, cyan) and nuclei (DAPI, blue) showed that, with both 
delivery platforms, ephrinB2-Fc treatment prevented the induction of aberrant vascular structure by high VEGF 
and yielded only normal capillary networks. * = lumen of an aberrant structure; scale bar = 25 μm. (C and F) 
Quantification of vessel diameter distributions showed a consistent decrease in vessel sizes after treatment with 
ephrinB2-Fc. Red arrows and numbers indicate the fraction of vessel diameters > 10 µm. 
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EphrinB2/EphB4 signaling controls the degree of initial vascular 
enlargement induced by VEGF 
In order to understand how ephrinB2/EphB4 signaling regulates the switch between 
normal and aberrant angiogenesis, we investigated the effects of EphB4 inhibition or 
stimulation on the early morphogenic events after delivery of low and high VEGF levels, 
respectively, which comprise an initial stage of circumferential enlargement of pre-existing 
vessels by 3-4 days, followed by longitudinal splitting by 7 days (9). As shown in Figure 4A, 
by 4 days both V-low and V-high myoblasts induced vascular enlargements, whose diameter 
was proportional to VEGF dose (V-low: median=8.8 µm, average=10.5±0.8 µm; V-high: 
median=11.9 µm, average=14.5±1.7 μm). However, co-expression of sEphB4 increased the 
average size of vascular enlargements induced by low VEGF (V-low sEphB4=15.1±1.1 μm, 
p<0.01 vs V-low; Figure 4E) to values similar to those caused by high VEGF alone (Figure 
4F). Conversely, EphB4 stimulation by systemic treatment with ephrinB2-Fc significantly 
reduced the diameter of vascular enlargements induced by high VEGF (Figure 4F; V-
high+ephrinB2-Fc=9.5±1.0 μm, p<0.05 vs V-high+Fc). By 7 days the smaller enlargements 
induced by V-low remodeled to normal capillaries, whereas the larger ones induced by V-high 
failed to split and some segments gave rise to aberrantly enlarged structures (Figure 4C-D). 
However, upon modulation of EphB4 signaling the fate of initial enlargements was determined 
by their size rather than the dose of VEGF. In fact, ephrinB2-Fc treatment caused proper 
remodeling to homogeneous normal capillary networks despite high VEGF, whereas EphB4 
inhibition led to failure of splitting despite low VEGF (Figure 4C-D), as shown also by the 
quantification of vessel diameters (Figure 4G-H). 
 The transition from normal to aberrant angiogenesis by increasing VEGF doses has 
been shown to be associated with loss of pericytes at the initial stage of circumferential 
enlargement 4 days after factor delivery (9). Analysis of mural cell coverage showed that 
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inhibition of ephrinB2/EphB4 signaling did not interfere with pericyte coverage of initial 
vascular enlargements induced by low VEGF, both at 3 and 4 days (Figure 5A). In the presence 
of low VEGF alone pericytes were positive for NG2 and negative for -SMA, as expected and 
typical for microvasculature of skeletal muscle. However, upon co-expression of the sEphB4 
blocker most mural cells associated with vascular enlargements became double-positive for 
both NG2 and α-SMA (Figure 5A). Co-staining for laminin revealed that NG2+/α-SMA+ mural 
cells were completely embedded into the vascular basement membrane (Figure 5B), thereby 
confirming their identity as pericytes and excluding a transition to a smooth muscle cell 
phenotype (31). In line with this, gene expression analysis in muscles 3 days after myoblast 
implantation, showed that both Pdgfb and its receptor Pdgfrb, which regulate pericyte 
recruitment, were similarly upregulated after stimulation with VEGF regardless of EphB4 
inhibition (Figure 5C). 
Altogether, these results indicate that ephrinB2/EphB4 signaling: 1) modulates the 
degree of vascular enlargement induced by a given VEGF dose, determining whether splitting 
into normal capillaries succeeds or fails; and 2) does not interfere with pericyte recruitment. 
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Figure 4. EphrinB2/EphB4 signaling regulates the degree of vascular enlargement by VEGF dose. Mouse 
limb muscles were implanted with myoblast clones expressing low (V-low) or high (V-high) VEGF doses, while 
the ephrinB2/EphB4 signaling pathway was inhibited by co-expression of the sEphB4 blocker (V-low sEphB4, 
A, C and E-F) or stimulated by intraperitoneal treatment with ephrinB2-Fc or control Fc protein (B, D and G-H). 
Immunostaining of frozen sections stained for endothelium (CD31, red), pericytes (NG2, green), smooth muscle 
cells (α-SMA, cyan) and nuclei (DAPI, blue) and quantification of vessel diameter distribution showed that 4 days 
after VEGF delivery the size of initial circumferential enlargements was increased by ephrinB2/EphB4 inhibition 
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and reduced by its stimulation (A and B). By 7 days, after completion of remodeling, EphB4 inhibition switched 
normal angiogenesis by V-low to aberrant (C) and its stimulation converted aberrant structures by V-high into 
normal capillary networks (D). Red arrows and numbers indicate the fraction of vessel diameters > 10 µm. * = 
lumen of aberrant structures; mf = muscle fibers; scale bar = 25 μm. (E-H) Quantification of vessel diameters 
after 4 days (E and G) and 7 days (F and H). Values represent means of individual measurements in each sample 
± SEM (n=3-4 independent samples/group). * p<0.05 and ** p<0.01 by one-tail t-test, after data normalization 
by logarithmic transformation. 
EphrinB2/EphB4 signaling modulates VEGF-induced endothelial 
proliferation 
The initial vascular enlargement caused by VEGF overexpression is associated with 
endothelial proliferation (9). Therefore, we investigated whether ephrinB2/EphB4 signaling 
may regulate the amount of endothelial proliferation induced by specific VEGF doses in vivo. 
The degree of proliferation depends both on the proportion of cycling cells and on the speed 
with which they cycle. Therefore, we performed co-immunostaining for CD31 and either Ki67, 
which is expressed throughout all phases of the cell cycle and marks all proliferating cells, but 
not quiescent ones in G0 (32), or phosphorylated Histone H3 (pHH3), which is only detectable 
during the G2-M phase (33, 34). Since the duration of the cell cycle depends on how long cells 
spend in G1, while the G2-M phase has a constant duration, the proportion of pHH3+ cells 
reflects how often proliferating cells are cycling and provides an indication of the endothelial 
proliferation rate. 
Vascular enlargements induced by V-low alone or with sEphB4 co-expression 
contained similar proportions of Ki67+ endothelial cells at both 3 and 4 days after myoblast 
implantation (Figure 6A). However, at 3 days EphB4 inhibition caused a significant increase 
by about 40% in the frequency of pHH3+ endothelial cells compared to low VEGF alone 
(Figure 6B), suggesting a faster proliferation rate. 
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Figure 5. Inhibition of ephrinB2/EphB4 signaling does not prevent pericyte-recruitment. Muscles were 
harvested 3 and 4 days after implantation of V-low or V-low sEphB4 myoblast clones. (A) Immunofluorescence 
staining of endothelium (CD31, red), pericytes (NG2, green), smooth muscle cells (α-SMA, cyan) and nuclei 
(DAPI, blue). In both conditions initial vascular enlargements were tightly associated with mural cells displaying 
a pericyte morphology, which however upregulated α-SMA expression in the presence of EphB4 blockade. (B) 
Co-staining for laminin (LAM, red) confirmed the pericyte identity of both α-SMA-positive and –negative mural 
cells, as both were embedded inside the endothelial basal lamina. * = vascular enlargements; scale bar = 25 μm. 
(C) Gene expression of Pdgfb and Pdgfrb was quantified in skeletal muscles 3 days after myoblast implantation 
and expressed as fold-change versus control muscles (n=4). ***, ### p<0.001 vs Ctrl (*) or vs sEphB4 (#) by 1-
way ANOVA with Bonferroni multiple comparisons test, after data normalization by logarithmic transformation. 
 
 At 7 days, most of the endothelial cells in the normal capillary networks induced by 
low VEGF were Ki67- and became quiescent, as expected, whereas 40% of the endothelium in 
the aberrant vascular structures generated in the presence of EphB4 blockade were still 
proliferating (Figure 6A), similarly to those induced by high VEGF alone (Figure 6C).  
Conversely, EphB4 stimulation by systemic ephrinB2-Fc treatment caused a significant 
reduction in the proportion of Ki67+ endothelial cells at both 4 and 7 days (Figure 6C), while 
the frequency of pHH3+ endothelial cells was significantly reduced by about 40% already by 
3 days (Figure 6D), reducing it to a similar value as that induced by low VEGF alone (Figure 
6B). Furthermore, EphB4 expression in angiogenic vessels in vivo was restricted to the 
endothelium, with no detectable signal on associated pericytes, and was not modified by either 
VEGF dose or its own stimulation by ephrinB2-Fc or inhibition by sEphB4 (Supplementary 
Figure 5). 
To determine whether EphB4 signaling regulated endothelial proliferation directly or 
indirectly, we investigated the effects of ephrinB2-Fc treatment on endothelial cell cycle 
progression in vitro. Human dermal microvascular cells (HDMEC), which strongly express 
EphB4 and are mostly negative for ephrinB2 (Supplementary Figure 6), were stimulated with 
recombinant VEGF or with the unrelated strong mitogen FGF-2 (35), with or without treatment 
with recombinant ephrinB2-Fc, and cell cycle analysis was performed by FACS after staining 
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for Ki67 and pHH3 (Figure 6E). As shown in Figure 6F, in control conditions (no VEGF and 
2000 ng/ml of ephrinB2-Fc) about 50% of HDMEC were in G0: VEGF stimulation reduced 
this percentage to 30%, but treatment with ephrinB2-Fc (50 and 2000 ng/ml) significantly and 
dose-dependently increased the proportion of non-cycling cells to 40%. Conversely, VEGF 
stimulation increased the amount of cells undergoing mitosis in the G2-M phase by about 50% 
(from 0.8% to 1.2%), while ephrinB2-Fc treatment dose-dependently reversed this effect 
(Figure 6G). Notably, the anti-proliferative effect of ephrinB2-Fc treatment was not restricted 
to VEGF, as it similarly reduced the mitogenic effects of FGF-2 (Figure 6F-G). 
Thus, combined in vivo and in vitro analyses indicate that EphB4 signaling regulates 
endothelial proliferation by modulating the mitogenic activity of VEGF. 
EphB4 modulates VEGF signaling output downstream of VEGF-R2 
activation 
In order to determine the mechanism by which EphB4 modulates VEGF activity, we 
assessed whether EphB4 stimulation regulated VEGF-R2 internalization, phosphorylation or 
downstream signaling in HDMEC in vitro (36, 37). VEGFR-2 internalization after treatment 
with VEGF was analyzed by FACS (Fig 7A). VEGF stimulation strongly reduced the staining 
for surface VEGF-R2 without changing the total amount of VEGF-R2 expressed by the cells. 
While surface receptor staining could be restored by co-treatment with the VEGF-R2 receptor 
tyrosine kinase inhibitor Axitinib (22), this was not observed upon co-treatment with 2000 
ng/ml of ephrinB2-Fc. Quantification of the fraction of VEGF-R2 internalization (Figure 7B) 
confirmed that Axitinib could robustly prevent VEGF-induced VEGF-R2 internalization, 
while ephrinB2-Fc caused a very small, albeit significant, reduction by <5%. Neither Axitinib 
nor ephrinB2-Fc had any effect in the absence of VEGF stimulation. 
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Figure 6. EphrinB2/EphB4 signaling modulates endothelial proliferation. (A-D) Muscles were harvested 3, 
4 and 7 days after implantation of V-low or V-low sEphB4 clones, or V-high cells while treating animals 
systemically with ephrinB2-Fc or control Fc proteins. Endothelial proliferation was assessed by quantifying the 
percentage of endothelial cells positive for Ki67, which marks all cycling cells (A and C), or phosphorylated 
Histone H3, which marks only cells in the G2/M phase (pHH3, B and D), by immunofluorescence staining on 
frozen muscle sections. EphB4 inhibition specifically increased the rate of endothelial proliferation (pHH3+ cells) 
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and its stimulation by ephrinB2-Fc conversely decreased it. * p<0.05, ** p<0.01 and *** p<0.001 by 1-way 
ANOVA with Bonferroni multiple comparisons test. (E-G) Human dermal microvascular endothelial cells 
(HDMEC) were treated in vitro with recombinant VEGF or FGF2, while EphB4 was stimulated with ephrinB2-
Fc (50 or 2000 ng/ml). Cell cycle analysis was performed by FACS after staining for Ki67 and pHH3 (E) and the 
proportion of cells withdrawn from cycle (G0) or in mitosis (M) were quantified (F-G). EphB4 stimulation dose-
dependently increased quiescence and decreased mitosis by both mitogens. # p<0.05, ## p<0.01 and ***, ### 
p<0.001 by 1-way ANOVA with Bonferroni multiple comparisons test (n=3 independent replicates). 
 
To determine whether the minimal reduction in VEGF-R2 internalization by ephrinB2 
was functionally relevant, phosphorylation of VEGF-R2 was quantified after staining with a 
specific antibody for phospho-tyrosine 1175 (pTyr1175), i.e. the key residue by which VEGF-
R2 activates the MAPK/ERK pathway and stimulates cell proliferation (38). EphrinB2-Fc 
treatment did not reduce the increase in pTyr1175 caused by VEGF (Figure 7C), suggesting 
that EphB4 stimulation did not directly affect VEGF-R2 activation.  
The effect of EphB4 activation on VEGF signaling downstream of the receptor was 
investigated by quantifying the expression of the VEGF-R2 target genes Esm-1/Endocan and 
Igfbp3. As shown in Figure 7D, both genes were upregulated by VEGF in HDMEC in vitro, as 
expected. However, ephrinB2-Fc treatment did not affect the expression of Esm-1/Endocan, 
which is regulated by the PI3-kinase/AKT signal transduction pathway (39), but it significantly 
down-regulated expression of Igfbp3, which is instead also regulated by ERK1/2 signaling (40, 
41). Therefore, the effects of EphB4 signaling on VEGF-induced ERK1/2 activation were 
assessed in vivo by quantifying the percentage of endothelial cells positive for phosphorylated 
ERK1/2 (pERK1/2) in the initial vascular enlargements induced 3 and 4 days after implantation 
of myoblasts expressing low or high VEGF levels and in the presence of EphB4 inhibition or 
stimulation, respectively, similarly to the experimental set-up described in Figure 4. 
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Figure 7. EphB4 regulates VEGF-induced phosphorylation of endothelial ERK1/2 downstream of VEGF-
R2 activation. (A-D) HDMEC were treated in vitro with VEGF alone or together with ephrinB2-Fc or the VEGF-
R2 small molecule inhibitor Axitinib as a positive control. VEGF-R2 internalization (A-B, n=6) and 
phosphorylation at tyrosine Y1175 (C, n=4) were quantified by FACS and immunocytochemistry, respectively. 
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Expression of VEGF-R2 target genes Igfpb3 and Esm1 was quantified by real-time qRT-PCR (D, n=8). EphB4 
activation by ephrinB2-Fc did not affect either VEGF-R2 internalization or phosphorylation or expression of 
Esm1, which is downstream of PI3K, but reduced that of Igfpb3, which is regulated by pERK1/2. (E-H) Muscles 
were harvested 3 and 4 days after implantation of V-low or V-low sEphB4 clones, or V-high cells while treating 
animals systemically with ephrinB2-Fc or control Fc proteins. Frozen sections were immunostained for 
phosphorylated ERK1/2 (p-ERK1/2) and the endothelial junctional protein VE-Cadherin (VE-CAD) (E and G) 
and the percentage of p-ERK1/2-positive endothelial cells was quantified (F and H, n=4 independent 
muscles/group). EphB4 inhibition and stimulation respectively increased and decreased ERK1/2 activation 
downstream of VEGF-R2. Scale bar = 20 μm; *, # p<0.05, ** p<0.01 and ***, ### p<0.001 by 1-way ANOVA 
with Bonferroni multiple comparisons test. Gene expression data (D) were first normalized by logarithmic 
transformation. 
 
After 3 days, about 10% of endothelial cells in vascular enlargements induced by low 
VEGF stained positive for pERK1/2, but EphB4 inhibition increased this proportion to about 
15%, which was similar to that induced by high VEGF alone. Conversely, EphB4 activation 
by treatment with ephrinB2-Fc significantly reduced the amount of pERK1/2-positive 
endothelial cells in structures induced by high VEGF to levels similar to those of low VEGF 
alone (Figure 7E-F). By 4 days, pERK1/2-positive cells dropped to about 3% with low VEGF 
alone, but EphB4 inhibition caused this fraction to remain at about 15%, similarly to high 
VEGF alone, and EphB4 activation in the presence of high VEGF again reduced it significantly 
to about 5% (Figure 7G-H), in agreement with the day 3 results. 
Altogether, these in vitro and in vivo data show that EphB4 activation by ephrinB2 
modulates endothelial proliferation induced by specific VEGF doses without affecting VEGF-
R2 activation, but rather by modulating the degree of ERK1/2 activation downstream of the 
receptor. 
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EphB4 stimulation prevents aberrant angiogenesis by uncontrolled 
adenoviral VEGF gene delivery and reduces muscle necrosis after ischemia 
Lastly, we sought to extend our findings, obtained with a controlled myoblast-based 
gene delivery platform, to a gene delivery system appropriate for clinical translation as a gene 
therapy approach. Therefore, first we tested whether ephrinB2-Fc treatment could prevent 
aberrant angiogenesis induced by intramuscular delivery of a VEGF-expressing adenoviral 
vector (Ad-mVEGF) in immune-deficient SCID mice, to avoid the confounding factor of 
immune clearance of the viral vector (42). After 2 weeks Ad-mVEGF induced several enlarged 
and multi-lumenized, smooth muscle-covered aberrant vascular structures, but ephrinB2-Fc 
treatment prevented their appearance and yielded only normal capillary networks associated 
with NG2+ pericytes (Figure 8A), with more homogeneous diameters (Figure 8B) and smaller 
in size (Figure 8C; Ad-mVEGF+Fc=7.4±0.5 µm vs Ad-mVEGF+ephrinB2-Fc=6.1±0.2 µm, 
p<0.05).  
To investigate the therapeutic potential of this approach, acute hindlimb ischemia was 
induced in immune-competent hyperlipidemic mice (24). Intramuscular adenoviral transfer of 
the human VEGF165 gene (Ad-hVEGF) induced capillary growth compared to control vector 
(Ad-LacZ), but also formation of aberrant, lacunae-like vascular structures (Figure 8D). 
Concomitant systemic treatment with ephrinB2-Fc prevented the formation of highly enlarged 
vascular lacunae (Figure 8D) and significantly reduced mean vessel size (Figure 8E; Ad-
hVEGF+Fc=5.6±0.2 µm vs Ad-hVEGF+ephrinB2-Fc=5.0±0.2 µm, p<0.05), confirming the 
results in non-ischemic muscle. 
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Figure 8. EphB4 stimulation prevents aberrant angiogenesis by uncontrolled VEGF expression and 
improves the outcome of adenoviral VEGF delivery in ischemia. (A-C) Immune-deficient SCID mice received 
intramuscular injections of adenovirus expressing murine VEGF164 (Ad-mVEGF) and were treated systemically 
with ephrinB2-Fc or control Fc proteins. Muscles were harvested 2 weeks later and frozen sections were stained 
for endothelium (CD31, red), pericytes (NG2, green) and smooth muscle cells (α-SMA, cyan) (A). Vessel 
diameters were quantified (n=4 independent samples/group) and results are shown as size distribution (B) and 
mean of individual measurements in each sample ± SEM (C). EphB4 stimulation prevented the appearance of 
aberrantly enlarged and smooth muscle-covered vascular structures, and reduced the average diameter of induced 
vessels. (D-H) Hindlimb ischemia was induced in immune-competent C57/Bl6 mice. Adenoviral vectors 
expressing human VEGF165 (Ad-hVEGF) or control LacZ (Ad-LacZ) were delivered by intramuscular injection 
and animals received systemic treatment with ephrinB2-Fc or control Fc proteins. After 11 days muscles were 
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harvested and immunohistochemical staining for CD31 was performed to assess vessel morphology (D) and to 
quantify vessel diameters (E, n=4-5 independent muscles/group), while tissue damage was quantified on H&E-
stained sections (F, n=4-5 independent muscles/group), distinguishing tissue areas as normal, necrotic, early- and 
late-regenerating (ER and LR, respectively); (G). Blood flow was measured non-invasively by laser Doppler (H, 
n=4-6 animals/group) before and after surgery (Pre op and Post op) and after 4, 7 and 11 days (d4, d7 and d11). 
EphB4 stimulation prevented the appearance of enlarged vascular lacunae, decreased the size of VEGF-induced 
vessels, reduced tissue necrosis while increasing regeneration, and normalized blood flow. Scale bars = 50 μm 
(A), 100 μm (D) and 2 mm (F); * p<0.05 by one-tail t-test, after data normalization by logarithmic transformation. 
 
Functionally, although the aberrant vasculature can be highly perfused, it can have 
deleterious effects on muscle function and recovery from ischemia, e.g. through the formation 
of arterio-venous shunts that actually reduce effective metabolic exchange in tissue (43). In 
agreement with the normalization of vascular structure, ephrinB2-Fc treatment also effectively 
normalized the supra-physiological perfusion increases induced by Ad-hVEGF (Figure 8H) 
and reduced ischemia-related muscle damage (necrotic area: Ad-hVEGF+Fc=26.2±16.0% vs 
Ad-hVEGF+ephrinB2-Fc=7.3±3.8%), while increasing tissue regeneration (regenerating area: 
Ad-hVEGF+Fc=50.9±12.3% vs Ad-hVEGF+ephrinB2-Fc=65.9±11.9%) (Figure 8F-G). 
Taken together, these results support the therapeutic potential of EphB4 simulation by systemic 
ephrinB2-Fc treatment in controlling undesired vascular responses of VEGF gene delivery and 
improving its efficacy. 
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Supplementary information 
Supplementary methods 
Retroviral transduction of myoblasts 
Primary myoblasts isolated from C57BL/6 mice were infected at high efficiency (44) 
with retroviruses carrying the cDNA of murine VEGF164 linked through an Internal Ribosome 
Entry Sequence (IRES) to a truncated murine CD8a as a FACS-sortable marker, or only CD8 
as controls (16). Early-passage myoblast clones were isolated using a FACS Vantage SE cell 
sorter (Becton Dickinson, Basel, Switzerland) as described (16), in order to obtain populations 
in which every cell expressed the same VEGF level. V-low and control cells were further 
infected with retroviruses expressing LAP, sTie2Fc or sEphB4, or only CD4 as control. 
Transduced populations were FACS-sorted based on the staining for the CD4 surface marker 
to eliminate non-infected cells. All myoblast populations were cultured in 5% CO2 on collagen-
coated dishes, with a growth medium consisting of 40% F10, 40% low-glucose DMEM, 20% 
FBS, 1% penicillin/streptomycin and 1% L-Glutamine, supplemented with 2.5 ng/ml basic 
FGF, as previously described (45). 
CD4 flow cytometric analysis 
Expression of the truncated CD4 marker was assessed by staining myoblasts with a 
FITC- conjugated antibody against rabbit CD4 (clone MCA799F, AbD Serotec, Raleigh, 
USA), using 0.4 µg of antibody/106 cells in 200 µl (1:50 dilution) of phosphate-buffered saline 
(PBS) with 5% BSA for 20 min on ice. Data were acquired using a FACS Calibur flow 
cytometer (Becton Dickinson) and analyzed using FlowJo software (Tree Star, Ashland, USA). 
Cell sorting was performed with a BD Influx cell sorter (Becton Dickinson). 
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Blocker expression by RT-PCR 
Specific expression of the correct blockers in each myoblast population was verified by 
RT-PCR using primers specific for LAP (FW 5’-GCTGTGGCTACTGGTGCTGA-3’ and RV 
5’-CCGGGAGCTTTGCAGATGCT-3’), sTie2Fc (FW 5’-GTGGAGTCAGCTTGCTCCTT-
3’ and RV 5’-TGCACACACAGCTCGTAGTC-3’), and sEphB4 (FW 5’-
TTTGGAAGAGACCCTGCTGA-3’ and RV 5’-CCGTTCAGGCGGGAAACC-3’). PCR was 
performed using HiFi PCR Premix (Takara Clonetech, St-Germain-en-Laye, France) with 35 
cycles of amplification consisting of denaturation at 98°C for 10 seconds, annealing at 55°C 
for 15 seconds and extension 72°C for 10 seconds, on a Veriti Thermal Cycler (Applied 
Biosystems, Basel, Switzerland). 
Blocker functional assays 
 
LAP. A TGF- reporter cell line was produced by transducing HEK293 cells with 
lentiviral vectors expressing luciferase under the control of a SMAD response element or a 
control minimal CMV promoter, according to the manufacturer’s instructions (pGreenFire™ 
Transcription Reporters, System Biosciences, Mountain View, USA). Cells were seeded in 96-
well plates at 50% confluency and cultured with high-glucose DMEM supplemented with 10% 
FBS, 1% penicillin/streptomycin, and 1% L-Glutamine. After 12 hours, medium was replaced 
with conditioned medium from either LAP or control CD4 myoblasts, which was previously 
incubated on ice for 30 minutes with different amounts of recombinant human TGF-β1 (R&D 
Systems) and then warmed at 37°C for 15 minutes. After 24 hours, medium was aspirated and 
cells were lysed on ice in 60 μl of ice-cold lysis buffer for 15 minutes and luciferase activity 
was measured with the BrightGlo Luciferase Assay System (Promega, Madison, USA), 
according to manufacturer’s instructions. Luminescence from reporter activation was 
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measured for 1 sec/well on a MicroLumatPlus luminometer (Berthold Technologies, Bad 
Wildbad, Germany). 
sTie2Fc. The RAW264.7 macrophage cell line (46) was seeded in 24-well plates at the 
density of 100,000 cells/well, and cultured with RMPI medium supplemented with 10% FBS, 
1% penicillin/streptomycin, and 1% L-Glutamine. For the assay, cells were incubated with 
conditioned medium from either sTie2Fc or control CD4 myoblasts that was previously kept 
on ice for 30 minutes with different amounts of recombinant COMP-Ang1 (AdipoGen, Liestal, 
Switzerland) and then warmed at 37°C for 15 minutes. After 60 minutes, conditioned medium 
was replaced with fresh RPMI containing 100 ng/ml of LPS and after 24 hours cells were 
collected for RNA extraction. 
sEphB4. Human Umbilical Vein Endothelial Cells (HUVEC) were seeded at the 
density of 500,000 cells/T25 flask and cultured overnight in M199 medium supplemented with 
20% FBS, 100 μg/ml Endothelial Cell Growth Supplement (Sigma-Aldrich, St. Louis, USA), 
50 U/ml sodium heparin (Sigma-Aldrich) and 1% penicillin/streptomycin. Afterwards, cells 
were incubated with conditioned medium from either sEphB4 or control CD4 myoblasts that 
was previously kept on ice for 30 minutes with 2 μg/ml mouse ephrinB2-Fc (R&D Systems) 
pre-clustered with anti-Fc Ab (27) and then warmed at 37°C for 15 minutes. After 30 minutes, 
HUVEC were lysed and the amount of phosho-EphB4 was quantified using a human 
Phosphotyrosine EphB4 ELISA kit (Raybiotech, Norcross, USA) according to manufacturer’s 
instructions. 
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Supplementary Figures 
 
 
 
 
 
Supplementary Figure 1. Development and validation of soluble blockers. (A) Retroviral construct carrying 
a bicistronic cassette coding for one of three signaling blockers (LAP, sEphB4 or sTie2Fc) linked to a truncated 
version of rabbit CD4 (tr.rbCD4), as a convenient cell surface FACS-sortable marker, through an internal 
ribosomal entry site sequence (IRES). LTR = retroviral Long Terminal Repeats. (B) Blocker-expressing myoblast 
populations, generated from control cells (Ctrl) or a clone expressing low VEGF (V-low), were FACS-sorted and 
their purity was determined by analysis of CD4 expression (black curves) vs isotype control (grey curves). (C) 
Expression specificity was determined by RT-PCR on RNA isolated from each population, using primers specific 
for LAP (L), sEphB4 (E) and sTie2Fc (T), amplifying products of 781, 963 and 1519 bp, respectively. (D) 
Functional activity of the LAP blocker. HEK293N cells were transfected with a TGF- reporter construct, 
expressing luciferase under a SMAD-dependent promoter. Conditioned medium from LAP-expressing myoblasts 
(LAP) inhibited luciferase activity induced by stimulation with 0.1 and 1 ng/ml of TGF-β1 compared to control 
conditioned medium from CD4 myoblasts (Ctrl). n=3/condition; R.L.U. = Relative Light Units. (E) Functional 
activity of the sTie2Fc blocker. Treatment of RAW264.7 macrophages with LPS causes upregulation of TNF, 
which is inhibited by COMP-Ang1. Real-Time qRT-PCR analysis of Tnfa gene expression shows that conditioned 
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medium from sTie2Fc myoblasts (LPS+sTie2Fc) prevented this inhibition by 50 ng/ml COMP-Ang1 compared 
to control conditioned medium from CD4 myoblasts (LPS+Ctrl). n=6/condition (F) Functional activity of the 
sEphB4 blocker. Human umbilical vein endothelial cells were treated with ephrinB2-Fc or control Fc and 
phosphorylation of the EphB4 receptor was measured by ELISA. Conditioned medium from sEphB4 myoblasts 
(sEphB4) inhibited EphB4 phosphorylation compared to control conditioned medium from CD4 myoblasts (Ctrl). 
n=3/condition; O.D. = Optical Density units. 
 
 
 
Supplementary Figure 2. Blockade of ephrinB2/EphB4 signaling does not affect perfusion of VEGF-
induced vessels. Mice received intravenous injections of FITC-lectin 2 weeks after implantation of myoblast 
clones expressing low VEGF levels alone (V-low) or co-expressing the sEphB4 blocker (V-low sEphB4). Frozen 
sections of limb muscles were immunostained for CD31 (endothelium, red) and perfused structures were 
visualized by FITC-lectin co-localization (green). Vascular perfusion was similar in both conditions. Scale bar = 
25 μm. 
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Supplementary Figure 3. Long-term evolution of aberrant vascular structures induced by low VEGF with 
ephrinB2/EphB4 blockade. Immunofluorescence staining of endothelium (CD31, red), pericytes (NG2, green), 
smooth muscle cells (α-SMA, cyan) and nuclei (DAPI, blue) on frozen sections of limb muscles injected with the 
V-low clone alone or co-expressing the sEphB4 soluble blocker (V-low sEphB4). Three months after cell 
implantation aberrant vascular structures induced by ephrinB2/EphB4 signaling blockade were still present and 
had further enlarged in size, acquiring a thicker smooth muscle coat. Scale bar = 25 μm. 
 
 
 
Supplementary Figure 4. EphB4 stimulation does not cause vessel regression. Mouse limb muscles were 
implanted with the V-high myoblast clone, while EphB4 signaling was stimulated by systemic treatment with 
ephrinB2-Fc or control Fc protein. As a positive control for vessel regression, mice implanted with the V-high 
clone were treated with the potent VEGF blocker Aflibercept (V-high + Aflibercept). Immunofluorescence 
staining for endothelium (CD31, green), basal lamina (laminin; lam, red) and nuclei (DAPI, blue) showed that 
ephrinB2-Fc treatment did not cause any vessel regression, as all basal laminas were associated with endothelial 
tubes. By contrast, after Aflibercept treatment widespread vessel regression was evident through the detection of 
empty sleeves of basal lamina (white arrows) devoid of endothelium, remnants of disappeared vessels. Size bar: 
25μm. 
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Supplementary Figure 5. EphB4 is expressed on endothelium of angiogenic microvessels in murine adult 
skeletal muscle. Immunofluorescence staining of endothelium (CD31, green), EphB4 (red) and pericytes (NG2, 
cyan) on frozen sections of limb muscles harvested 4 days after implantation of the V-low clone alone or co-
expressing the sEphB4 soluble blocker (V-low sEphB4), or with the V-high clone while EphB4 signaling was 
stimulated by systemic treatment with ephrinB2-Fc or control Fc protein. EphB4 was strongly expressed by the 
endothelium of angiogenic micro-vascular structures and not by pericytes. Blockade or activation of EphB4 
signaling did not change its expression pattern. Scale bar = 20 μm. 
 
 
 
Supplementary Figure 6. Flow cytometry phenotype of human dermal microvascular endothelial cells 
(HDMEC). HDMEC robustly expressed endothelial markers CD31 and VE-Cadherin, as well as EphB4, while 
ephrinB2 expression was limited to 10% of the cells. 
  
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
145 
 
Discussion 
By complementary loss- and gain-of-function approaches we have identified the EphB4 
receptor as a key regulator of intussusceptive angiogenesis and a target to control the dose-
dependent outcome of VEGF delivery to skeletal muscle for therapeutic purposes. EphB4 
activation by systemic treatment with recombinant ephrinB2-Fc protein effectively prevented 
aberrant vascular growth without interfering with normal angiogenesis, thereby promoting 
normal microvascular network formation despite high and uncontrolled VEGF doses. 
Mechanistically, EphB4 activity finely tuned the degree of endothelial proliferation induced 
by specific VEGF doses without affecting activation of VEGF-R2, but rather converging on its 
downstream signaling and tuning the phosphorylation of ERK1/2. 
While sprouting requires a coordinated interplay between directed migration of tip cells 
and proliferation of stalk cells behind the tip (47), during intussusceptive angiogenesis pre-
existing vessels initially undergo circumferential enlargement that entails exclusively 
endothelial proliferation without migration (6). The degree of vascular enlargement is 
proportional to VEGF dose and determines the outcome of subsequent intussusceptive 
remodeling, as excessive diameters prevent the successful completion of transluminal pillars, 
leading to failure to split and progressive growth into angioma-like vascular structures (9). 
Here we identified EphB4 activation as a specific mechanism controlling the outcome of 
intussusceptive angiogenesis in adult skeletal muscle, by fine-tuning the endothelial 
proliferation induced by specific doses of VEGF and therefore controlling the degree of 
circumferential enlargement achieved before transluminal pillar formation and vessel splitting. 
It is interesting to note how the total amount of proliferating Ki67+ cells 3 days after VEGF 
delivery was similar with both low and high VEGF doses, in agreement with our previous 
findings (9), and it was not altered by EphB4 stimulation or inhibition (Figure 6A and 6C). 
Rather, both VEGF dose and EphB4 activity controlled the proportion of endothelial cells in 
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the G2-M phase, marked by the phosphorylation of Histone H3 (Figure 6B and 6D), suggesting 
an effect on the speed of proliferation, i.e. the frequency of transition from G1 to the S-G2-M 
phase, rather than on the re-entry into the cell cycle from quiescence (G0 to G1 transition) (32, 
33). 
Pericyte recruitment to nascent vascular structures is crucial for normal morphogenesis, 
stabilization and function of microvascular networks, through a complex array of signals with 
endothelial cells (31). Pericyte loss by interference with PDGF-BB/PDGF-R signaling by 
genetic means during development (48, 49) or blockade during VEGF-induced angiogenesis 
in adult tissue (12) leads to unabated endothelial proliferation and the growth of aberrantly 
enlarged vascular structures, which are fragile and cause lethal hemorrhages. Despite the 
complexity of the pericyte-endothelial molecular crosstalk, here we provide evidence that the 
ephrinB2-EphB4 pathway is responsible for the pericyte function of regulating the switch 
between normal and aberrant angiogenesis by VEGF dose. In fact, the effects of EphB4 
inhibition or stimulation reported here mimic closely the results obtained in a similar setting 
by blocking or promoting pericyte recruitment through manipulation of PDGF-BB signaling, 
respectively (12). Interestingly, the observed lack of effect by TGF- blockade by LAP over-
expression is in agreement with our own recent results, showing that a blocking anti-TGF-1 
antibody did not affect the normal angiogenesis induced by low VEGF, although it significantly 
impaired endothelial expression of Semaphorin3A and the recruitment of a pro-stabilizing 
monocyte population (19). These results suggest non-overlapping roles for the two pathways 
in vascular morphogenesis and stabilization in the setting of intussusceptive angiogenesis. 
EphrinB2/EphB4 signaling has well-established functions in arterio-venous 
differentiation, where ephrinB2 and EphB4 selectively mark the arterial and venous 
endothelium, respectively (50), and in sprouting angiogenesis. During sprouting, functions of 
the ephrinB2/EphB4 pathway have been ascribed most clearly to the ephrinB2 partner. In fact, 
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ephrinB2 was found to localize on the filopodia of tip cells, where it stimulates their motility 
and sprout formation by increasing endocytosis and signal activity of both VEGF-R2 and -R3 
(38, 51), but it does not appear to affect endothelial proliferation during sprouting (38). The 
role of EphB4, which is absent from the tips and expressed on cells behind the growing front, 
remains to be elucidated. On the other hand, EphB4 over-expression has been described to 
suppress sprouting and switch vascular growth to circumferential enlargement, but 
independently of its kinase activity and rather through stimulation of ephrinB2 reverse 
signaling (52). In contrast, here we found that EphB4 forward signaling is crucial to regulate 
intussusceptive angiogenesis, which takes place essentially without migration and rather only 
through proliferation. In fact, treatment with monomeric sEphB4 not only inhibits activation 
of endogenous EphB4, but also interferes with ephrinB2 reverse signaling, by preventing 
interaction and productive multimerization of the two binding partners. While this would be 
expected to cause reduced VEGF-R2 activation and tip cell migration in the setting of 
sprouting, we rather observed an increase in the outcome of VEGF signaling specifically on 
proliferation through ERK1/2 phosphorylation during the process of circumferential 
enlargement and intussusception, in the absence of tip cells. Conversely, specific activation of 
EphB4 by treatment with ephrinB2-Fc had the opposite effect, with reduction of ERK1/2 
phosphorylation and endothelial proliferation, both in vitro and in vivo. Taken together, these 
data suggest a complementary function for ephrinB2 to stimulate VEGF-induced tip cell 
migration in sprouting and for EphB4 to reduce VEGF-induced ERK1/2 phosphorylation and 
endothelial proliferation in the absence of tip cells during intussusceptive angiogenesis. 
From a therapeutic perspective, it is particularly important that EphB4 stimulation did 
not completely abolish VEGF-induced endothelial proliferation, but rather only reduced it by 
about 40%, thereby preventing aberrant angiogenesis without interfering with normal vascular 
growth. This can be explained considering that VEGF-R2 stimulates endothelial proliferation 
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through two parallel pathways, one through RAS and the other through PKC, which then 
converge on the RAF-MEK-ERK1/2 cascade (53, 54). The major contributor to ERK1/2 
activation by VEGF-R2 in vivo has been found to be the PKC pathway, through recruitment 
of PLC upon phosphorylation of tyrosine Y1175/1173 (54). However, while mutation of 
Y1775/1173 both abolished VEGF-induced ERK1/2 activation and caused embryonic lethality 
(55, 56), global disruption of the Prkcb gene, encoding PKC, did not cause major vascular 
phenotypes (57), showing that the control of ERK1/2 activation by VEGF-R2 is redundant 
downstream of Y1175/1173 phosphorylation. On the other hand, EphB4 directly binds and 
activates the RAS GTPase Activating Protein RASA1, which negatively regulates RAS 
activity through its GTPase function (58, 59). Therefore, by inhibiting one branch of a 
redundant circuit, EphB4 stimulation can achieve modulation of ERK1/2 activation and 
endothelial proliferation, while sparing sufficient activity to avoid disruption of vascular 
growth. 
Controlling precisely the outcome of VEGF signaling for therapeutic purposes is a 
significant clinical challenge (60). Recent findings show that delivery of an alternative ligand 
may activate VEGF-R2 more gently and with less stringent requirements for dose control. For 
example, VEGF-B binds VEGF-R1 and not VEGF-R2, but it has been found to effectively 
induce both cardiac angiogenesis and arteriogenesis by displacing R1-bound VEGF-A and 
making it available for signaling through R2 (61, 62). Since VEGF-R2 is activated only 
indirectly by endogenously available VEGF-A, even significant VEGF-B overexpression does 
not cause excessive stimulation of R2 signaling (61). However, the vascular effects of VEGF-
B appear restricted to the heart and its delivery does not induce any angiogenesis in skeletal 
muscle or other tissues (62). 
The results reported here show that targeting a separate pathway that converges on 
downstream signaling provides a new paradigm to modulate VEGF-R2 output. Pharmacologic 
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targeting of EphB4 can be achieved with systemic treatments offering significant translational 
potential e.g. in conjunction with VEGF gene therapy. 
  
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
150 
 
References 
1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug 
Discov. 2007;6(4):273-86. 
2. Annex BH. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol. 
2013;10(7):387-96. 
3. Giacca M, Zacchigna S. VEGF gene therapy: therapeutic angiogenesis in the clinic and 
beyond. Gene Ther. 2012;19(6):622-9. 
4. Yla-Herttuala S, Bridges C, Katz MG, Korpisalo P. Angiogenic gene therapy in 
cardiovascular diseases: dream or vision? Eur Heart J. 2017;38(18):1365-71. 
5. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. 
Cell. 2011;146(6):873-87. 
6. Gianni-Barrera R, Trani M, Reginato S, Banfi A. To sprout or to split? VEGF, Notch 
and vascular morphogenesis. Biochem Soc Trans. 2011;39(6):1644-8. 
7. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. 
Nature. 2011;473(7347):298-307. 
8. De Spiegelaere W, Casteleyn C, Van den Broeck W, Plendl J, Bahramsoltani M, 
Simoens P, et al. Intussusceptive angiogenesis: a biologically relevant form of angiogenesis. J 
Vasc Res. 2012;49(5):390-404. 
9. Gianni-Barrera R, Trani M, Fontanellaz C, Heberer M, Djonov V, Hlushchuk R, et al. 
VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than 
sprouting. Angiogenesis. 2013;16(1):123-36. 
10. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, et al. 
Microenvironmental VEGF concentration, not total dose, determines a threshold between 
normal and aberrant angiogenesis. J Clin Invest. 2004;113(4):516-27. 
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
151 
 
11. von Degenfeld G, Banfi A, Springer ML, Wagner RA, Jacobi J, Ozawa CR, et al. 
Microenvironmental VEGF distribution is critical for stable and functional vessel growth in 
ischemia. FASEB J. 2006;20(14):2657-9. 
12. Banfi A, von Degenfeld G, Gianni-Barrera R, Reginato S, Merchant MJ, McDonald 
DM, et al. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and 
PDGF-BB. FASEB J. 2012;26(6):2486-97. 
13. Bottinger EP, Factor VM, Tsang ML, Weatherbee JA, Kopp JB, Qian SW, et al. The 
recombinant proregion of transforming growth factor beta1 (latency-associated peptide) 
inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A. 
1996;93(12):5877-82. 
14. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor 
angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. 
J Clin Invest. 1997;100(8):2072-8. 
15. He S, Kumar SR, Zhou P, Krasnoperov V, Ryan SJ, Gill PS, et al. Soluble EphB4 
inhibition of PDGF-induced RPE migration in vitro. Invest Ophthalmol Vis Sci. 
2010;51(1):543-52. 
16. Misteli H, Wolff T, Fuglistaler P, Gianni-Barrera R, Gurke L, Heberer M, et al. High-
throughput flow cytometry purification of transduced progenitors expressing defined levels of 
vascular endothelial growth factor induces controlled angiogenesis in vivo. Stem Cells. 
2010;28(3):611-9. 
17. Zisch AH, Schenk U, Schense JC, Sakiyama-Elbert SE, Hubbell JA. Covalently 
conjugated VEGF--fibrin matrices for endothelialization. J Control Release. 2001;72(1-
3):101-13. 
18. Sacchi V, Mittermayr R, Hartinger J, Martino MM, Lorentz KM, Wolbank S, et al. 
Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, 
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
152 
 
sustained delivery of recombinant VEGF164. Proc Natl Acad Sci U S A. 2014;111(19):6952-
7. 
19. Groppa E, Brkic S, Bovo E, Reginato S, Sacchi V, Di Maggio N, et al. VEGF dose 
regulates vascular stabilization through Semaphorin3A and the Neuropilin-1+ monocyte/TGF-
beta1 paracrine axis. EMBO Mol Med. 2015;7(10):1366-84. 
20. Kimura M, Kato Y, Sano D, Fujita K, Sakakibara A, Kondo N, et al. Soluble form of 
ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck. Int J 
Oncol. 2009;34(2):321-7. 
21. Tsaryk R, Peters K, Barth S, Unger RE, Scharnweber D, Kirkpatrick CJ. The role of 
oxidative stress in pro-inflammatory activation of human endothelial cells on Ti6Al4V alloy. 
Biomaterials. 2013;34(33):8075-85. 
22. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. 
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, 
and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. 
Clin Cancer Res. 2008;14(22):7272-83. 
23. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, et al. Autocrine 
VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor 
growth. J Exp Med. 2012;209(3):507-20. 
24. Leppanen P, Koota S, Kholova I, Koponen J, Fieber C, Eriksson U, et al. Gene transfers 
of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular 
endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on 
atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-
deficient mice. Circulation. 2005;112(9):1347-52. 
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
153 
 
25. Rissanen TT, Korpisalo P, Karvinen H, Liimatainen T, Laidinen S, Grohn OH, et al. 
High-resolution ultrasound perfusion imaging of therapeutic angiogenesis. JACC Cardiovasc 
Imaging. 2008;1(1):83-91. 
26. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev 
Mol Cell Biol. 2002;3(7):475-86. 
27. Noren NK, Foos G, Hauser CA, Pasquale EB. The EphB4 receptor suppresses breast 
cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol. 2006;8(8):815-25. 
28. Schense JC, Bloch J, Aebischer P, Hubbell JA. Enzymatic incorporation of bioactive 
peptides into fibrin matrices enhances neurite extension. Nat Biotechnol. 2000;18(4):415-9. 
29. Schense JC, Hubbell JA. Cross-linking exogenous bifunctional peptides into fibrin gels 
with factor XIIIa. Bioconjug Chem. 1999;10(1):75-81. 
30. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, et al. Cellular changes 
in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J 
Physiol Heart Circ Physiol. 2006;290(2):H547-59. 
31. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and 
pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193-215. 
32. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell 
Physiol. 2000;182(3):311-22. 
33. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, et al. Mitotic 
phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol 
Cell Biol. 2002;22(3):874-85. 
34. Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H, Steiniche T. Proliferation indices 
of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage 
I/II melanoma. Mod Pathol. 2013;26(3):404-13. 
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
154 
 
35. Sahni A, Francis CW. Stimulation of endothelial cell proliferation by FGF-2 in the 
presence of fibrinogen requires alphavbeta3. Blood. 2004;104(12):3635-41. 
36. Eichmann A, Simons M. VEGF signaling inside vascular endothelial cells and beyond. 
Curr Opin Cell Biol. 2012;24(2):188-93. 
37. Simons M. An inside view: VEGF receptor trafficking and signaling. Physiology 
(Bethesda). 2012;27(4):213-22. 
38. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. 
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 
2010;465(7297):487-91. 
39. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, et al. Endocan is 
a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell 
Res. 2007;313(7):1285-94. 
40. Schweighofer B, Testori J, Sturtzel C, Sattler S, Mayer H, Wagner O, et al. The VEGF-
induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and 
inflammation. Thromb Haemost. 2009;102(3):544-54. 
41. Sivaprasad U, Fleming J, Verma PS, Hogan KA, Desury G, Cohick WS. Stimulation 
of insulin-like growth factor (IGF) binding protein-3 synthesis by IGF-I and transforming 
growth factor-alpha is mediated by both phosphatidylinositol-3 kinase and mitogen-activated 
protein kinase pathways in mammary epithelial cells. Endocrinology. 2004;145(9):4213-21. 
42. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral 
immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX 
and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 
1995;92(5):1401-5. 
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
155 
 
43. Zacchigna S, Tasciotti E, Kusmic C, Arsic N, Sorace O, Marini C, et al. In vivo imaging 
shows abnormal function of vascular endothelial growth factor-induced vasculature. Hum 
Gene Ther. 2007;18(6):515-24. 
44. Springer ML, Blau HM. High-efficiency retroviral infection of primary myoblasts. 
Somat Cell Mol Genet. 1997;23(3):203-9. 
45. Banfi A, Springer ML, Blau HM. Myoblast-mediated gene transfer for therapeutic 
angiogenesis. Methods Enzymol. 2002;346:145-57. 
46. Gu H, Cui M, Bai Y, Chen F, Ma K, Zhou C, et al. Angiopoietin-1/Tie2 signaling 
pathway inhibits lipopolysaccharide-induced activation of RAW264.7 macrophage cells. 
Biochem Biophys Res Commun. 2010;392(2):178-82. 
47. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, et al. 
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 
2003;161(6):1163-77. 
48. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, et al. Lack of 
pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 
2001;153(3):543-53. 
49. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm 
formation in PDGF-B-deficient mice. Science. 1997;277(5323):242-5. 
50. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction 
between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 
1998;93(5):741-53. 
51. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, et 
al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 
2010;465(7297):483-6. 
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
156 
 
52. Erber R, Eichelsbacher U, Powajbo V, Korn T, Djonov V, Lin J, et al. EphB4 controls 
blood vascular morphogenesis during postnatal angiogenesis. EMBO J. 2006;25(3):628-41. 
53. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of 
the angiogenic phenotype requires Ras activation. J Biol Chem. 2001;276(52):49289-98. 
54. Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial 
VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17(10):611-25. 
55. Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. Essential role of Flk-1 
(VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci U S A. 
2005;102(4):1076-81. 
56. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on 
KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis 
in vascular endothelial cells. EMBO J. 2001;20(11):2768-78. 
57. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, et al. 
Immunodeficiency in protein kinase cbeta-deficient mice. Science. 1996;273(5276):788-91. 
58. Kawasaki J, Aegerter S, Fevurly RD, Mammoto A, Mammoto T, Sahin M, et al. 
RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity. J 
Clin Invest. 2014;124(6):2774-84. 
59. Kim I, Ryu YS, Kwak HJ, Ahn SY, Oh JL, Yancopoulos GD, et al. EphB ligand, 
ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein 
kinase pathway in venous endothelial cells. FASEB J. 2002;16(9):1126-8. 
60. Martino MM, Brkic S, Bovo E, Burger M, Schaefer DJ, Wolff T, et al. Extracellular 
matrix and growth factor engineering for controlled angiogenesis in regenerative medicine. 
Front Bioeng Biotechnol. 2015;3:45. 
III. EphrinB2/EphB4 signaling regulates intussusceptive angiogenesis by VEGF   
157 
 
61. Kivela R, Bry M, Robciuc MR, Rasanen M, Taavitsainen M, Silvola JM, et al. VEGF-
B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the 
heart. EMBO Mol Med. 2014;6(3):307-21. 
62. Lahteenvuo JE, Lahteenvuo MT, Kivela A, Rosenlew C, Falkevall A, Klar J, et al. 
Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and 
arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-
dependent mechanisms. Circulation. 2009;119(6):845-56. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
IV. The crosstalk between Notch4 and 
ephrinB2/EphB4 signaling in VEGF-
induced angiogenesis 
 
 
 
 
 
 
 
 
 
 
  
 
The crosstalk between Notch4 and ephrinB2/EphB4 
signaling in VEGF-induced angiogenesis  
 
Sime Brkic1,2, Elena Groppa1,2,3, Andrea Uccelli1,2, Roberto Gianni-Barrera1,2 and Andrea 
Banfi1,2 
 
1Department of Biomedicine, University Hospital, University of Basel, Basel, Switzerland. 
2Department of Surgery, University Hospital, Basel, Switzerland. 
3Current address: The Biomedical Research Centre, The University of British Columbia, 
Vancouver, Canada. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. The crosstalk between Notch4 and ephrinB2/EphB4 signaling in VEGF-induced angiogenesis 
161 
 
Introduction 
Therapeutic angiogenesis is a promising strategy for treatment of ischemic diseases like 
peripheral and coronary artery disease. However, to date gene therapy approaches using VEGF 
delivery failed to show efficacy in clinical trials, despite the established biological function of 
the factor as master regulator of vascular growth (1). Angiogenesis is controlled by the 
concerted actions of different signaling pathways (2). In order to design rational strategies for 
therapeutic angiogenesis, it is crucial to identify the molecular crosstalk governing the process 
of both physiological and pathological blood vessel growth. In fact, aberrant vessel growth 
induced by excessive VEGF stimulus is a significant hurdle for therapeutic benefit, since it can 
cause the growth of angioma-like vascular tumors. Adenoviruses are robust, clinically 
established vectors for VEGF gene delivery with many desirable features, such as high 
transduction rate for efficacy and transient duration of expression for safety (3). However, viral 
transduction in vivo leads to heterogeneous levels of expression in different cells, due to the 
variable efficiency of infection. This can lead to localized overproduction of VEGF, which 
remains bound to extracellular matrix in the cellular microenvironment, and these hotspots of 
excessive VEGF concentration cause aberrant vessel growth. Therefore, it is essential to 
understand the molecular basis governing the switch between normal and aberrant 
angiogenesis in order to develop pharmacological targets to prevent angioma growth without 
interfering with induction of normal microvascular networks. In the previous Chapter we 
identified ephrinB2/EphB4 signaling as a key molecular pathway responsible for the switch 
between normal and aberrant angiogenesis by increasing VEGF doses. We demonstrated that 
EphB4 signaling modulates VEGF-induced endothelial proliferation and therefore the size of 
initial vascular enlargements, enabling their successful splitting into morphologically normal 
capillary networks despite high VEGF doses. The molecular mechanism by which EphB4 
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regulates VEGF signaling does not involve direct regulation of VEGF-R2 activation, but rather 
modulation of its downstream signaling through pERK1/2. 
The Notch4 signaling pathway has also been implicated in the generation of aberrantly 
enlarged vessels, namely arterio-venous malformations (AVM) (4, 5). Gene polymorphisms in 
the Notch4 gene are associated with development of brain arterio-venous malformations and 
hemorrhagic presentations (6). Notch signaling plays a key role in arterio-venous 
differentiation during development by inducing an arterial phenotype through expression of 
the arterial marker ephrinB2 and simultaneous downregulation of the venous marker EphB4 
(7, 8). Interestingly, single nucleotide polymorphisms in the EphB4 gene have also been 
associated with higher risk of intracranial hemorrhaging presentations in patients with brain 
arterio-venous malformations (9). While other Notch receptors are expressed in multiple tissue, 
Notch4 is predominantly restricted to endothelial cells (10). Overactivation of Notch4 in 
endothelium causes lack of small branched vessels and loss of vessel integrity (11). Using a 
tetracycline-regulated system, it was shown that mice expressing a constitutively active Notch4 
form, develop arterio-venous malformations in the brain that regress once the Notch4 
overactivation is abrogated by doxycycline treatment (5, 12-14). It was demonstrated that 
regression of these AVMs happens by direct restoration of the venous programming and by 
normalization of blood flow without change in endothelial cell number (5, 13). Furthermore, 
Murphy et al. demonstrated that expression of EphB4 is markedly reduced during formation of 
AVM and restored after repression of Notch4 signaling and normalization of vessel 
morphology. Inhibition of EphB4 signaling by sEphB4 dramatically reduced AVM 
normalization demonstrating that EphB4 signaling is necessary for this process in this model 
(5). In a separate project, we have recently investigated the role of Notch4 signaling in the 
switch between normal and aberrant angiogenesis by increasing VEGF doses. It was found that 
aberrant angiogenesis, induced by high VEGF doses, was switched to normal capillary growth 
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in Notch4-deficient mice (Gianni-Barrera, et al, in preparation). On the other hand, in the 
previous Chapter we demonstrated that EphB4 gain-of-function can similarly normalize 
aberrant angiogenesis induced by high doses of VEGF. As both Notch4 loss-of-function and 
EphB4 gain-of-function caused similar effects on VEGF-induced angiogenesis, preventing 
aberrant vascular growth and enabling microvascular normalization, here we aimed at 
determining whether ephrinB2/EphB4 signaling may act via Notch4. 
In order to investigate whether Notch4 signaling is necessary for this process, we took 
advantage of a mouse line carrying a mutated Notch4 allele with a 1.0-kb deletion in the region 
of exons 21 and 22, coding for a part of the extracellular domain adjacent to the transmembrane 
domain (B6;129S1-Notch4tm1Grid/J; here referred as Notch4d1) (15). These mice are fertile and 
viable, with slightly elevated systolic blood pressure after experimental induction of hindlimb 
ischemia (16), delayed tumor onset and decreased tumor perfusion (17). This mutation leads 
to production of a truncated Notch4 protein lacking all the transmembrane and intracellular 
domains (NICD), which is therefore unable to transmit downstream signaling (15). To 
determine whether EphB4 requires active Notch4 signaling to control the outcome of VEGF 
dose-dependent angiogenesis, we investigated whether the switch from normal to aberrant 
angiogenesis caused by EphB4 loss-of-function (sEphB4 co-expression), as described in the 
previous Chapter, would be prevented in Notch4d1 mice. 
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Materials and methods 
In vivo myoblast implantation 
B6;129S1-Notch4tm1Grid/J (referred as Notch4d1) carrying a Notch4 allele with 1.0-kb 
deletion in the region of exons 21 and 22 (Charles River Laboratories, Sulzfeld, Germany) (15) 
and control C57BL/6 mice of 8-12 weeks age with equal representation of both genders, were 
randomly assigned to experimental groups, with a minimum of n=4 mice/group.  Monoclonal 
populations of transduced myoblasts expressing homogeneous levels of VEGF alone or co-
expressing sEphB4 were used for all the experiments. Myoblasts expressing CD4 were used as 
control. Myoblasts were dissociated in trypsin, resuspended in sterile PBS with 0.5% BSA 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and one or two injections of 10 µl of 
cell suspension containing 106 cells were injected into the Tibialis anterior (TA) or 
Gastrocnemius (GC) lower hindlimb muscles, respectively, using a 30-gauge needle syringe, 
as previously described (18). All experiments were performed with similar number of samples 
from both muscle locations and the results were pooled together. 
Histology 
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and 
sacrificed by intravascular perfusion of 1% paraformaldehyde in PBS pH 7.4. TA and GC 
muscles were harvested, post-fixed in 0.5% paraformaldehyde in PBS for 2 h, cryoprotected in 
30% sucrose in PBS overnight at 4°C, embedded in OCT compound (CellPath, Newtown, 
Powys, UK), frozen in isopentane, and cryosectioned. The areas of engraftment were identified 
by tracking implanted myoblasts by X-gal staining (20-µm sections) in adjacent serial sections, 
as described previously (18). For immunofluorescence staining, 10-µm tissue sections were 
blocked with 5% goat serum and 2% BSA in PBS with 0.3% Triton-X, for 1h at RT and stained 
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for 1h at RT with the following primary antibodies and dilutions: rat monoclonal anti-mouse 
CD31 (clone MEC 13.3, BD Biosciences, Basel, Switzerland) at 1:100; mouse monoclonal 
anti-mouse α-SMA (clone 1A4, MP Biomedicals, Basel, Switzerland) at 1:400; rabbit 
polyclonal anti-NG2 (Merck Millipore, Darmstadt, Germany) at 1:200; rabbit polyclonal anti-
pHH3-Ser28 (Cell Signaling Technology, Danvers, USA) at 1:100 and anti-Notch4 labeled 
with Alexa647 (clone HMN4-14, Biolegend, USA) at 1:100; rabbit polyclonal anti-Caspase-
3-Asp175 (Cell Signaling Technology, Danvers, USA) at 1:150. Fluorescently labeled 
secondary antibodies (Invitrogen) were used at 1:200. 
For pERK1/2 staining, tissue sections were permeabilized with ice-cold methanol for 
10 min, and blocked with 5% goat serum and 2% BSA in PBS with 0.3% Triton-X for 1h at 
RT. Rabbit monoclonal anti-phospho-ERK1/2 antibody (Thr202/Tyr204, clone D13.14.4E, 
Cell Signaling Technology) was used at dilution of 1:100.  
RNA extraction and quantitative real-time PCR 
Freshly harvested Tibialis anterior and Gastrocnemius muscles were frozen in liquid 
nitrogen and disrupted using a Qiagen Tissue Lyser (Qiagen, Basel, Switzerland) in 1 ml 
TRIzol reagent (Invitrogen, Basel, Switzerland) for 100 mg of tissue. Total RNA was isolated 
according to manufacturer’s instructions. Two micrograms of RNA were reverse transcribed 
into cDNA using the Omniscript Reverse Transcription kit (Qiagen) at 37°C for 60 minutes. 
Quantitative Real-Time PCR (qRT-PCR) was performed on an ABI 7300 Real-Time PCR 
system (Applied Biosystems, Basel, Switzerland). Expression of genes of interest was 
determined using the following TaqMan Gene Expression assays (Applied Biosystems) 
according to manufacturer’s instructions: Gapdh (Mm03302249_g1), Notch4 extracellular 
domain (Mm00440525_m1), Notch4 exons 21 and 22 (Mm01134996_g1), Notch1 
(Mm00435249_m1), Dll1 (Mm01279269_m1), Dll4 (Mm00444619_m1), Jag1 
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(Mm00496902_m1), Hes1 (Mm01342805_m1), Hey2 (Mm00469280_m1), Egfl7 
(Mm00618004_m1), Rasa1 (Mm00520858_m1), Klf2 (Mm01244979_g1), Klf4 
(Mm00516104_m1), ephrinB2 (Mm01215897_m1), EphB4 (Mm01201157_m1), Vegfr2 
(Mm01222421_m1), Pdgfrb (Mm00435546_m1). Reactions were performed in duplicate for 
each template, averaged and normalized to expression of the Gapdh housekeeping gene. 
Vascular analyses 
Qualitative analysis of vascular morphology in immunofluorescence was performed on 
images acquired on an LSM710 3-laser scanning confocal microscope (Carl Zeiss, Feldbach, 
Switzerland). Images of vascular structures were acquired with 40X objective in at least 5 
sections/muscle, cut at 100-150 μm of distance from each other (n = 4 muscles/group). 
Vessel diameters were measured on fluorescently immunostained sections as described 
(18). Briefly, 10 fields/muscle (n = 4 muscles/group) were analyzed, measuring a total of 
minimum 100 diameters/muscle. Images were overlaid with a square grid, squares were 
randomly chosen and the diameter of each vessel in the center of selected squares was 
measured. To avoid selection bias, the shortest diameter in the selected vascular segment was 
systematically measured.  
Vessel length density (VLD) was quantified in fluorescently immunostained 
cryosections as described (18). Briefly, 5 fields per muscle (n = 4 muscles/group) were 
analyzed by tracing the total length of vessels in the acquired field and dividing it by the area 
of the fields. All images for both diameter quantification and vessel length density analysis 
were acquired with a 20X objective on an Olympus BX63 microscope (Olympus, Volketswil, 
Switzerland) and analyses were performed with Cell Sens software (Olympus). 
The percentage of pHH3+ endothelial cells was quantified for every image based on 
the total number of endothelial cells and the average value for every experimental group was 
IV. The crosstalk between Notch4 and ephrinB2/EphB4 signaling in VEGF-induced angiogenesis 
167 
 
calculated. In total, 3000–6000 endothelial cells were analyzed per group. At least 10 areas 
with a clear angiogenic effect were analyzed per group (n=6 muscles/group). 
Statistical analysis 
Data are presented as mean±standard error. The significance of differences was 
assessed with the GraphPad Prism 6 software (GraphPad Software). The normal distribution 
of all data sets was tested and, depending on the results, multiple comparisons were performed 
with the parametric 1-way analysis of variance (ANOVA) followed by the Bonferroni post-
hoc test, or with the non-parametric Kruskal-Wallis test followed by Dunn’s post-test, while 
single comparisons were analyzed with the non-parametric Mann-Whitney test or the 
parametric one-tailed t-test. Gene expression data representing fold-changes versus control, 
which are asymmetrically distributed, were first normalized by logarithmic transformation and 
then by t-test with Welch’s correction for single comparisons. Vessel diameter values were 
first normalized by log2-transformation and then analyzed by 1-way ANOVA followed by 
Bonferroni test for multiple comparisons. p<0.05 was considered statistically significant. 
Study approval 
Animal studies were performed in accordance with the Swiss Federal guidelines for 
animal welfare and were approved by the Veterinary Office of the Canton of Basel-Stadt 
(Basel, Switzerland; Permit 2071).  
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Results 
Notch4d1 mice upregulate expression of truncated Notch4 during 
angiogenesis 
Notch4d1 mice carry a deletion of exons 21 and 22 in Notch4 gene, with an out-of-frame 
mutation leading to the translation of a truncated Notch4 protein comprising only an 
incomplete extracellular domain (N4 ECD) (15) (Figure 1A). This was confirmed by qRT-PCR 
on RNA isolated from unperturbed muscle tissues (Figure 1B), showing that Notch4d1 mice 
express similar basal levels of N4 ECD as wild-type, whereas the mutated exons are absent. 
However, during active angiogenesis (4 days after injection of myoblast expressing low levels 
of VEGF) expression of truncated Notch4 transcript in Notch4d1 mice appear to increase more 
than in wild-type mice (Figure 1C). This was confirmed at the protein level, by 
immunofluorescence staining. Notch4 ECD was detected essentially only in blood vessels 
stained with CD31 (Figure 1D).  
Differential gene expression in skeletal muscle of Notch4d1 mice 
Baseline expression of genes associated with Notch signaling (Notch1, Dll1, Dll4, 
Jag1, Hes1, Hey2 and Egfl7), as well as other angiogenic key players, such as the modulator 
of the MAPK pathway Rasa1, the transcription factors Klf2 and Klf4, as well as ephrinB2, 
EphB4, Vegfr2 and Pdgfrb, was analyzed in TA and GC skeletal muscles of Notch4d1 and 
control wild-type mice. Analysis by qRT-PCR showed that Notch-related genes were generally 
downregulated in Notch4d1 mice as compared to the control, with Dll4, Hey2 and Egfl7 
recaching statistical significance, whereas other angiogenic genes were not differentially 
expressed in two mouse strains (Figure 2). 
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Figure 1. Notch4d1 mice overexpress truncated extracellular portion of Notch4 protein. Notchd1 mice carry a 
mutated Notch4 allele with a deletion of exons 21 and 22, leading to out-of-frame mutation and production of 
truncated protein lacking a part of extracellular domain, entire transmembrane (TM) and intracellular domains 
[Adapted from James, A.C. et al. 2014 (19)] (A). Level of Notch4 transcript was determined on total RNA isolated 
form TA and GC muscles from wild-type (wt) and Notch4d1 mice by two different probes; one recognizing 
sequence coding for extracellular domain (ECD) and the other region spanning exons 21 and 22. Presence of 
truncated Notch4 transcript containing extracellular portion, but lacking exons 21 and 22, was confirmed in 
Notch4d1 mice, n=6 muscles/group (B). Amount of Notch4 transcript was also assessed in muscle samples 
harvested 4 days after injection of myoblasts expressing low levels of VEGF. Analysis showed overexpression of 
truncated Notch4 transcript in Notch4d1 mice, as compared to wt mice (n=8 muscles/group), ** p<0.01 by t-test, 
after data normalization by logarithmic transformation. (C). Immunofluorescence analysis was performed on the 
same samples as the one from (B), confirming the overexpression of Notch4 protein in blood vessels (stained with 
CD31) of Notch4d1 mice. Antibody specific for extracellular domain of Notch4 protein was used, size bar=25µm 
(D).  
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Figure 2. Differential gene expression in skeletal muscles of wild-type and Notch4d1 mice. Level of expression 
of different angiogenesis-related genes was determined on total RNA isolated form TA and GC muscles from 
wild-type (wt) and Notch4d1 mice, n=6 muscles/group, * p<0.05 by t-test, after data normalization by logarithmic 
transformation. 
Aberrant angiogenesis induced by EphB4 blockade requires Notch4 activity 
We injected myoblasts co-expressing low levels of VEGF (77.6 ± 0.96 ng/106 cells/day) 
and sEphB4, inhibitor of ephrinB2/EphB4 pathway (V-low sEphB4) in limb muscles of both 
control C57BL/6 (referred as wild type; wt) and Notch4d1 mice. After two weeks, animals were 
sacrificed and the muscles were harvested and analyzed histologically. Morphological analysis 
showed that in wild-type mice, blockade of ephrinB2/EphB4 signaling induced irregularly 
enlarged aberrant vessels covered with α-smooth muscle actin-positive (αSMA+) mural cells, 
while in Notch4d1 mice we could observe only morphologically normal capillaries. Some of 
these were associated with αSMA+ mural cells, which however displayed the typical 
morphology of pericytes rather than smooth muscle cells (Figure 3A). Vessel diameter analysis 
showed that blockade of ephrinB2/EphB4 signaling in wt mice induced vessels of larger 
average diameter, as compared to Notch4d1 mice (7.4 ± 0.8 µm in wt vs 5.0 ± 0.2 µm in 
Notch4d1, p<0.01; Figure 3B). Quantification of vessel diameter distributions on the same 
samples showed that ephrinB2/EphB4 inhibition in wt mice gave rise to a fraction of 
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significantly enlarged vessel, with 19% of them being >10 µm, while in Notch4d1 this was only 
4%. The 90th percentile in wt mice was 12.1 µm, while the median was 6.5 µm. In Notch4d1 
mice the 90th percentile was 7.6 µm and the median 4.9 µm (Figure 3C). 
 
Figure 3. Aberrant angiogenesis by ephrinB2/EphB4 blockade is prevented in Notch4d1 mice. (A) Limb 
muscles of both wild-type (wt) and Notch4d1 mice were implanted with myoblast clones co-expressing low levels 
of VEGF and sEphB4, inhibitor of ephrinB2/EphB4 signaling (V-low sEphB4). The muscles were harvested after 
14 days and vessel morphology and diameter were analyzed histologically. Morphological analysis was performed 
by staining for endothelium (CD31, red), pericytes (NG2, green), smooth muscle cells (α-SMA, cyan) and nuclei 
(DAPI, blue) and it showed that in wt mice, sEphB4 induced aberrant vessels covered with α-SMA coating, while 
only morphologically normal capillaries were found in Notch4d1 mice, * = lumen of aberrant structure, size 
bar=25µm. (B) Vessel diameter analysis on the same samples showed that ephrinB2/EphB4 inhibition led to 
induction of vessels of significantly higher average diameter in Notch4d1 mice as compared to control mice, n=4-
5 muscles/group, ** p<0.01 by t-test, after data normalization by logarithmic transformation. (C) The diameter 
distribution analysis showed a decrease of percentage of vessels >10 µm in diameter in Notch4d1 mice, as 
compared to wt mice, i.e. from 19% to 4%, respectively.   
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Notch4 activity does not control initial vascular enlargements, but is 
necessary specifically for aberrant remodeling 
We have previously found that VEGF-induced angiogenesis in skeletal muscle takes 
place without sprouting, but rather through the mechanism of intussusception, where pre-
existing vessel circumferentially enlarge in response to VEGF and then longitudinally split to 
form two new vessels (20). We quantified the diameter of initial vascular enlargements 4 days 
after myoblast implantation and we observed that low and safe VEGF levels (V-low) led to 
similar size of vascular enlargements irrespectively of Notch4 signaling inactivation (average: 
13.9±1.3 µm in wild-type vs. 13.1±2.1 µm in Notch4d1 mice, 90th percentile: 22.9 µm vs. 23.5 
µm, median: 11.5 µm vs. 10.2 µm, respectively; Figure 4A-B, E). As expected, inhibition of 
ephrinb2/EphB4 signaling by sEphB4 (V-low sEphB4) caused a significant increase in the size 
of vascular enlargements in wt mice compared to VEGF alone, but again this was not affected 
by Notch4 signaling (average: 18.5 ± 1.8 µm in wild-type, p<0.05 vs V-low, 19.9 ± 0.9 µm in 
Notch4d1 mice, p<0.01 vs V-low, 90th percentile: 32.5 µm in wt, 36.9 µm in Notch4d1, median: 
14.9 µm in wt, 16.7 µm in Notch4d1 mice; Figure 4C-E). Seven days after myoblast 
implantation the process of vessel splitting is normally completed and the appearance of 
aberrant structures or homogeneous capillary networks can be distinguished. After 7 days, low 
levels of VEGF induced normal capillaries in both wild-type and Notch4d1 mice (average: 
8.4±0.6 µm in wild-type vs. 7.9±0.4 µm in Notch4d1 mice, 90th percentile: 14.3 µm vs. 12.1 
µm, median: 7.6 µm vs. 7.2 µm, respectively; Figure 4F-G, J). Inhibition of ephrinB2/EphB4 
signaling in wild-type mice induced aberrant vessels with irregular shapes and significantly 
enlarged diameters compared to VEGF alone (average: 14.0±1.6 µm, p<0.001, 90th percentile: 
24.1 µm, median: 11.0 µm). In contrast, the appearance of aberrant structures was prevented 
in Notch4d1 mice despite inhibition of ephrinB2/EphB4 pathway, and only normal capillary 
networks were detectable, similar to those induced by low VEGF alone (average: 8.5±0.4 µm, 
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90th percentile: 14.2 µm, median: 7.3 µm). There was a statistical significance between average 
vessel diameter between the two mouse strains injected with V-low sEphB4 myoblast clone 
(p<0.001). The percentage of vessels of diameter >10 µm in V-low condition in wild-type and 
Notch4d1 mice was 25% and 20%, respectively. Inhibition of ephrinB2/EphB4 pathway 
increased that percentage to 55% in wild-type mice, while in Notch4d1 mice it was reduced to 
27% (Figure 4F-J). As previously shown in Figure 3A, 2 weeks after myoblast implantation, 
aberrant structures induced by inhibition of ephrinB2/EphB4 continued to grow in control 
mice, while only normal capillaries were still found in Notch4d1 mice.  
Vessel length density (VLD) was quantified after 7 days to assess the extent of neo-
angiogenesis induced by different stimuli. Analysis showed that stimulation with either VEGF 
alone or parallel inhibition of ephrinB2/EphB4 pathway, induced growth of new blood vessels, 
as compared to VLD in control condition where myoblast expressed only CD4 marker, but no 
VEGF. Additionally, VLD was consistently higher in Notch4d1 mice as compared to wild-type 
mice in both condition with VEGF stimulation alone or when ephrinB2/EphB4 was also 
inhibited (Figure 4K). Therefore, the prevention of aberrant vascular growth by Notch4 
inactivation was not due to a general inhibition of angiogenesis. 
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Figure 4. Notch4 signaling is not controlling initial vascular enlargements, but prevents aberrant 
angiogenesis by ephrinB2/EphB4 inhibition. Mouse limb muscles of both wild-type (wt) and Notch4d1 mice 
were implanted with myoblast clones expressing only low level of VEGF (V-low) or co-expressing sEphB4, 
blocker of ephrinB2/EphB4 pathway (V-low sEphB4). Immunostaining of frozen sections stained for endothelium 
(CD31, red), pericytes (NG2, green), smooth muscle cells (α-SMA, cyan) and nuclei (DAPI, blue) and 
quantification of vessel diameter distribution 4 days after myoblast implantation showed that ephrinB2/EphB4 
inhibition increased the size of initial vessel enlargements as compared to VEGF alone, in both wt and Notch4d1 
mice, n=4-5 muscles/group,  * <0.05, ** p<0.01 by 1-way ANOVA with Bonferroni multiple comparisons test, 
after data normalization by logarithmic transformation, *=lumen of vascular enlargement, size bar=25 µm (A-E). 
After 7 days, VEGF alone induced normal capillaries in both mouse strains, with similar percentage of vessels of 
diameter >10 µm (25% and 20% in wt and Notch4d1 mice, respectively) (F-G) and similar average vessel diameter 
(J), while inhibition of ephrinB2/EphB4 pathway led to induction of irregular aberrant vessels only in wt, but not 
in Notch4d1 mice (H), with lower percentage of enlarged vessels (I) and overall decrease of average vessel 
diameter (J), n=3-4 muscles/group, *** p<0.001 by 1-way ANOVA with Bonferroni multiple comparisons test, 
after data normalization by logarithmic transformation. Analysis of vessel length density (VLD), performed at 7 
days showed higher vessel length density in Notch4d1 mice as compared to wild type mice, both with or without 
inhibition of ephrinB2/EphB4 pathway. The data is expressed as fold increase in VLD normalized to VLD of 
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control condition (wt mice injected with myoblasts expressing only CD4; marked with red line). n=4 
muscles/group, * p<0.05, by Kruskal-Wallis test followed by Dunn’s post-test. (K).   
 
Both EphrinB2/EphB4 and Notch4 signaling control endothelial cell 
proliferation, but not apoptosis 
Endothelial cell proliferation has previously been associated with formation of VEGF-
induced vascular enlargements, as the initial step of intussusceptive angiogenesis (20). We 
performed immunofluorescence co-staining using antibodies against endothelial marker CD31 
and a proliferation marker, phospho-histone H3 (pHH3), found only in G2-M phase of the cell 
cycle (21, 22). We asked whether inhibition of ephrinB2/EphB4 signaling requires active 
Notch4 signaling to stimulate endothelial cell proliferation. Four days after myoblast 
implantation, VEGF alone caused about 50% less endothelial proliferation in Notch4d1 mice 
compared to control animals (pHH3+ endothelial cells = 1.8±0.2% vs. 0.9±0.2%; Figure 5A). 
As expected, inhibition of ephrinB2/EphB4 led to a 30% increase in endothelial cell 
proliferation in wild type mice (2.7±0.2%, p<0.01). Interestingly, ephrinB2/EphB4 inhibition 
increased endothelial proliferation by about 50% compared to V-low alone also in Notch4d1 
mice (1.8±0.2%, p<0.01). However, Notch4 inactivation still partially inhibited endothelial 
proliferation caused by ephrinB2/EphB4 inhibition, as this was about 30% lower than in wild-
type mice (p<0.05; Figure 5A). Representative immunofluorescence images are shown in 
Figure 5B. 
  Endothelial cell apoptosis was assessed by the number of cleaved-Caspase-3+ECs and 
analyzed in muscles collected 7 days after implantation of myoblast expressing only VEGF or 
co-expressing sEphB4, into Notch4d1 mice and wild-type mice. No difference in number of 
apoptotic ECs was observed among different conditions and/or mouse strains (Figure 5C). 
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Figure 5. Both Notch4 and ephrinB2/EphB4 signaling control endothelial cell proliferation, but not 
apoptosis. Limb muscles of both wild-type (wt) and Notch4d1 mice were injected with myoblasts expressing only 
a low dose of VEGF (V-low) or co-expressing also sEphB4, blocker of ephrinB2/EphB4 pathway (V-low 
sEphB4). Endothelial cell (EC) proliferation was quantified 4 days after myoblast implantation by 
immunostaining for endothelium (CD31, green) and proliferation marker phospho-histone H3 (pHH3, red). (A) 
Four days after myoblast implantation, Notch4 inactivation inhibited endothelial proliferation both after delivery 
of low levels of VEGF alone and with ephrinB2/EphB4 inhibition. However, Notch4 inactivation did not prevent 
the increase in endothelial proliferation caused by ephrinB2/EphB4 inhibition, as pHH3+ ECs were still about 
50% more frequent in the V-low sEphB4 condition than in V-low in Notch4d1 mice; n=6 muscles/group, * p<0.05, 
** p<0.01 by Kruskal-Wallis test followed by Dunn’s post-test. (B) Representative immunofluorescent images. 
Phospho-HH3+ ECs are marked with white arrows. Size bar=25 µm. (C) Apoptotic endothelial cells were analyzed 
after 7 days by immunofluorescence staining using antibody against cleaved Caspase-3 and CD31. The analysis 
showed no apparent difference among conditions and/or mouse strains; n=4 muscles/group. 
 
EphrinB2/EphB4 signaling does not require Notch4 activity to modulate 
pERK1/2 
As shown in the previous Chapter, ephrinB2/EphB4 signaling modulates the MAPK 
pathway and endothelial proliferation after VEGF stimulation through pERK1/2 (Chapter III, 
Figure 7E-H). We found that pERK1/2 is controlled without direct modulation of VEGF-R2 
activation, i.e. both its internalization and phosphorylation (Chapter III, Figure 7A-C). Here 
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we investigated whether Notch4 signaling is necessary for this process. The analysis was 
performed 3 days after myoblast implantation, as VEGF downstream signaling is activated 
early on during the angiogenic process. Quantification of pERK1/2+ endothelial cells 
(pERK1/2+ EC) was performed by immunofluorescence co-staining using antibodies against 
CD31 and pERK1/2 (Figure 6A). Low levels of VEGF induced pERK1/2 in endothelial cell 
similarly in both mouse strains. Inhibition of ephrinB2/EphB4 signaling by sEphB4 led to a 
significant increase in the frequency of pERK1/2+ ECs in both wt mice (5.5±0.9% with V-low 
vs 9.9±1.0% with V-low sEphB4, p<0.001) and in Notch4d1 mice (6.3±0.8% with V-low vs 
10.3±1.2% with V-low sEphB4, p<0.05), but with no significant differences between wt and 
Notch4d1 mice in each condition (Figure 6B), showing that Notch4 inactivation did not affect 
endothelial ERK1/2 phosphorylation. 
 
Figure 6. Notch4 signaling does not regulate endothelial pERK1/2 after VEGF delivery. Myoblast expressing 
only VEGF (V-low) or co-expressing sEphB4 (V-low sEphB4) were injected in limb muscle of wild-type (wt) 
and Notch4d1 mice. Three days after myoblast implantation, frozen section of injected muscles were 
immunostained to visualize endothelium (CD31, green) and pERK1/2 (red). The frequency of pERK1/2+ 
endothelial cells was quantified and the analysis showed that sEphB4 could induce significantly higher amount 
of pERK1/2+ECs compared to VEGF alone. However, this effect was similar in both mouse strains (A-B); n = 6 
muscles/group, * p<0.05, *** p<0.001 by Kruskal-Wallis test followed by Dunn’s post-test. Size bar=25µm 
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Discussion 
VEGF gene therapy is a promising strategy for treatment of ischemic disease, but 
aberrant vessel growth, as a consequence of high VEGF dose, is a limitation for achievement 
of therapeutic benefit (23). Here, we investigated the crosstalk between Notch4 and EphB4 
signaling in the switch between normal and aberrant angiogenesis by increasing doses of VEGF 
and we found that: 1) active Notch4 is required for aberrant angiogenesis induced by EphB4 
blockade; 2) Notch4 inactivation reduces, but does not abolish, the increase in endothelial 
proliferation caused by EphB4 blockade; and 3) while EphB4 blockade stimulates endothelial 
proliferation by activating ERK1/2 phosphorylation, Notch4 inactivation does not affect this 
pathway. Taken together, these findings suggest that Notch4 does not control the switch 
between normal and aberrant vascular growth through EphB4, but rather that both pathways 
regulate endothelial proliferation in parallel, providing the basis for potential synergistic 
targeting. 
We have previously shown that VEGF delivery to skeletal muscle does not induce 
angiogenesis by the well-characterized mechanism of sprouting, but rather through an initial 
step of circumferential vascular enlargement, followed by longitudinal vessel splitting, i.e. 
intussusception (20). As shown in the previous Chapter of this thesis, inhibition of 
ephrinB2/EphB4 signaling by sEphB4, caused aberrant vessel growth despite low and safe 
VEGF levels. This process was characterized by alteration of different cellular and molecular 
events during early angiogenic response to VEGF (3 and 4 days after myoblast implantation), 
like increase in the size of initial vascular enlargements and speed of endothelial cell 
proliferation, as well as increase in pERK1/2 activation. Ultimately, this led to the development 
of aberrant vessels at later stage (7 and 14 days after myoblast implantation). Here we 
investigated whether active Notch4 signaling is required for the process of aberrant 
angiogenesis caused by EphB4 blockade and whether one of the two pathways may control the 
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other, or they may work in synergy. We made use of the Notch4d1 mouse model, in which the 
Notch4 protein is truncated and unable to signal due to a lack of the intracellular and 
transmembrane domains (15). We have shown that deprivation of Notch4 signaling reduced, 
but did not abolish, the increase in endothelial cell proliferation caused by EphB4 blockade 
with sEphB4 and successfully prevented the development of aberrant vascular structures, 
although it did not affect activation of pERK1/2 that is instead controlled by EphB4 signaling. 
It is known that Notch signaling acts upstream of ephrinB2 and EphB4, as it can upregulate 
ephrinB2 and downregulate EphB4, an in that way, promote arterial and suppress venous 
phenotype (7, 8). However, this function of Notch upstream of ephrinB2/EphB4 does not 
explain our observations. In fact, a reduction in ephrinB2 caused by a loss of Notch signaling 
would be expected to rather further reduce EphB4 activity and potentiate the induction of 
aberrant angiogenesis by EphB4 blockade, rather than preventing it. Further, if Notch4 acted 
through EphB4 signaling, its loss should decrease the levels of pERK1/2, whereas no such 
effect was observed. On the other hand, over-activation of Notch4 using a tetracycline-
inducible model, causes arterio-venous malformations (AVM) in the brain (5, 12-14). It was 
also shown that development of AVMs is accompanied by a decrease in EphB4 expression, 
which is again normalized, after AVMs regress. Furthermore, blockade of ephrinB2/EphB4 
signaling by sEphB4 significantly impaired regression of AVMs after termination of Notch4 
overactivation (5). These results are in agreement with our previous findings that EphB4 
blockade promotes the transition to aberrant vascular growth and here we sought to investigate 
whether ephrinB2/EphB4 signaling may also act upstream of Notch4. The results showed that, 
while active Notch4 is required for the induction of aberrant angiogenesis by EphB4 blockade, 
it does not fully control ephrinB2/EphB4 downstream effects. Rather, the data suggest that 
both pathways modulate endothelial cell proliferation, but with different non-overlapping 
mechanisms. While ephrinB2/EphB4 modulates the amount of pERK1/2, a signaling branch 
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known to regulate VEGF-induced proliferation (24, 25), absence of Notch4 did not affect the 
amount of VEGF-induced pERK1/2 (Figure 6). Interestingly, it has been shown that 
overactivation of Notch4 induces vessel enlargement and AVM formation without change in 
number of endothelial cells (5, 13). Contrary to that, we have observed a decrease in endothelial 
cell proliferation in Notch4d1 mice (Figure 5A). It is important to note that VEGF is 
overexpressed in our model, as compared to the AVM model presented by Murphy et al, and 
could potentially account for these differences. It was also reported that Notch4 can prevent 
apoptosis of endothelial cells by both RBPJ-κ-dependent and RBPJ-κ-independent mechanism, 
and ankyrin repeats in intracellular domain are necessary for anti-apoptotic activity (26), but 
we did not observe any difference in number of apoptotic cells during active angiogenesis in 
two different mouse strains (Figure 5C). Given that ephrinB2/EphB4 inhibition can increase 
endothelial proliferation in Notch4d1 mice, we can conclude that both Notch4 and 
ephrinB2/EphB4 signaling can regulate VEGF-induced endothelial proliferation by two 
independent mechanisms. 
It was reported that Notch inhibition enhances intussusceptive angiogenesis by 
increasing the number of transluminal pillars, leading to higher microvascular density (27). In 
accordance to that, 7 days after myoblast implantation, we also observed an increase in vessel 
length density in Notch4d1 mice as compared to control mice. This increase is noticeable both 
after stimulation with VEGF alone and together with inhibition of ephrinB2/EphB4 signaling, 
where normalization of aberrant vessel morphology could also be observed (Figure 4K). This 
observation suggests that absence of active Notch4 downstream signaling may enhance 
intussusceptive remodeling of the vessels also in our model, leading to more efficient vessel 
splitting, although this aspect remains to be investigated by high-resolution morphological 
analyses and pillar quantification. It is interesting to note that increased efficacy of vessel 
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splitting may also contribute to the prevention of aberrant angiogenesis, by blocking the 
process of continued circumferential enlargement. 
It was reported that Notch4 can be activated by Notch ligands in vitro (28, 29), but 
others failed to confirm this finding (19, 30). Interestingly, it was shown that Notch4 has a very 
weak ability to activate downstream signaling, as compared to Notch1 (19). Furthermore, 
truncated Notch4d1 protein, released from expressing endothelium, has the potential to dose-
dependently inhibit ligand-induced activation of Notch1 receptor in cultured cells (19). Since 
the truncated Notch4 protein is overexpressed in the Notch4d1 mice (19), here used for the 
experiments, it is possible that Notch1 inhibition in cis may contribute to the observed 
reduction in endothelial proliferation. Whether Notch4 inactivation may inhibit endothelial 
proliferation directly or indirectly through inhibition of Notch1 remains to be investigated. 
In conclusion, both ephrinB2/EphB4 and Notch4 signaling control the process of 
aberrant angiogenesis induced by VEGF, but with distinct mechanism that do not necessarily 
have same dynamics and could be critical at different stages of the angiogenic process. From a 
therapeutic perspective, these findings provide a basis to hypothesize that activation of EphB4 
and inhibition of Notch4 could have synergistic effects on controlling endothelial proliferation 
by excessive doses of VEGF and therefore be more efficient in prevention of aberrant 
angiogenesis compared to targeting each pathway alone. 
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Ischemic diseases are one of the leading causes of death in Western societies. Peripheral 
artery disease, caused by atherosclerotic occlusions of arteries, has different grades of severity 
of symptoms, ranging from pain during exercise to limb amputation (1-3). Therapeutic 
angiogenesis is a promising strategy to induce growth of new blood vessels and restore blood 
flow in the ischemic tissues by VEGF stimulation (3). Despite the clear biological efficacy of 
the factor, clinical trials of VEGF gene therapy failed to show patient benefit (2). One of the 
reasons for disappointing results are low transduction efficiency and insufficient local protein 
production at safe vector doses (3, 4). Higher VEGF doses, on the other side, lead to induction 
of aberrant, dysfunctional angioma-like vascular structures (5). Therefore, in order to take 
advantage of VEGF’s therapeutic potential and enable safe delivery of effective doses, we 
sought to identify molecular targets responsible for normalization of aberrant vascular growth. 
We found that ephrinB2/EphB4 signaling between pericytes and endothelium controls the 
switch between normal and aberrant angiogenesis with increasing VEGF doses. We 
demonstrated that ephrinB2/EphB4 determines the outcome of VEGF-induced angiogenesis 
by modulating VEGF downstream signaling through pERK1/2, but without directly affecting 
VEGF-R2 activation, either through its internalization or phosphorylation. This has important 
therapeutic implications. In fact, by inhibiting one branch of a redundant circuit downstream 
of VEGF-R2, EphB4 stimulation can achieve modulation of ERK1/2 activation and endothelial 
proliferation, while sparing sufficient activity to avoid disruption of vascular growth, and 
therefore ensuring robust normal angiogenesis. We delivered VEGF by three platforms, 
namely myoblast-based delivery system, fibrin-bound VEGF, and adenoviral delivery. Using 
all three delivery systems, we showed that aberrant angiogenesis by high VEGF doses can be 
normalized by systemic treatment with ephrinB2-Fc. Finally, we investigated the therapeutic 
potential of this approach in a mouse model of limb ischemia and we found that activation of 
EphB4 signaling together with uncontrolled VEGF delivery by adenoviral vectors yields only 
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normal and functional vascular growth, decreasing tissue necrosis and increasing tissue 
regeneration.  
As inhibition of Notch4 signaling was found to have a similar effect as stimulation of 
EphB4, namely preventing aberrant vascular growth by high VEGF doses while enabling only 
robust normal angiogenesis, we next investigated the crosstalk between the ephrinB2/EphB4 
and Notch4 pathways. We found that aberrant angiogenesis induced by inhibition of 
ephrinB2/EphB4 with low VEGF can be prevented in Notch4d1 mice, in which the Notch4 
protein is mutated and unable to signal (6). Endothelial cell proliferation induced by VEGF 
stimulation was reduced in these mice compared to controls. Interestingly, upon VEGF 
stimulation, higher vessel length density was observed in Notch4d1 mice comparing to control 
mice. This observation is in line with recent finding that inhibition of Notch signaling during 
intussusceptive angiogenesis can increase microvascular density (7). The absence of active 
Notch4 signaling reduced, but did not completely prevent, the increase in endothelial cell 
proliferation caused by inhibition of the ephrinB2/EphB4 pathway, whereas it had no effect on 
pERK1/2 activation. These observations suggest that both ephrinB2/EphB4 and Notch4 
cooperate in aberrant vessel normalization, but appear to do so via two independent molecular 
mechanisms. While EphB4 works through the kinase cascade and pERK1/2, the path linking 
Notch4 to endothelial proliferation remains to be elucidated. 
As a future perspective, further development of preclinical proof-of-concept studies of 
ephrinB2/EphB4 signaling is one of the main objectives. It is known that ephrinB2/EphB4 
complexes multimerize upon interaction, and that this is required for maximal activation of 
downstream signaling (8-10). In order to further develop its therapeutic potential, we are 
aiming to produce a recombinant ephrinB2-Fc protein that is able to multimerize, creating a 
stronger activator than the dimers formed by the commercially available IgG-Fc fusion protein. 
For this, we will exploit a recently published recombinant Fc fragment (11), based on the fusion 
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of IgG-Fc with an 18-amino acid peptide sequence of the carboxyl-terminus of IgM antibody 
Fc, responsible for pentamer complexes formation. Two point-mutations in the 18-aa clustering 
sequence were introduced to achieve that the protein complex assembles as a hexamer, rather 
than as a pentamer, further improving its activating power. The recombinant IgG-Fc fragment 
with short peptide elongation can be fused to the ephrinB2 extracellular domain, enabling 
multimerization of the resulting protein. After in vitro characterization of the potency of the 
novel engineered protein, where it will be compared to the commercially available ephrinB2-
IgG-Fc, its ability to normalize aberrant angiogenesis, as well as its stability would be a tested 
in vivo in a mouse model. Next, pre-clinical translation should be carried out in clinically 
predictive large-animal models of ischemia (rabbit hindlimb or pig heart) by combining a 
clinically applicable robust vector for gene therapy (adeno-associated or adenovirus) at 
efficient titers with systemic EphB4 stimulation. 
Here, for the first time, we identify specific signaling pathways regulating the outcome 
of intussusceptive angiogenesis, namely ephrinB2/EphB4 and Notch4, as their previously 
known functions related to sprouting angiogenesis (12) or arterio-venous malformation 
development (13, 14), respectively. Further downstream effectors of these pathway need to be 
identified, possibly by transcriptomic analysis of FACS-sorted endothelial cells isolated after 
inhibition/activation of ephrinB2/EphB4 or inhibition of Notch4 pathway. This could be 
complemented by (phospho-)proteomic analysis in order to systematically investigate the 
downstream molecular network and its interaction with VEGF and other signaling pathways. 
It would be also interesting to investigate the effect of ephrinB2/EphB4 signaling 
modulation on pericyte biology. We have observed that inhibition of ephrinB2/EphB4 pathway 
changes pericyte characteristics during the early phase of angiogenesis, as they become double 
positive for NG2 and αSMA, and activation of the pathway, on the other side, recruits pericytes. 
It will be important to investigate how their gene expression profile and proliferation change 
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upon modulation of this pathway. Generally, very little is known about downstream mechanism 
of action of ephrin/Eph pathway. These signaling molecules have been connected with other 
pathologies, like cancer and neurodegeneration, so this could also open possibilities for 
treatment of these conditions (10). 
Taking advantage of the unique model provided by the monoclonal populations 
expressing specific doses of VEGF in skeletal muscle, the kinetics of EphB4 and Notch4 
actions and the underlying cellular mechanisms should be rigorously investigated by in vivo 
imaging of early morphological changes during angiogenesis by two-photon microscopy. 
These experiments would be performed in the ear muscle of Tie2-GFP mice that have 
spontaneously fluorescent endothelium, as this muscle is superficial and accessible to imaging 
without surgical procedures. This would help us understand how ephrinB2/EphB4 modulates 
the growth of initial vascular enlargements, and how Notch4 signaling influences vessel 
remodeling at later stages of angiogenesis. 
Finally, activating EphB4 by ephrinB2-Fc recombinant protein in Notch4-deficient 
mice would answer the question whether the double targeting is more efficient in normalization 
of aberrant angiogenesis by high VEGF, as compared to modulation of only EphB4 or Notch4 
pathways alone. In case double therapy would be proven more efficient, one could increase the 
dose of VEGF in order to identify the upper limit of the putative therapeutic window to 
normalize aberrant vessel growth. Ultimately, this would set the stage to design rational 
therapeutic approaches that could overcome current limitations of VEGF gene delivery and 
lead to a clinical benefit. 
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